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Abstract 
 
In neurons, hyperpolarization-activated cyclic nucleotide-regulated (HCN1-4) channels are the 
molecular determinants of the Ih current, which controls several cognitive processes. Unique 
among the voltage-gated ion channel superfamily, HCN channels are modulated by the direct 
binding of cAMP to their cytoplasmic cyclic nucleotide binding domain (CNBD). Thus, cyclic 
nucleotide-dependent conformational changes of CNBD are determinant in the regulation of HCN 
channel opening. The rearrangements induced by cAMP in HCN CNBD are not yet elucidated, since 
for this protein is known only the cAMP-bound form. HCN channels are further regulated by their 
association with the auxiliary protein TRIP8b, which preferentially binds to the cAMP-unbound 
CNBD and opposes cAMP regulation. Recently, we proposed a cyclic allosteric model to explain the 
mutual antagonistic effect of TRIP8b and cAMP. Here, to validate this model, we first determined 
the model structure of the human HCN2 CNBD in the cAMP-unbound form using NMR 
methodologies. By comparing the cAMP-unbound and cAMP-bound structures we highlighted all 
the conformational changes allosterically coupled to the channel opening transition. 
Subsequently, we mapped the TRIP8b binding site onto the cAMP-unbound CNBD. Our results 
show that cAMP and TRIP8b do not compete for the same binding region, and support our 
allosteric antagonistic model for the dual regulation of HCN channels by cAMP and TRIP8b. 
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1 STATE OF THE ART 
 
1.1 Ih current 
Ih is a mixed cationic (Na
+ and K+) current activated by the hyperpolarization of the plasma 
membrane and regulated by cyclic nucleotides (cAMP and cGMP) (Fig. 1) [1]. Given its peculiar 
voltage dependence, which is contrary to the vast majority of the voltage-gated current 
activated upon membrane depolarization, it was called with the name of “funny current” (If) in 
the heart cells [2], and with the names of “queer current” (Iq) [3] or “hyperpolarization 
activated current” (Ih) in neurons [4]. In this work the term Ih will be used. 
 
 
 
Fig. 1: Biophysical properties of Ih current. 
Left: Ih activates faster in the presence (red) than in the absence (black) of cAMP at maximal 
activation voltage (-140mV). Right: activation curve of Ih in the absence (black) and presence 
(red) of cAMP. In the presence of cAMP, the activation curve of Ih is shifted to the right [5]. 
 
 
Ih current controls, among other functions, the resting membrane potential, the regulation of 
dendritic integration and the pacemaking activity (in both heart and brain). Since Ih has a 
reversal potential of around -20 mV, at physiological ionic conditions and resting potential it is 
partially open and inwardly directed and consequently sets the level of the resting membrane 
potential at a somewhat depolarized level [5]. Furthermore, Ih current seems to function as a 
slow “voltage clamp”, counteracting both hyperpolarizing and depolarizing inputs, respectively 
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by producing a depolarizing inward current, due to its activation, or by facilitating the 
hyperpolarization, because of its deactivation [6]. In neurons, this ability to oppose to 
excitatory and inhibitory stimuli is crucial for the modulation of the amplitude and passive 
propagation of the excitatory postsynaptic potentials (EPSPs) and inhibitory postsynaptic 
potentials (IPSPs) [7, 8] (Fig. 2A). Moreover, Ih current contributes to the genesis of the action 
potential in the SAN cells and Purkinje cardiac fibers [9], as well as in neuronal cells, such as 
the talamocortical relay neurons [10] and the hippocampal stratum oriens interneurons [11]. 
The activation of Ih current at negative voltages, due to the repolarization phase of the action 
potential, generates an excitatory inward current, which drives the membrane potential to the 
threshold for firing a subsequent action potential (Fig. 2B). 
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Fig. 2: Multiple functions of Ih in neurons and cardiac myocytes: 
A, The somato-dendritic gradient of Ih effectively filters the propagation of inputs through 
dendrites and then normalizes their temporal summation at the soma. Right: Summation of 
EPSPs from proximal (black trace) and distal (gray trace) dendrites recorded at the soma after 
propagation. The voltage recordings are shown before (top panel) and after (bottom panel) 
inhibition of Ih by the selective Ih blocker ZD 7288 [image modified from Ref. 5]. B, Pacemaking 
function of Ih in a cardiac sinoatrial node myocyte (left) and in a thalamocortical relay neuron 
(right). In both cells, Ih activation following an action potential produces a slow depolarization 
that triggers an action potential through activation of calcium channels (It current). Red box 
indicates the temporal shadow of action of the Ih current [image modified from Ref. 1]. 
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 1.2 HCN channels 
Hyperpolarization-activated cyclic nucleotide-gated (HCN1-4) channels are the molecular 
determinants of Ih current. HCN channels belong to the superfamily of the voltage-gated K
+ 
(Kv) channels [12]. Thus, the “core” unit of these channels reflects the typical architecture of 
the voltage-gated K+ channel, which is constituted by the assembly of four α-subunits, 
integrally embedded in the cell membrane to create an ion-conducting pore. In mammals four 
protein isoforms (HCN1-4) were found [13], which are able to organize either in homo or 
hetero-tetramers [14]. HCN channels are expressed mainly in the central nervous system and 
heart. All the four isoforms are present in the brain, even though with different expression 
profiles: of all HCN3 shows the weakest expression, by contrast HCN2 presents the widest 
expression profile, in particular reaching high levels in the thalamus. The second brain isoform 
is HCN1, that shows a more selective expression profile compared with HCN2. HCN1 is highly 
expressed in the hippocampus, neocortex, cerebellar cortex and neuronal stem cells. HCN4 
isoform, which expression is generally low, is restricted to specific regions, such as thalamus 
nuclei and mitral cells of the olfactory bulb [15, 16]. All the four isoforms are present in cardiac 
tissues, though HCN4 is the predominant, accounting for >80% of the total HCN mRNA in the 
SAN, the pacemaker region of the heart [16, 17]. The α-subunit of HCN channels has six 
transmembrane segments (S1-S6), of which, segment S4 forms the voltage sensor domain, 
while S5-S6 comprise the pore region. HCN channel have both intracellular N- and C-termini. 
The N-terminus is different in every isoform, while the C-terminal tail contains the CNBD (cyclic 
nucleotide binding domain), which determines the modulation of the HCN channel activity by 
the cyclic nucleotides. Right upstream of the CNBD the C-linker domain is present, which 
connects the CNBD to the pore region, and therefore conveys the regulation of channel gating 
exerted by the CNBD (Fig. 3) [5]. The amino acid sequence of the C-linker/CNBD region is highly 
conserved among the four isoforms [1, 5]. 
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Fig. 3: Topology of HCN channels. Two of the four subunits of an HCN channel are shown. The 
transmembrane segments (S1–S6) are shown in black, except for the pore region (S6 and pore 
loop), which is shown in red. The voltage sensor (S4) is indicated by positive charges. The C-
terminal region contains the cyclic nucleotide binding domain (CNBD, blue, shown with cAMP 
bound) and the C-linker (green), which connects the CNBD to the pore [5]. 
 
 
1.3 The role of the cyclic nucleotide 
HCN channels are directly modulated by cAMP and cGMP, which enhance channel opening in 
hyperpolarization by binding to the CNBD. In HCN channels CNBD exerts a tonic inhibition on 
the channel pore, shifting the gating in absence of the cyclic nucleotide to more negative 
potentials (Fig. 1). This inhibition is released by ligand binding, with a consequent increase of 
the open probability at hyperpolarizing voltages and a shift of the voltage dependence of 
activation at more depolarizing potentials [18] (Fig. 1 and 4B). The inhibitory effect of CNBD is 
supported by the fact that the deletion of this domain causes the same effect of facilitation in 
channel opening, that is determined by cAMP binding [18]. The proposed mechanism of HCN 
channel opening is complex, requiring the allosteric interactions between four domains: the 
pore, the S4 voltage sensor, the C-linker, and the CNBD (Fig. 4A). Each domain is in equilibrium 
between two possible conformations. The pore can be closed or open, the voltage sensor and 
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the C-linker can be resting or activated, and the CNBD can be unbound or bound to ligand. The 
domains are then coupled to each other, indicating that the conformation of one module 
affects the conformation of another module [19]. Hence, the opening transition of the channel 
is allosterically coupled to a conformational change both in the voltage sensor (S4) domain, 
due to hyperpolarization of the membrane potential and in the CNBD, caused by cyclic 
nucleotide binding [20]. Despite the complexity of the mechanism of channel opening, it can 
be asserted that the closed-to-open transition of the channel reflects the transition from the 
cAMP-unbound to the bound conformation of the CNBD, which indeed stabilizes the closed 
and open state of the channel, respectively [18-20] (Fig. 4B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Molecular mechanism of cAMP modulation of HCN channel opening.  
A, Proposed activation mechanism for HCN channels. Voltage sensor (S4), C-linker (CL). States 
are shown as closed (C), open (O), resting (R), activated (A), unbound (U), and bound with 
ligand (B). Boxes around states indicate separable gating modules. Single-headed arrows 
indicate equilibrium between states, and double-headed arrows indicate coupling between 
gating modules [19]. B, Effect of cAMP on the HCN channel. The figure illustrates two adjacent 
α-subunits of the four comprising the channel. The core transmembrane domain (S1-S6) is 
A 
B 
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indicated in grey. In orange is represented the cyclic nucleotide-binding domain (CNBD), as a 
semicircular region (b-roll) and two cylinders  (B/C helix element) (see Par. 1.5 for a detailed 
explanation of the CNBD elements). Left, the CNBD in the cAMP-unbound conformation inhibits 
the gating of the core transmembrane domain by a strain coupled through the C-linker 
(indicated in red). Right, in the presence of cAMP (blue circle), a conformational change in the 
CNBD leads to relief of strain on the C-linker (indicated in green), which promotes channel 
opening [image modified from Ref. 18]. 
 
 
1.4 The role of TRIP8b  
In addition to cAMP, HCN channels are further regulated by proteins such as TRIP8b (TPR-
containing Rab8b interacting protein), a cytoplasmic β-subunit of neuronal HCN channels, 
which regulates ion channel trafficking and gating [21-23]. TRIP8b is subjected to alternative 
splicing at its N-terminus, giving rise to different isoforms with diverse effects on HCN channel 
trafficking. In contrast, all TRIP8b isoforms inhibit HCN channel opening by antagonizing the 
effect of cAMP (Fig. 5) [21]. TRIP8b directly binds the cytoplasmic C-terminal region of HCN 
through two distinct sites conserved in all isoforms: the tetratricopeptide repeat (TPR) domain, 
which binds the last three aminoacids (SNL) of HCN [24], and an 80 amino acid sequence 
located in its central core (miniTRIP8b), that interacts with the CNBD domain [25]. It has been 
argued that, whereas the TPR domain stabilizes the interaction between HCN channels and 
TRIP8b, miniTRIP8b is necessary and sufficient to antagonize the cAMP-induced effect on 
channel opening (Fig. 6) [25, 26]. Furthermore, it was demonstrated that miniTRIP8b fragment 
also reduces the maximal current through the channel in the absence of cAMP (Fig. 7B) [26]. 
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Fig. 5: TRIP8b antagonizes the cAMP-induced effect on HCN channel opening. Steady-state 
activation curves of HCN2 channels (black) and HCN2 and TRIP8b channels (red) before (filled 
symbols) and after application of 100 µM cAMP (open symbols). The right shift of the curve of 
activation due to cAMP is significantly reduced for HCN2 that is in complex with TRIP8b, 
indicating that TRIP8b is able to partially inhibits the cAMP effect [image modified from Ref. 
22]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Effects of miniTRIP8b on action of cAMP on HCN2 channel voltage gating.  
(A) Shift in V1/2 as a function of [cAMP] in the absence (open circles) or presence (filled circles) 
of 4 μM miniTRIP8b. Solid lines show fits of the Hill equation, which yield: ΔVmax= 18.1 mV for 
HCN2; ΔVmax= 15.8 mV for HCN2 plus 4 μM miniTRIP8b. for HCN2 co-expressed with TRIP8b 
ΔVmax= 14.2 mV [image modified from Ref. 26]. 
 
 
Although the interaction of TRIP8b with HCN channels has been characterized at both the 
functional and biochemical level, high-resolution structural data of the TRIP8b-HCN CNBD 
 HCN2  
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complex have not yet been obtained, preventing the development of a decisive molecular 
model to explain the mutual inhibitory effect of TRIP8b and cAMP. In a recent work it was 
shown that cAMP acts by competitively displacing TRIP8b from HCN CNBD [27]. Furthermore it 
has been suggested that TRIP8b and cAMP compete for the same binding site, as the mutation 
of a conserved Arginine residue of the cyclic nucleotide binding site (R538E in human HCN1 
and R591E in human HCN2), which is known to severely decrease the affinity of the CNBD for 
the cAMP, abolishes the interaction with TRIP8b [27]. On the contrary, we have shown that the 
interaction of HCN1 and TRIP8b is maintained in the HCN1 R538A mutant and strongly 
decreased, but not abolished, in the R538E mutant and that miniTRIP8b effect on HCN2 R591E 
mutant is not altered (Fig. 7) [26]. Moreover, our electrophysiological results demonstrated 
that the mutual antagonistic effects of TRIP8b and cAMP are better described by a cyclic 
allosteric mechanism rather than a direct competition of the two ligands [26]. These data 
strongly support the hypothesis that TRIP8b and cAMP binding sites do not overlap, and 
indeed structural data of the TRIP8b-CNBD complex are now required to validate the allosteric 
antagonism between the ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: TRIP8b does not bind to the cyclic nucleotide binding site of the CNBD. 
A, The effect of mutations in the HCN1 CNBD residue R538 on TRIP8b binding. Western blot 
analysis shows binding of HCN1, HCN1R538A and HCN1R538E mutants to wild-type TRIP8b 
assessed by coimmunoprecipitation from Xenopus oocyte extracts co-expressing TRIP8b and 
HCN1. The top row shows the HCN1 input signal using an anti-HCN1 antibody. The middle row 
HCN1 
HCN1 
TRIP8b 
(imput) 
(Co-IP) 
(imput) 
HCN1 HCN1R538A HCN1R538E 
HCN2 
HCN2R591E 
+ miniTRIP8b 
+ miniTRIP8b 
A B 
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shows the TRIP8b input signal using an anti-TRIP8b antibody. The bottom row shows the 
amount of HCN1 protein coimmunoprecipitated with the TRIP8b antibody (western blot probed 
using anti-HCN1 antibody). Note that exposure times are directly comparable along each row, 
but not down each column. B, TRIP8b reduces maximal current by interacting to the CNBD. 
Currents through HCN2 WT and R591E mutant channel before (black trace) and after (blue 
trace) the application of 4 µM miniTRIP8b to inside-out patches (no cAMP present). The effect 
of miniTRIP8b on the maximal current reduction is not altered by R591E mutation highlighting 
that TRIP8b and cAMP binding sites do not overlap [images modified from Ref. 26].  
 
 
1.5 The CNB domain 
The CNBD is a structural domain found in several different kinds of prokaryotic and eukaryotic 
cyclic nucleotide-binding proteins: from the bacterial MloK1 channel [28] to the mammalian 
PKA enzyme [29]. It consists of an N-terminal helical bundle, followed by an 8-stranded 
antiparallel β-roll, and two terminal α-helices (Hinge and Lid). The cyclic nucleotide binding site 
(known as PBC, Phosphate Binding Cassette) is a pocket formed by the β-roll of the CNBD (Fig. 
8) [30]. In HCN channels, the first two helices of the N-terminal helical bundle have been 
conventionally associated to the upstream C-linker sequence (Fig. 8A). Although only the 
structure of the cAMP-bound form of HCNs CNBD is known [31, 32], structural data coming 
from other CNBDs in the cAMP-unbound configuration demonstrate that the cyclic nucleotide 
induces the reorientation of the N-terminal helical bundle, as well as of the Hinge and Lid 
helices (Fig. 9). These movements are essential for the CNBD to perform its function. Once the 
cyclic nucleotide binds the PBC, this interaction causes the approach of the hinge and lid 
helices to the β-roll. In the new position adopted, the lid helix is able to interact with the base 
of the cyclic nucleotide and this binding stabilizes its own orientation and that of the hinge 
helix. Furthermore, the new conformation adopted by the hinge-Lid helix element causes the 
reorientation of the N-terminal helical bundle. The movement of the N-terminal helical bundle 
is important for cyclic nucleotide signalling, as it gives rise to conformational changes, that are 
translated into activation mechanisms specific for the different cyclic nucleotide-regulated 
proteins [30]. 
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Fig. 8: The structural elements and topology of CNBD-containing proteins are universally 
conserved. 
A, HCN2 CNBD in the cAMP-bound conformation. B, CNBD of EAG1 channel, which belongs to 
the voltage-gated potassium channel family together with EAG and ELK channels. C, CNBD 
from the prokaryotic cyclic nucleotide-gated channel MloK1 in the cAMP-bound conformation. 
D, cAMP-bound CNBD site B of protein kinase A (PKA). The evolutionarily conserved elements of 
these four proteins are coloured: N-terminal helical bundle in orange, 8 β-strands in blue, B and 
C-helix in red. Structures were generated from the Protein Data Bank accession codes 3U10 
(HCN2, Ref. 31), 4F8A (EAG1, Ref. 33), 2KXL (MloK1, Ref. 28) and 1RL3 (PKA, Ref. 29) using 
PyMOL. 
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Fig. 9: Universally conserved movements of the CNBD protein caused by cyclic nucleotide 
binding. 
A, Superimposition of the CNBD in the cAMP-unbound and -bound conformations from the 
prokaryotic MloK1 channel. β -roll subdomain of both forms is coloured gray, while the N-
terminal helical bundle and the B/C-helices are coloured in light blue (cAMP-bound form) and 
blue (cAMP-unbound form), respectively . cAMP is in orange. Red arrows indicate movements 
of the N-terminal helical bundle and yellow arrows movement of the B/C-helices. Both groups 
of movements are consequence of the binding of cAMP to the PBC. Structures were generated 
from the Protein Data Bank accession codes 2KXL (cAMP-unbound CNBD) and 2K0G (cAMP-
bound CNBD) using PyMOL. 
 
 
1.6 The binary cAMP-TRIP8b regulatory system 
In the central nervous system cAMP signaling is important for the regulation of different 
cognitive processes [34, 35] and emotional aspects [36]. Moreover, HCN channels have been 
shown to mediate long-term memory processes [37] and misregulation of Ih occurs in several 
neurological disorders [38-40]. Several works established a direct connection between cAMP 
and HCN channels in the development of neuronal functions, as in the case of the prefrontal 
cortex, in which cAMP-modulation of HCN channel activity is involved in the regulation of 
MloK1 CNBD 
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working memory networks [41]. As for cAMP, a role in the regulation of HCN-mediated 
neuronal activity has been robustly established for TRIP8b [42, 43] and the combined effect of 
cAMP and TRIP8b as well. For example, in the hippocampus and entorhinal cortex HCN 
channels control the development of place and grid cells, respectively, which are critical for 
spatial memory and navigation [44, 45]. In these two regions of the brain HCN channels show a 
dorsoventral gradient of sensitivity for cAMP. In particular, in the hippocampus it was 
highlighted that this different response to cAMP is due to a dorsoventral gradient of 
expression of TRIP8b (Fig. 10) [44]. The increased expression of TRIP8b in the dorsal region, 
compared to the distal region, corresponds to a decreased cAMP sensitivity of Ih in dorsal cells, 
and viceversa for the ventral cells. Thus, the binary cAMP-TRIP8b modulation of HCN channels 
is relevant for the spatial and temporal development of the hippocampus properties. 
Moreover, such mechanism of HCN channel regulation accounts for the peculiar role of cAMP 
in the ventral hippocampus, where cyclic nucleotide levels are specifically increased during 
strong emotional conditions [36]. The high similarity with the hippocampus in the spatial 
profile of cAMP-dependent modulation of HCN channels led to argue the involvement of the 
cAMP-TRIP8b regulatory pathway also for Ih current present in the enthorinal cortex [45]. 
Indeed, the combined action of cAMP and TRIP8b signaling in the modulation of HCN channels 
is becoming even more crucial for the understanding of an increasing number of physiological 
functions and diseases affecting cognition. 
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Fig. 10: The dorsoventral distribution of TRIP8b as a molecular substrate for the different 
sentitivity of Ih to cAMP in the hippocampus [44]. 
A, Western blots of HCN1, HCN2, and TRIP8b proteins from ventral and dorsal hippocampus 
demonstrate that HCN1, HCN2, and TRIP8b protein levels are significantly larger in dorsal than 
ventral hippocampus. B, Application of cAMP increases Ih amplitude and kinetics and resonance 
in ventral place cells. Histograms of Ih current properties before and after cAMP. Note the 
cAMP-dependent increase in amplitude and faster kinetics in ventral, but not dorsal place cells. 
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2 AIMS OF THE PROJECT 
 
Assuming that HCN CNBD undergoes the same extensive spatial rearrangements upon cAMP 
binding as for the known CNBD-containing proteins, one plausible hypothesis for the 
explanation of the mutual allosteric antagonism of TRIP8b and cAMP is that each of the two 
ligands stabilizes the CNBD in a conformation that decreases the affinity for the antagonist. A 
conclusive validation of this assumption requires the structural description of the complex 
between HCN CNBD and TRIP8b. Thus the main purpose of this work was to obtain structural 
information on this protein complex. Since our efforts to crystallize the CNBD-TRIP8b complex 
failed, we employed soluble NMR methodologies. First, we set out to obtain the structure of 
the human HCN2 CNBD in the cAMP-unbound form. The determination of the cAMP-unbound 
CNBD structure was essential to clarify all of the conformational changes occurring in the 
transition from the cAMP-unbound to the bound state of the CNBD. Furthermore, since we 
established that TRIP8b binds preferentially the cAMP-unbound form of the CNBD, the 
determination of this CNBD conformation was a necessary prerequisite for the study of the 
TRIP8b binding site on HCN CNBD. The second goal of the project was to identify the TRIP8b 
binding region on the CNBD, using NMR titration experiments. Finally, the identification of the 
TRIP8b binding site on CNBD led to the description of a molecular mechanism of competition 
occurring between cAMP and TRIP8b that supported the proposed model of the mutual 
allosteric antagonism. 
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3 RESULTS 
 
3.1 cAMP destabilizes the miniTRIP8b-HCN2 Clinker/CNBD complex 
Electrophysiological experiments have shown that the antagonistic role of TRIP8b on the 
cAMP-dependent effect on HCN currents is due to miniTRIP8b fragment, the 80 amino acid 
core moiety of the full length protein [26]. Furthermore, we and others have previously shown 
that TRIP8b preferentially interacts with HCN channel having their CNBD in the cAMP-unbound 
conformation and that such interaction decreases at increasing cAMP concentrations [25-27]. 
We decided to investigate if this behavior is maintained also in vitro, between the isolated HCN 
C-linker/CNBD and miniTRIP8b proteins, using a direct biochemical analysis. To this end, we co-
expressed in E. coli the HCN2 C-terminal region including the C-linker and the CNBD tagged 
with the His6-MBP sequence (herafter CNBDc-linker), with the miniTRIP8b fragment tagged with 
the Strep sequence. The bacterial lysate was supplemented with increasing cAMP 
concentrations (from 0 to 1 mM) and the complex subsequently purified by means of the 
Nickel affinity column. As expected, increasing cAMP concentration in the lysate decreased the 
amount of miniTRIP8b protein co-purified with CNBDc-linker, highlighting the destabilizing effect 
of the cyclic nucleotide on the TRIP8b-CNBD interaction (Fig. 1). These results confirmed that 
miniTRIP8b and cAMP are competing for the binding to CNBD, and that TRIP8b preferentially 
binds the cAMP-unbound conformation of the CNBD. The question remains whether a direct 
(for the same binding site) or an indirect (allosteric) competition event occurs between the 
two ligands. To answer this question we employed soluble NMR methodologies to obtain the 
structure of the HCN2 CNBD in the cAMP-unbound conformation and subsequently map the 
TRIP8b binding site on it. 
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Fig. 1: cAMP disrupts the miniTRIP8b-CNBDc-linker complex formation. 
Coomassie blue staining following SDS-PAGE separation of the complex eluted from a Nickel 
affinity column, after pre-incubation with increasing cAMP concentrations (indicated on the 
top) . Green arrowhead marks the position of CNBDc-linker, while blue arrowhead that of 
miniTRIP8b. Numbers to the left refers to molecular weight markers (kDa), loaded in the first 
lane. 
 
 
 
3.2 Biochemical characterization of the miniTRIP8b-CNBD complex 
Since the most usual soluble NMR techniques restricts the analysis to proteins below 30-40 
kDa, we prepared a shorter construct of the C-linker + CNBD fragment, removing the first three 
α-helices (A’-C’) of the C-linker (hereafter CNBD, residues 521-672 of the human HCN2 
channel). This was also necessary in order to prevent the C-linker-driven tetramerization of the 
protein at the high concentrations required for the NMR experiments [31, 46]. First we tested 
the capability of the CNBD to interact with miniTRIP8b. To this end, we coexpressed it with the 
strep-tagged miniTRIP8b in E.coli and purified the complex by means of a strep-tactin affinity 
column. As shown in Fig. 2A the CNBD efficiently co-purifies with miniTRIP8b, confirming that 
neither the complete C-linker domain, nor the oligomerization of the HCN2 protein are 
required for the interaction with miniTRIP8b sequence. In order to validate this assay, but 
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mostly to obtain biochemical information about the stoichiometry and the affinity constant of 
miniTRIP8b-CNBD interaction, we performed isothermal titration calorimetry (ITC) on the 
complex. Titration of miniTRIP8b fragment onto the CNBD produced exothermic binding 
signals, which can be fit with a single-site binding model. The generated binding curve (Fig. 2B) 
yields a binding affinity of 1.3 μM, and a binding stoichiometry ≈1. This result is in agreement 
with the 1:1 stoichiometry recently determined between HCN2 channel and full-length TRIP8b 
[24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Interaction between CNBD  and miniTRIP8b. 
A, Coomassie Blue staining following SDS-PAGE separation of the complex purified on a strep 
tactin affinity column  by means of the Strep tag of  miniTRIP8b,: lysate (1), flow-through (2), 
eluate (3). Green arrowhead marks the position of CNBD, while blue arrowhead Strep-
miniTRIP8b. Numbers indicate molecular weight markers (kDA), loaded in the first lane. B, 
Isotermal titration calorimetry Interaction of miniTRIP8b to CNBD. (a) Heat changes during 
successive injections of 1 μl of miniTRIP8b (200 μM) to the CNBD protein (20μM). (b) Binding 
curve obtained by data in (a). The peaks have been integrated, normalized to the miniTRIP8b 
concentration and plotted against the molar ratio of miniTRIP8b to the CNBD. The solid line 
represents a nonlinear least-square fit to a single–site binding model, which yields a Kd of 1.30 
± 0.03 μM and a stoichiometric ratio N of 0.982 ± 0.006 (n = 3). 
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3.3 cAMP-unbound structure of the CNBD and comparison to the bound form 
In order to acquire double and triple resonance NMR spectra of the human HCN2 CNBD in the 
cAMP-unbound conformation, we have produced and purified [15N, 13C], or [15N] isotopically 
enriched protein (see PART III). All spectra of the CNBD show a single set of resonance signals, 
indicating that the protein is pure and adopts a single conformation. Moreover, the linewidths 
of the NMR spectra reflect a monomeric form, in line with the removal of the first three α-
helices (A’-C’) of the C-linker, which drives tetramerization of the protein. Using a combination 
of the collected spectra (see PART III), we were able to identify 91% of the backbone and 76% 
of the side chain atom resonances. No residue-specific assignments could be made for residues 
534-535, 619 and 666-667. These residues are located in highly dynamic regions (Fig. 5B) and 
this can explain the absence of signal. For residues 579, 595, 633, 658 no amide backbone 
resonances could be observed. The lack of HN signals can be due to the fact that all these 
residues are expected to be solvent-exposed and not participating in hydrogen bonding.  Fig 3 
shows the assigned [1H, 15N] HSQC spectrum of the cAMP-unbound CNBD.  [1H, 15N] HSQC 
correlates 15N with the attached 1H, and is considered the protein fingerprint, with the amide 
groups of the protein backbone and side-chain being visualized in the spectrum as spherical 
signals, except that of proline residues, which lack HN and of the first residue.  
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Fig. 3: HN resonances assignment of the cAMP-unbound CNBD. 
A, [1H, 15N] HSQC spectrum of the 15N-labeled cAMP-unbound CNBD (protein concentration = 1 
mM) acquired in 150 mM KCl, 20 mM phosphate buffer, pH 7.0, at 298K, in a 600 MHz 
spectrometer equipped with a cryoprobe. B, small regions of the [1H, 15N] HSQC spectrum of 
the 15N-labeled cAMP-unbound CNBD. Signals  of the side-chain amide groups of asparagine 
and glutamine residues are connected by horizontal lines. Backbone and side- chain resonance 
assignments are indicated by one-letter amino acid code and the sequence number. 
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The first stage of the classical NMR structure determination process involves assignment of the 
1H, 15N, and 13C NMR resonances of the polypeptide backbone atoms. The second stage 
focuses on the assignment of the side chain atom resonances. This is a crucial step in the 
structure determination process, as it allows to obtain interproton distance restraints needed 
to generate the tertiary structure [47]. The spectra of CNBD for the assignment of side chain 
atom resonances exhibit a remarkable degree of resonance overlap, which have complicated 
the analysis. Thus, to date interproton distance restraints identified are not enough to 
generate a solid NMR structure of the cAMP-unbound CNBD. NMR signals are highly sensitive 
to local structure and indeed resonance values of the 1H, 15N, and 13C belonging to the 
polypeptide backbone reflect a wide array of structural factors, such as backbone 
conformations and secondary structures (Φ and Ψ dihedral angles), hydrogen bond strength, 
and the position of aromatic rings [48-50]. Fig. 4 shows the secondary structure prediction of 
cAMP-unbound CNBD based on the 13Cα,13Cβ, 13C’, 15N, 1Hα, and 1HN chemical shifts.  
 
 
 
 
 
Fig. 4: Comparison of the secondary structure elements between cAMP-unbound and bound 
CNBD. 
Secondary structure prediction for the cAMP-unbound CNBD calculated on the 13Cα, 13Cβ, 13C’, 
15N, 1Hα, and 1HN chemical shifts using TALOS+ (upper line) and secondary structure elements of 
the cAMP-bound CNBD from the X-ray structure [31, 32] (lower line). Red cylinders indicate α-
helices and blue arrows β-strands.  
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The comparison of the predicted secondary structures of the cAMP-unbound form to the 
secondary structures of cAMP-bound form coming from the X-ray structure [31, 32], suggests 
that the typical topology of HCN CNBD is maintained in the ligand-unbound state, with the 
exception of the absence of the F’-helix (within the N-terminal helical bundle) and the second 
half of the C-helix. Moreover, residues 521-532 forming D’-helix, which belong to the end of 
the C-linker, appear to be unstructured. Misfolding of the D’-helix can be explained by the 
absence of the C-linker. In order to obtain the cAMP-unbound CNBD structure using the NMR 
data already collected, we used CS-ROSETTA structure calculation program [51]. The unfolded 
residues 521-532 were removed from the calculation. Generation of a protein structure using 
CS-ROSETTA involves two separate stages. First, the query protein is divided in small segments 
and for each of these a polypeptide fragment from Protein Data Bank (PBD) is selected, based 
on the combined use of the amino acid sequence pattern and 13Cα,13Cβ, 13C’, 15N, 1Hα, and 1HN 
chemical shifts. CS-ROSETTA is able to predict chemical shifts of Cα,Cβ, C’, N, Hα, and HN atoms 
for known protein structures available in the PDB, allowing to significantly increase the 
accuracy of selected fragments over the use of sequence information alone. The selected 
fragments are then used for de novo structure generation, using the ROSETTA RASREC protocol 
[52]. During CS-ROSETTA structure generation, the input chemical shifts are further used to re-
score the generated structures. Evaluation of the agreement between the models and the 
input experimental data provides an important selection criterion for eliminating structures 
whose backbone angles have diverged from those of the original input fragments during the 
Rosetta optimization procedure. Furthermore, we used residual dipolar coupling (RDC) 
orientation data to improve the accuracy of the model generation [53]. RDCs provide 
orientation restraints, as they give information about the angle of a specific bond vector (in 
our case the backbone HN bond) relative to the external magnetic field, and thus display the 
relative orientation of parts of the molecule that are far apart in the structure. The decision on 
whether the CS-ROSETTA structure generation process has converged is based on how well the 
coordinates of the lowest energy structures agree with one another. In Fig. 5A the all atom 
energy of the generated models is plotted as a function of the Cα RMSD relative to the model 
with the lowest energy. This diagram shows the presence of about 20 structures that have less 
than 2 Å Cα RMSD from the lowest energy model. Indeed, the structure generation process is 
considered successful as it converged to a unique structural model, represented in Fig. 5B by 
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the 10 lowest energy models, all differing less than 1.5 Å Cα RMSD from the lowest energy 
model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: CS-ROSETTA structure generation process. 
A, Plots of CS-ROSETTA all atom energy versus Cα RMSD of CS-ROSETTA models relative to the 
lowest-energy model. B, Superimposition of the ten lowest energy structures generated by CS-
ROSETTA calculation. Α-helices are colored red, β-strands blue and loop regions grey. 
 
 
Fig. 6A shows the lowest energy structure of cAMP-unbound CNBD, which resembles the 
general architecture of the CNBD proteins. It is constituted by an eight-stranded antiparallel β-
roll, containing a short helix (P) and the following loop, collectively called PBC. The β-roll is 
connected at the N-terminus through β-1 to the N-terminal helical bundle, composed of a 
helix-turn-helix motif (helices E’ and A) connected by a short loop, and through β-8 to the C-
terminal helices B and C, also termed “hinge + lid”. A remarkable observation is that the C-helix 
loses its secondary structure character in the central portion and is split into two. The accuracy 
of CS-ROSETTA approach is adversely affected by the presence of long disordered loops [51] 
and this explains the alternative conformations adopted by the C-terminal portion of the C-
helix in the 10 models, compared to the well folded regions like the β-roll (Fig. 5B). By 
analysing 15N and 13C NOESY spectra no interproton distance restraints between residues in 
the N- and C-terminal part of the C-helix, as well as between the B-helix and the C-terminal 
A       B       
N-terminal 
helical bundle 
PBC 
β-Roll 
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portion of the C-helix were found to support the helix-turn-helix conformation. We then 
concluded that the CS-ROSETTA model structure accounts for the low-ordered state adopted 
by the C-terminal half of the C-helix (Fig. 4 and 6A, residues 656-663), but not for its 
orientation. This structural instability is confirmed by the NMR relaxation data. Fig. 6B shows 
steady-state {1H}-15N-NOE experiments for the HN backbone signals of cAMP-unbound CNBD 
residues. Heteronuclear NOEs are sensitive to dynamics processes occurring in the 
subnanosecond time scale. In the absence of rapid internal motions of the protein backbone, 
NOE values are close to 0.8, whereas internal motions decrease NOE values proportionally to 
the increase in the mobility of the residues [54]. As highlighted in the diagram, residues 656-
663 forming the C-teminal half of the C-helix undergo an increase in motions on 
subnanosecond time scale compared to the ones forming the N-terminal portion (residue 647-
655), indicating substantial flexibility of the second half of the C-helix. One caveat of CS-
ROSETTA  is the tendency to generate secondary structures for disordered regions. This caveat 
is due the fact that ROSETTA all-atom energy function favors the formation of intramolecular 
hydrogen bonds [51]. Since 13Cα,13Cβ, 13C’, 15N, 1Hα, and 1HN chemical shifts of residues 656-663 
do not predict helical structure (Fig. 4), and steady-state {1H}-15N-NOEs indicate a flexible 
region, we consider the helical folding of residues 661-663 in the CS-ROSETTA model structure 
to be an artifact (Fig. 6A). Notably, no heteronuclear NOE values were reported for most of the 
residues forming the PBC (609-616) because of the low intensity of their HN signals. NMR 
results suggest that PBC undergoes a conformational exchange phenomenon in absence of the 
ligand, probably shifting between cAMP-unbound and cAMP-bound-like conformations. 
Residues forming PBC show low 1H-1H NOEs content, which confirms their dynamic behaviour. 
This agrees with the CS-ROSETTA models, which fail to converge to a single conformation for 
this region (Fig. 5B). Such a behaviour is in line with the role of the PBC as binding site of the 
cyclic nucleotide, which is prone to undergo conformational changes that are crucial for the 
rearrangement of the entire CNBD.  
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Fig. 6: CS-ROSETTA model structure and NMR relaxation analysis. 
A, Ribbon representation of lowest energy model of cAMP-unbound CNBD. Secondary structure 
elements are labelled. Α-helices are colored red, β-strands 
blue, loop regions grey and the C-terminal flexible potion of C-helix (residues 656-663) yellow. 
B, NMR relaxation analysis of picosecond-to-nanosecond (ps-ns) time-scale motions of cAMP-
unbound CNBD. Steady-state heteronuclear {1H}-15N-NOE values of amide resonances at 298 K, 
18.8 T, plotted against residue number. Secondary structure elements are shown on top of the 
graph: blue arrows indicate β-strand, red cylinders indicate α-helices. The yellow cylinder 
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indicates the flexible part of the C-helix. The spectra for the heteronuclear {1H}-15N-NOE 
calculation were acquired in 150 mM KCl, 20 mM phosphate buffer, pH 7.0, at 298K, in a 600 
MHz spectrometer equipped with a cryoprobe. 
 
 
Superimposition of the cAMP-unbound model structure with the cAMP-bound X-ray structure 
[32] reveals the major rearrangements occurring in the CNBD upon ligand binding (Fig. 7).  
Notably, no significant differences are observed in the β-roll. Panel 7A shows that this fold is 
rather stable and the eight β-strands undergo only minor displacement upon ligand binding (Cα 
RMSD of 0.45 Å between cAMP-unbound and –bound forms). On the contrary, remarkable 
rearrangements are observed in the helical components of the CNBD. In details, we highlighted 
three regions involved in the conformational changes caused by ligand binding: the PBC, the N-
terminal helical bundle and the hinge + lid helices (B and C) (Fig. 7B-D). Fig 7B shows a close 
look of the PBC in the unbound (dark green) and bound (light green) form. It is known that the 
phosphate-sugar moiety of cyclic nucleotide directly interacts with conserved residues of PBC 
(Glu582, Cys584, Arg591 and Thr592 for human HCN2), causing the tightening of this element. The 
rearrangement in the PBC in turn forces the movements of the helical components at the N- 
and C-termini of the β-roll. The PBC tightening directly controls the orientation of the B-helix 
by a conserved Leu-Phe regulatory system. In the absence of cAMP, the position adopted by a 
leucine (585 in HCN2) of the PBC sterically prevents the movement of a phenilalanine (611 in 
HCN2) of the B-helix. cAMP binding forces the leucine in a new conformation, which allows the 
phenilalanine to occupy the position previously adopted by the leucine [30]. Though in the ten 
model structures PBC does not assume a stable conformation (Fig. 5B), for eight of them Leu585 
displays a typical position of a ligand-unbound CNBD (highlighted by the arrow in panel B), 
suggesting that both the tightening of the PBC and the Leu-Phe regulatory system is conserved 
in HCN CNBD. B (hinge) and C (lid) helices, as a single element, move closer to the β-roll cavity. 
As shown by Fig. 7C, the position of the two helices relative to each other is quite similar in the 
cAMP-unbound and bound structures, as the angle between the two helices does not 
remarkably change (48.6° and 54° respectively). The new position adopted by B and C helices is 
stabilized by the interaction of cyclic nucleotide with Arg659 of the C-helix (Fig. 7C). As shown in 
Fig. 7D, the conformational change of the PBC is indirectly forcing the movement of the N-
terminal helical bundle, because, by moving closer to the β-roll, the C-helix displaces the N-
terminal helical bundle. The reorientation of the N-terminal helical bundle is coupled to a 
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restructuration of the loop connecting helices E’ and A, which becomes the F’-helix in the 
cAMP-bound form (Fig. 7D). Though the cAMP-unbound model structure in this region does 
not show secondary structure, heteronuclear NOE values around 0.7 (see Fig. 6B, N terminal 
helical bundle) indicate that the loop between the first and the second helices of the N-
terminal helical bundle has some rigidity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Conformational changes following cyclic nucleotide binding. 
A, Superposition of CS-ROSETTA cAMP-unbound (dark green) and X-ray cAMP-bound (light 
green, Ref. 32) CNBD structures. B, close view of the PBC. The phosphate-sugar moiety of cAMP 
binds E582, C584, R591 and T592 of PBC, inducing its rearrangement. In the absence of cAMP, L585 
of PBC occupies the space that is filled by F611 of the B-helix in the cAMP-bound conformation. 
C, translation movement of the B/C-helix element upon binding of cAMP to PBC. D, close view 
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of the N- and C-helical components of CNBD. The movement of the B/C-helix element forces the 
N-terminal helical bundle  to adopt a new position. 
 
3.4 TRIP8b binding site on CNBD  
Protein-protein interaction changes the chemical environment of the residues that compose 
the protein interfaces and, hence, affects the chemical shifts of the nuclei in that area. Thus, to 
identify the TRIP8b binding site on cAMP-unbound CNBD we used the chemical shift 
perturbation method, which allows to monitor changes of the chemical shifts of a labelled 
protein when the unlabeled interacting partner is titrated in [55]. Backbone amide resonance 
signals were used to monitor the chemical shifts changes and hence [1H, 15N] HSQC spectra 
were collected to follow the perturbation of their chemical shifts. We titrated unlabeled 
miniTRIP8b onto 15N-labeled CNBD. The titration was performed maintaining the 
concentration of CNBD constant and increasing the amount of miniTRIP8b, bringing the 
miniTRIP8b/CNBD molar ratio from 0 to 2. With increasing amounts of miniTRIP8b, the CNBD 
amide resonances lost intensity and a new set of resonances started appearing, indicating that 
the complex is in the slow-exchange regime in the NMR time scale. At a ratio of 2.0 it is clear 
that a single set of amide resonances is observed (Fig. 8). 
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Fig. 8: Chemical shift perturbation of CNBD amide HN signals due to miniTRIP8b interaction. 
A, Superimposition of the [1H, 15N] HSQC of miniTRIP8b-free CNBD (blue) and miniRTIP8b-bound 
CNBD (red, last point of the titration). B and C, Small regions of the superimposed spectra of 
panel A. B, amide HN peaks are labeled in order to illustrate different degree of miniTRIP8b-
induced changes in chemical shift. C, * indicate possibly chemical shift changes for amide HN 
signal of residue Lysine 665. The spectra were acquired in 150 mM KCl, 20 mM phosphate 
buffer, pH 7.0, at 298K, in a 600 MHz spectrometer equipped with a cryoprobe. 
 
 
The slow chemical exchange regime generally corresponds to a complex having a Kd < 10 μM 
[55]. Our NMR data are therefore consistent with the Kd of miniTRIP8b-CNBD complex 
determined using ITC (Fig. 2). Fig. 9A shows the backbone amide chemical shift change for the 
A       
B      
C       
 33 
 
residues of CNBD upon miniTRIP8b interaction. Under the titration conditions, 129 HN cross 
peaks were observable in the CNBD spectrum out of the expected 150. Since miniTRIP8b-CNBD 
complex is prone to precipitate at the high concentrations required for the NMR experiments, 
we were not able to carry out the assignment procedure for the HN resonances of the 
miniTRIP8b-bound state of CNBD. Thus, making the assumption that new resonances 
appearing close to the "free" resonances correspond to their bound state [55, 56], we have 
unambiguously identified pairs of resonances from the two spectra with small chemical shift 
difference (HN) (86 residues) (see example in Fig. 8B). Certain resonances were characterized 
as significantly shifted based on the fact that no other bound state resonances could be 
identified within a HN < 0.1 ppm (29 residues) (see example in Fig. 8B, M647). An additional 
set of resonances (14 residues) were impossible to be unambiguously identified due to the 
presence of multiple unassigned bound resonances in their close vicinity  (see example in Fig. 
8C, K665). These were characterized as ambiguous and were not included in the subsequent 
analysis (identified with a * in Fig. 9A). A threshold of 0.1 ppm was chosen to identify residues 
primarily involved in the binding (Fig. 9A). The majority of residues with a remarkable chemical 
shift change cluster in two regions of the CNBD sequence: the loop between E’ and A α-helices 
of the N-terminal helical bundle (hereafter “N-bundle loop”), and the region which includes 
the C-helix plus the C-terminal peptide of the construct (hereafter “C-helix/stretch”). A 
schematic representation of these two regions, highlighted in red, is shown on the top of Panel 
A of Fig. 9, displaying the secondary structure of the CNBD. Figure 9B shows a ribbon 
representation of the cAMP-unbound CNBD, highlighting the TRIP8b interaction sites on the 
tertiary structure. Notably, both in the cAMP-unbound and bound configurations, the N-
bundle loop and the C-helix/stretch are positioned on the same plane (Fig. 9B, C). 
Furthermore, in the quaternary structure they are not involved in the interaction between 
adjacent subunits and generate a surface that is exposed to the solvent (Fig. 9C). Therefore, we 
can assume that these two elements form a plausible binding region, accessible to the soluble 
TRIP8b protein. This confirms the electrophysiological result showing the effect of TRIP8b even 
in the presence of saturating concentrations of cAMP [26]. Notably, Figure 9A shows that the 
majority of residues forming the β-roll, as well as A and B helices are not significantly affected 
by the miniTRIP8b presence, suggesting that TRIP8b may act by stabilizing the cAMP-unbound 
conformation of the CNBD. Though miniTRIP8b binding does not appear to significantly alter 
the β-roll structure, some residues positioned in flexible regions adjacent to β-strands display a 
 34 
 
remarkable chemical shift change (Fig. 9A), possibly due to local rearrangements of the H-bond 
network upon miniTRIP8b-CNBD binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Titration of miniTRIP8b onto the cAMP-unbound form of CNBD. 
A, Chemical shift changes of the HN backbone resonances in the [1H, 15N] HSQC spectrum of 
CNBD caused by the presence of miniTRIP8b. The maximum value of chemical shift difference 
measured is attributed to all HN cross-peaks showing more than 0.1ppm of chemical shift 
difference for each possible options (remarkable chemical shift change). Residues for which no 
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results are shown correspond to prolines (525, 543, 550, 567, 646) and residues not detected in 
the miniTRIP8b-free form of CNBD (534, 535, 579, 582, 595, 609-613, 615, 618-620, 633, 658, 
660, 662, 666-668). Asterisk indicates ambiguous residues not identified in the miniTRIP8b-
bound state due to the presence of multiple unassigned bound resonances in their close vicinity  
(536, 537, 554, 556, 559, 597, 605, 643, 645, 653, 657, 659, 661, 665). Chemical shift changes 
of the HN resonances are plotted against CNBD residue numbers. At the top of the graph the 
secondary structure of the cAMP-unbound form of CNBD is represented. Cylinders represent α-
helices, while arrows β-strands. The regions formed by residues strongly affected by the 
presence of miniTRIP8b are colored red. B, Ribbon representation of the cAMP-unbound CNBD 
showing in red the N-bundle loop and C-helix/stretch. C, ribbon representation of C-
linker/CNBD (cAMP-bound form) in its tetrameric conformation. The N-bundle loop and C-
helix/stretch are colored red in two of the four subunits. cAMP molecules are blue sticks. 
 
 
3.5 Structural characterization of miniTRIP8b 
The identification of TRIP8b residues involved in the binding to CNBD would be equally 
interesting in order to complete the structural information about CNBD-TRIP8b complex. To 
this end, the assigned [1H, 15N] HSQC spectrum of miniTRIP8b is required and subsequently the 
miniTRIP8b structure to map onto it the CNBD binding site. First of all, [1H, 15N] HSQC spectrum 
of miniTRIP8b was acquired to test the feasibility of the NMR approach for this polypeptide. 
[1H, 15N] HSQC is a relative simple and fast NMR spectrum that can be used as a preliminary 
test to discriminate between folded and unfolded proteins [57]. Fig. 10 shows [1H, 15N] HSQC 
spectra of miniTRIP8b and CNBD (cAMP-unbound and bound state). The comparison of the 
miniTRIP8b spectrum with the CNBD spectra highlights a different degree in folding between 
miniTRIP8b and CNBD. In the case of CNBD most of the HN signals are spread all over the 
spectrum, which is an indication of folding, whereas miniTRIP8b HN signals mainly collapses to 
the center of the spectrum.  
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Fig. 10: Comparative analysis of folding of miniTRIP8b and CNBD. 
Left: [1H, 15N] HSQC spectra of CNBD in the cAMP-unbound (blue) and cAMP-bound (red) form. 
Right: [1H, 15N] HSQC spectrum of miniTRIP8b. All spectra were acquired in 150 mM KCl, 20 mM 
phosphate buffer, pH 7.0, at 298K, in a 600 MHz spectrometer equipped with a cryoprobe. The 
spectra were acquired in 150 mM KCl, 20 mM phosphate buffer, pH 7.0, at 298K, in a 600 MHz 
spectrometer equipped with a cryoprobe. 
 
 
This feature of the miniTRIP8b spectrum is presumably due to intrinsic disorder of this 
polypeptide. Indeed, parallel in silico analysis predicts that the N-terminus is α-helically folded, 
and the C-terminus is unstructured (Fig. 11A). This structural prediction was confirmed by 
Circular Dichroism (CD) spectroscopy by comparing the CD spectrum of miniTRIP8b with the 
CD spectrum of a mutant lacking the C-terminal part (hereafter “microTRIP8b”). As shown in 
Fig. 11B, CD spectrum of miniTRIP8b confirms the presence of the α-helical folding as well as 
the unfolded region, as the typical α-helix shape of a CD spectrum is partially affected by the 
unfolded component. On the contrary, microTRIP8b spectrum is no longer affected by the 
contribution of an unfolded element (Fig. 11B), confirming that the C-terminal portion of 
miniTRIP8b is indeed unfolded. To further validate the location of the α-helical element in the 
microTRIP8b sequence, CD spectra of miniTRIP8b and microTRIP8b were normalized to their 
respective number of residues. Fig. 11C shows the normalized CD spectra, in which the α-
helical content is calculated per residue, leading to directly compare the amount of secondary 
structures in the two polypeptides. As expected, the α-helical content in microTRIP8b 
A       B      
 37 
 
spectrum is increased compared to miniTRIP8b spectrum, proving that the α-helical element is 
indeed located in microTRIP8b. We further characterized the properties of the tertiary 
structure of microTRIP8b, in particular asking whether the predicted α-helices display residue-
residue contacts. To this end, we performed a thermal denaturation curve of microTRIP8b, 
increasing temperature from 5°C to 80°C and measuring CD absorption at 222 nm, wavelength 
that reflects changes in α-helical content. As shown in Fig. 11D the measured values fit a linear 
curve, which is an indication of the absence of allosteric cooperativeness in the unfolding, and 
thus no residue-residue interactions. This feature can be due to either the absence of 
interactions between the predicted α-helices, or the presence of a unique α-helix 
encompassing all of them. To clarify the role of the C-terminal unstructured region of 
miniTRIP8b in the binding to CNBD, we repeated the NMR titration using microTRIP8b. 
Superimposition of the two [1H, 15N] HSQC of CNBD corresponding to the last point of the 
titration (mini or microTRIP8b/CNBD molar ratio of 2) identified no differences in the chemical 
shift perturbation due to miniTRIP8b and microTRIP8b presence (Fig. 12). Therefore, we can 
argue that the portion of miniTRIP8b relevant for the interaction is its N-terminal part 
(microTRIP8b sequence). To unambiguously validate that microTRIP8b includes all the relevant 
residues that are needed for full effect, we tested the effect of this fragment on the full-length 
HCN2 channel. The perfusion of the channel with microTRIP8b gave rise to similar effects to 
the ones obtained with miniTRIP8b (Fig. 13) [26]. Given that microTRIP8b is the relevant 
portion of TRIP8b for antagonizing the cAMP effect, and does not contain a remarkable 
unfolded region, which may explain the low quality data of miniTRIP8b NMR spectra, further 
NMR analysis will be performed on microTRIP8b in order to test its feasibility for the NMR 
methodology. Notably, as for miniTRIP8b, microTRIP8b-CNBD complex is also susceptible to 
precipitation at the high concentrations required for the NMR  experiments. Thus, the 
instability of the complex is not due to the unfolded region of miniTRIP8b, but appears to be 
an intrinsic property of mini/microTRIP8b-CNBD complex. 
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Fig. 11: Structural characterization of mini/microTRIP8b. 
A, Amino acid sequence of human mini/microTRIP8b fragment. Below the sequence a 
schematic cartoon represents the secondary structure consensus prediction calculated by the 
following servers: nnPREDICT, PREDICTPROTEIN, JUFO, CFSSP. Red cylinders represent α-
helices, while black lines represent unstructured regions. B, CD spectra of miniTRIP8b (red line) 
and microTRIP8b (blue line) in the far-UV region. C, CD spectra shown in panel B represented as 
Mean Residue Ellipticity, which reports the molar ellipticity for individual protein residues 
instead of the whole protein molecules. Arrows point the value of far UV-CD measured at 
222nm. D, Analysis of the thermal denaturation of microTRIP8b observed by the far UV-CD at 
222 nm. 
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Fig. 12: mini and microTRIP8b bind to the same residues of CNBD. 
Superimposition of [1H, 15N] HSQC spectra of cAMP-unbound CNBD in the miniTRIP8b-bound 
(blue) and microTRIP8b-bound (red) form. The spectra were acquired in 150 mM KCl, 20 mM 
phosphate buffer, pH 7.0, at 298K, in a 600 MHz spectrometer equipped with a cryoprobe. 
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Fig. 13: mini and microTRIP8b display the same antagonistic action on the cAMP-dependent 
HCN channel voltage gating. 
Left, Normalized G-V relationship for HCN2 channel tail currents in 0, 0.1, or 10 μM cAMP (up) 
and normalized G-V relationship for HCN2 channel tail currents in the presence of 4 μM 
miniTRIP8b plus 0 (V1/2 = -120.5 mV), 0.1 (V1/2 = -119 mV), or 10 μM cAMP (V1/2 = -110.1 mV) 
(down) [26]. Right, Normalized G-V relationship for HCN2 channel tail currents in 0, 0.1, or 10 
μM cAMP (up) and normalized G-V relationship for HCN2 channel tail currents in the presence 
of 4 μM microTRIP8b plus 0 (V1/2 = -121.1 mV), 0.1 (V1/2 = -119.5 mV), or 10 μM cAMP (V1/2 = -
109.5 mV) (down). Measurements and analysis of the data were performed as described in 
reference 26. 
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3.6 Biochemical confirmation of TRIP8b binding site  
Using NMR titration analysis, we identified two regions of the cAMP-unbound form of CNBD 
affected by mini/microTRIP8b addition: the N-bundle loop and the C-helix/stretch (Fig. 9). In 
order to validate our NMR results, we biochemically tested the relevance, for the complex 
formation, of the two elements forming the TRIP8b binding site. First of all, we tested the C-
helix/stretch. Given that HCN1, HCN2 and HCN4 have a total sequence identity in the N-bundle 
loop and the C helix/stretch, we performed a binding assay under native conditions by 
expressing wild-type TRIP8b in Xenopus oocytes, together with truncated HCN1 missing CNBD 
(HCN11-472, canonical nomenclature [31, 32]) or only the C-helix/stretch (HCN11-565). These 
channels constructs were previously shown to be functional [18]. As shown in Fig. 14, the 
truncation of the CNBD (HCN11-472), as well as the removal of the C-helix/stretch (HCN11-565), 
completely abolish TRIP8b binding. Therefore, these findings already demonstrate that the C-
helix/stretch is essential for TRIP8b binding even in the presence of the N-bundle loop. We can 
postulate that the N-bundle loop, though involved in binding, is not sufficient to stabilize the 
interaction with TRIP8b. As the C-helix/stretch is necessary for TRIP8b binding, we analyzed 
further this region in order to restrict the area that is essential for the interaction with TRIP8b. 
To this end, we have used an in vitro assay co-expressing miniTRIP8b with CNBD mutants 
lacking the C-helix/stretch, or truncated at different points of the C-helix/stretch. In particular, 
the eighteen residues forming the C-helix were divided in three groups, as well as the nine 
residues forming the stretch after the C-helix. The complex formation was tested by means of 
a strep-tactin affinity purification. In agreement with our previous finding (Fig. 14), the removal 
of the C-helix/stretch impairs the complex formation (Fig. 15) confirming its importance in the 
interaction with TRIP8b. The inability to bind miniTRIP8b is specifically due to the lack of the C-
helix/stretch, rather than a problem associated to a general loss of structure, since the mutant 
protein retains the regular fold as the wild-type. (Fig. 16). The progressive increment of the C-
helix does not rescues the binding with miniTRIP8b and even its full presence confers only a 
minimal binding under these conditions (Fig. 15). Unexpectedly, the interaction with 
miniTRIP8b is fully restored with the CNBD mutant containing the first three residues of the 
stretch following the C-helix (GKK, residues 664-666) (Fig. 15). This finding clearly underlines 
the relevance, on the complex formation, of the small unstructured stretch following the C-
helix and in particular the GKK sequence. This finding is in agreement with the NMR titration, 
which shows that chemical shift of HN backbone signal of G664, the first residue belonging to 
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the nine of the stretch, is strongly affected by mini/microTRIP8b addition (Fig. 9A). On the 
entire sequence GKKNSILLH (residues 664-672) of the stretch, the last three residues are not 
affected by mini/microTRIP8b presence (Fig. 9A), therefore they are not involved in the binding 
with TRIP8b. For the remaining six residues (GKKNSI), the biochemical assay highlights the 
relevance of the GKK sequence for the binding (Fig. 15), but does not exclude the contribution 
of the NSI tripeptide sequence. Given the fact that the chemical shift of HN signal of I669 is 
strongly affected by the presence of mini/microTRIP8b (Fig. 9A), a conclusive study of the 
relative contribution for the binding of the residues forming GKKNSI sequence will require 
further site-directed mutational analysis tested by means of a quantitative approach for the 
study of protein-protein interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: Contribution on the C-helix and the small following fragment for the binding to TRIP8b. 
The interaction of HCN1, its deletion mutants, and the chimera membrane proteins with wild 
type TRIP8b was assessed by co-immunuprecipitation from Xenopus oocyte extracts. In the 
icons on the right are represented HCN1 channel domains and amino acid positions (GFP in 
green; transmembrane domain in black; C-linker in orange; CNBD in purple; small unstructured 
fragment immediately after the Lid α-helix in light green, C-terminal SNL tripeptide in red, N 
and C-terminal regions in gray). Left and middle columns shows Western blots using 
respectively anti-GFP and anti-TRIP8b antibody as input signals. Right column shows the 
amount of target proteins co-immunoprecipitated with anti-TRIP8b antibody (Western blot 
using anti-GFP antibody). Individual bands were cut from the intact gel pictures and aligned to 
allow direct comparison of intensities for wild-type and mutants, having different molecular 
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weight. It is to note that exposure times are directly comparable down each column, but not 
along each row. ). Results obtained  by Dr. Bina Santoro using the procedure described in 
reference 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: Contribution of the C-helix/stretch on the binding to TRIP8b. 
Bacterial lysates from cells co-expressing Strep-miniTRIP8b (Blue arrowhead) and CNBD wild-
type and mutants (Green arrowhead) were loaded onto a Strep-tactin affinity column for Strep-
tag purification. Samples corresponding to the eluate fractions were analyzed by Coomassie 
Blue staining following SDS-PAGE separation. Numbers indicate molecular weight markers 
(kDa), loaded in the first lane. The C-helix/stretch was removed, or truncated introducing a stop 
codon after the following residues: Y645 (1), A651 (2), I657 (3), I663 (4), K666 (5), I669 (6). Y645 and I663 
correspond respectively  to the first and last aminoacid of the C α-helix.  
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Fig. 16: Structural Comparison of CNBD wild-type and ΔC-helix/stretch. 
1H-monodimensional spectra of CNBD wild-type (up) and mutant ΔC-helix/stretch (down). 
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4 DISCUSSION AND FUTURE PROSPECTS 
 
In this study we propose a molecular mechanism, based on NMR structural data, accounting 
for the mutual allosteric antagonism of cAMP and TRIP8b, which regulates HCN channel 
activity. Recently, our electrophysiological results showed that the mutual antagonistic effects 
of cAMP and TRIP8b can be explained by an allosteric mechanism [26]. Thus, structural 
information on CNBD accounting for the transition due to cAMP binding, as well as the 
identification of the TRIP8b binding site on CNBD are crucial to validate the allosteric model.   
 
 
4.1 cAMP-induced structural rearrangements in HCN CNBD 
We show here, for the first time, a structural model of the human HCN2 CNBD in the cAMP-
unbound form generated by CS-ROSETTA, which now allows us to identify all conformational 
transitions occurring upon ligand binding. By the comparison of the unbound and bound 
structures we highlighted that HCN CNBD behaves in line with the universally conserved 
mechanism of CNBDs [30]. In our opinion, this mechanism justifies the inclusion of the last two 
helices of the C-linker among the N-terminal helical bundle, which we recommend for all 
future descriptions of the HCN CNBD, as well as CNBD-containing channel family. The cAMP-
unbound structure clearly highlights that the N-terminal helical bundle plays a key role in the 
cAMP regulation of channel opening. Given that the N-terminal helical bundle undergoes a 
large reorientation upon cAMP binding and connects the CNBD with the C-linker, we argue 
that this is the element by which CNBD affects the rearrangement of the C-linker, though the 
precise movements of the C-linker, as well as how they affect the pore module remain unclear. 
Moreover, both CS-ROSETTA structure and dynamics data provide direct structural evidence 
that the second half of the C-helix is flexible and less ordered in the absence of cAMP. Thus, 
the cAMP-unbound structure confirms the stabilization of the F’ and C-helix upon cAMP 
binding, that had been indirectly suggested using transition metal ion FRET [58, 59]. A previous 
cAMP-free CNBD X-ray structure, containing bromide ions in contact to the PBC, shows an 
overall conformation very similar to the cAMP-bound form, because bromide-induced PBC 
rearrangements propagate to the helical components, forcing CNBD to a cAMP-bound like 
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conformation [58]. Notably, in this structure the C-terminal half of C-helix is not resolved, 
indicating that in the absence of ligand this region is less ordered and indeed cAMP binding 
directly promotes structural stabilization of the C-helix. For this reason, we suggest that the C-
helix stabilization following ligand interaction constitutes a mechanism of regulation of cAMP-
affinity among the CNBD-containing proteins. Arginine 659, the key residue for the binding to 
cAMP, localizes in the flexible region of the C-helix. Thus, in HCN the capture of the ligand onto 
the CNBD requires the stabilization of a dynamic element, a process that can affect the affinity 
of the protein for cyclic nucleotides. This is in agreement with the fact that the affinity of HCN 
CNBD for cAMP is about 15 times lower than MloK1 CNBD, which presents a rigid C-helix in the 
cAMP-unbound form [60]. Evolutionarily linked to HCN channels, the voltage-dependent 
potassium channel (KCNH) family shares a cyclic nucleotide binding homologous domain 
(CNBHD), in which the C-helix is partially unstructured [33, 61, 62]. Although KCNH have lost 
the cyclic nucleotide regulation, and therefore their C-helices have a different function, the 
absence of a defined secondary structure in the second half of the C-helix appears to be a 
conserved feature of the eukaryote family of CNBD-containing channels. 
 
 
4.2 The binding site of TRIP8b on CNBD 
In this work we have identified the TRIP8b binding site on HCN CNBD. Our results definitely 
prove that TRIP8b and cAMP do not compete for the same binding region and provides a 
strong structural support to the allosteric antagonistic model recently proposed [26]. The NMR 
titration identified two regions of CNBD that are equally affected upon mini/microTRIP8b 
addition: the N-bundle loop and the C-helix/stretch. Using deletion mutants, both in the full 
length HCN channel and in the isolated CNBD protein, we provided biochemical evidence that 
the C-helix/stretch is necessary for the interaction of CNBD with TRIP8b. Moreover, we 
highlighted the importance of the unstructured stretch following the C-helix for the binding 
event. In particular, we showed that the GKK sequence of the stretch is necessary for complex 
formation. Interestingly, microTRIP8b includes the acidic stretch of residues (EEEFE) that have 
been shown to be essential for the binding [26], suggesting the involvement of an electrostatic 
interaction between CNBD and TRIP8b. The relevance of the stretch sequence following the C-
helix in the regulation of channel activity appears to be evolutionarily conserved in the 
eukaryote family of CNBD-containing channels, since KCNH channels show an intrinsic 
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mechanism of regulation that involved the stretch following the C-helix [33, 61, 62]. Though 
our biochemical analysis does not attribute a direct role to the N-bundle loop in the complex 
formation, the NMR titration clearly showed that this sequence is strongly affected by 
mini/microTRIP8b as much as the C-helix/stretch. Moreover, the N-bundle loop and the C-
helix/stretch are in close proximity in the CNBD tertiary structure (both in the cAMP-unbound 
and bound forms) and in the quaternary structure are exposed to the solvent. These data 
strongly suggest that the N-bundle loop and the C-helix/stretch generate the CNBD binding 
area of TRIP8b. This new structural information will allow a full understanding of this 
important molecular complex, leading to a better understaning of the molecular bases of 
neurological disorders originated by CNBD mutations and possibly the design of drugs able to 
modulate HCN channel-mediated cognitive processes.  
 
 
4.3 Molecular model of the binary cAMP-TRIP8b regulatory system of HCN 
channels  
It is known that the cAMP-induced conformational changes in the CNBD are determinant in 
shifting the equilibrium of the closed-open transition of the channel towards the open state 
[18, 20, 59]. Here, we demonstrate that, both the N-bundle loop, which is part of the N-
terminal helical bundle, and the C-helix constitute the elements of CNBD that undergo the 
largest structural rearrangement in the cAMP-unbound/bound transition of CNBD. Thus, we 
can argue that TRIP8b allosterically antagonizes the effect of cAMP by blocking both the N-
terminal helical bundle and the C-helix in the conformation they adopt in the cAMP-unbound 
state. This molecular model of interaction between TRIP8b and CNBD can easily explain the 
mutual antagonistic effect of TRIP8b and cAMP that we proposed [26]. The stabilization of the 
CNBD in its cAMP-unbound conformation shifts the closed-open transition of the channel 
toward the closed one: exactly the opposite versus of the effect caused by the cyclic 
nucleotide. In our model, the binding of TRIP8b to the CNBD does not block the entry of the 
cyclic nucleotide in the cavity of the β-roll, but interacts with the C-helix, preventing its 
movement. Thus, CNBD bound to TRIP8b has a decrease in affinity for cAMP, as recently 
estimated from electrophysiological results [26]. Moreover, here we showed that N-terminal 
helical bundle is a crucial element for the regulation of channel opening. Therefore, in the 
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proposed model TRIP8b causes the stabilization of the closed state of the channel blocking the 
C-linker in its resting conformation via the stabilization of the cAMP-unbound conformation of 
the N-terminal helical bundle. Since HCN channels are involved in a wide number of cognitive 
processes, understanding the molecular mechanism of regulation of this family of channels is 
critically important. Thus, our work offers an important contribute to the understanding of the 
binary cAMP-TRIP8b regulatory system of HCN channels, a powerful topic as it pertains to the 
physiological processes and diseases associated with dysfunction in Ih conductance in neurons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
REFERENCES 
 
1. Robinson R. B., Siegelbaum S. A., “ hyperpolarization-activated cation currents: From 
Molecules to Physiological Function”, Annu. Rev. Physiol., vol. 65, pp. 453-480, 2003; 
2. Brown H.F., DiFrancesco D., Noble S.J., “How does adrenaline accelerate the heart?”, Nature, 
vol 280, pp. 235–36, 1979; 
3. Halliwell J.V., Adams P.R., “Voltage-clamp analysis of muscarinic excitation in hippocampal 
neurons”, Brain Res., vol. 250, pp. 71–92, 1982; 
4. Yanagihara K., Irisawa H., “Inward current activated during hyperpolarization in the rabbit 
sinoatrial node cell”, Pflugers Arch., vol. 385, pp. 11–19, 1980; 
5. Biel M., Wahl-Schott C., Michalakis S., Zong X., “Hyperpolarization-Activated Cation Channels: 
From Genes to Function”, Physiol Rev, vol. 89, pp. 847–885, 2009; 
6. Nolan M.F., Dudman J.T., Dodson P.D., Santoro B., “HCN1 channels control resting and active 
integrative properties of stellate cells from layer II of the entorhinal cortex”, 
J Neurosci, vol. 27, pp. 12440–12451, 2007; 
7. Magee J.C., “Dendritic lh normalizes temporal summation in hippocampal CA1 neurons”, Nat. 
Neurosci., vol. 2, pp. 508–14, 1999; 
8. teriade M., McSCormick D.A, Sejnowski T.J., “Thalamocortical oscillations in the sleeping and 
aroused brain” Science, vol. 262, pp. 679–685, 1993; 
9. DiFrancesco D., “Pacemaker mechanisms in cardiac tissue”, Annu. Rev. Physiol., vol. 55, pp. 
455–72, 1993; 
10. Luthi A., McCormick D.A., “H-current: properties of a neuronal and network pacemaker”, 
Neuron, vol. 21, pp. 9–12, 1998; 
11. Maccaferri G., McBain C.J., “The hyperpolarization-activated current (Ih) and its contribution to 
pacemaker activity in rat CA1 hippocampal stratum oriens-alveus interneurons”, J. Physiol., vol. 
497(Pt.1), pp. 119–30, 1996; 
12. Ludwig A., Zong X., Jeglitsch M., Hofmann F., Biel M., “A family of hyperpolarization-activated 
mammalian cation channels” Nature, vol. 393, pp. 587–91, 1998; 
13. Santoro B., Tibbs G.R., “The HCN gene family: molecular basis of the hyperpolarization-
activated pacemaker channels”, Ann. NY Acad. Sci., vol.  868, pp. 741–64, 1999; 
14. Altomare C., Terragni B., Brioschi C., Milanesi R., Pagliuca C., Viscomi C., Moroni A., Baruscotti 
M., DiFrancesco D., “Heteromeric HCN1-HCN4 channels: a comparison with native pacemaker 
channels from the rabbit sinoatrial node”, J Physiol, vol. 549, pp. 347–359, 2003; 
 50 
 
15. Santoro B., Chen S., Luthi A., Pavlidis P., Shumyatsky G.P., et al. “Molecular and functional 
heterogeneity of hyperpolarization-activated pacemaker channels in the mouse CNS”, J. 
Neurosci., Vol. 20, pp. 5264–75, 2000; 
16. Moosmang S., Stieber J., Zong X., Biel M., Hofmann F., Ludwig A., “Cellular expression and 
functional characterization of four hyperpolarization-activated pacemaker channels in cardiac 
and neuronal tissues”, Eur. J. Biochem.,  vol. 268, pp. 1646–52, 2001; 
17. Shi W., Wymore R., Yu H., Wu J., Wymore R.T., et al. “Distribution and prevalence of 
hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues”, Circ. 
Res., vol.  85, pp. E1–6, 1999; 
18. Wainger B.J., DeGennaro M., Santoro B., Siegelbaum S.A., Tibbs G.R, “Molecular mechanism of 
cAMP modulation of HCN pacemaker channels”, Nature, vol. 411(6839), pp. 805-809, 2001; 
19. Craven K.B, Zagotta W.N., “CNG and HCN channels: Two Peas, One Pod”, Annu. Rev. Physiol., 
vol. 68, pp. 375–401, 2006; 
20. Chen S., Wang J., Zhou L., George M.S,Siegelbaum S.A., “Voltage Sensor Movement and cAMP 
Binding Allosterically Regulate an Inherently Voltage-independent Closed−Open Transition in 
HCN Channels”, J. Gen. Physiol. vol. 129 (2), pp. 175–188, 2007; 
21. Santoro B., Piskorowski R.A., Pian P., Hu L., Liu H., Siegelbaum S.A., “TRIP8b splice variants 
form a family of auxiliary subunits that regulate gating and trafficking of HCN channels in the 
brain”, Neuron, vol. 62, pp. 802-813, 2009; 
22. Zolles G., Wenzel D., Bildl W., Schulte U., Hofmann A., Muller C.S., Thumfart J.O., Vlachos A., 
Deller T., Pfeifer A., Fleischmann B.K., Roeper J., Fakler B., Klocker N.,  “Association with the 
auxiliary subunit PEX5R/Trip8b controls responsiveness of HCN channels to cAMP and 
adrenergic stimulation”, Neuron, vol.  62, pp. 814-825, 2009; 
23. Lewis A.L., Schwartz E., Chan C.S., Noam Y., Shin M., Wadman W.J., Surmeier D.J., Baram T.Z., 
Macdonald R.L., Chetkovich D.M., “alternatively spliced isoforms of TRIP8b differentially 
control h channel trafficking and function”, J. Neurosci., vol.  29(19), pp. 6250–6265, 2009; 
24. Bankston J.R., Camp S.S., DiMaio F., Lewis A.S., Chetkovich D.M., Zagotta W.N., “Structure and 
stoichiometry of an accessory subunit TRIP8b interaction with hyperpolarization activated 
cyclic nucleotide-gated channels”, PNAS, vol. 109(20), pp. 7899-904, 2012; 
25. Santoro B., Hu L., Liu H., Saponaro A., Pian P., Piskorowski R.A., Moroni A., Siegelbaum S.A., 
“TRIP8b Regulates HCN1 Channel Trafficking and Gating through Two Distinct C-Terminal 
Interaction Sites”, J. Neurosci., vol. 31(11), pp. 4074-86, 2011; 
26. Hu L., Santoro B., Saponaro A., Liu H., Moroni A., Siegelbaum S.A., “binding of the auxiliary 
subunit TRIP8b to HCN channels shifts  the mode of action of cAMP”,  J. Gen. Physiol, vol. 
142(6), pp. 599-612, 2013; 
27. Han Y., Noam Y., Lewis A.S., Gallagher J.J., Wadman W.J., Baram T.Z., Chetkovich D.M., 
“trafficking and gating of hyperpolarization-activated cyclic nucleotide-gated channels are 
 51 
 
regulated by interaction with tetratricopeptide repeat-containing rab8b-interacting protein 
(TRIP8b) and cyclic AMP at distinct sites”, J Biol Chem., vol. 286(23), pp. 20823–20834, 2011; 
28. Schünke S., Stoldt M., Lecher J., Kaupp U.B., Willbold D., “Structural insights into 
conformational changes of a cyclic nucleotide-binding domain in solution from Mesorhizobium 
loti K1 channel”, PNAS, vol. 108(15), pp. 6121–6126, 2011; 
29. Wu J., Brown S.,Xuong N.,. Taylor S.S., “RIα subunit of PKA: A cAMP-free structure reveals a 
hydrophobic capping mechanism for docking cAMP into Site B”, Structure, vol. 12, pp. 1057–
1065, 2004; 
30. Rehmann H., Wittinghofer A.,  Bos J.L., “Capturing cyclic nucleotides in action: snapshots from 
crystallographic studies”, Nature Reviews, vol.  8(1), pp. 63-73, 2007; 
31. Lolicato M., Nardini M., Gazzarrini S., Möller S., Bertinetti D., Herberg F.W., Bolognesi M., 
Martin H., Fasolini M., Bertrand J.A., Arrigoni A., Thiel G, Moroni A., “tetramerization dynamics 
of C-terminal domain underlies isoform-specific cAMP gating in hyperpolarization-activated 
cyclic nucleotide-gated channels”, J BiolChem., vol.  286(52), pp. 44811-20, 2012; 
32. Zagotta W.N., Olivier N.B., Black K.D., Young E.C., Olson R., Gouaux E., “Structural basis for 
modulation and agonist specificity of HCN pacemaker channels”, Nature, vol. 425, pp. 200-205, 
2003; 
33. Marques-Carvalho M.J., Sahoo N., Muskett F.W., Vieira-Pires R.S., Gabant G., Cadene M., 
Schonherr R., Morais-Cabral J.H., “Structural, biochemical, and functional characterization of 
the cyclic nucleotide binding homology domain from the mouse eag1 potassium channel”, 
J.Mol.Biol., vol. 423, pp.34-46, 2012; 
34. Titus D. J., Furones C., Kang Y.,  Atkins C. M., “age-dependent alterations in cAMP signaling 
contribute to synaptic plasticity deficits following traumatic brain injury”, Neuroscience, vol. 
231, pp. 182–194, 2013; 
35. Ramos B., Stark D., Verduzco L., van Dyck C.H., Arnsten A.F.T., “Alpha-2A-Adrenoceptor 
stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP 
signaling in aging animals”,  Learn. Mem., vol. 13, pp. 770–776, 2006; 
36. Klamer D., Palsson E., Fejgin K., Zhang J., Engel J.A., Svensson L., “Activation of a nitric-oxide-
sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally 
associated with deficits in prepulse inhibition”, Psychopharmacology (Berl), vol. 179, pp. 479–
488, 2005; 
37. Nolan M.F., Malleret G.I., Dudman J.T., Buhl D.L., Santoro B., Gibbs E., Vronskaya S., Buzsàki G., 
Siegelbaum S.A., Kandel E.R., Morozov A., “A Behavioral Role for Dendritic Integration: HCN1 
Channels Constrain Spatial Memory and Plasticity at Inputs to Distal Dendrites of CA1 
Pyramidal Neurons”, Cell, vol. 119, pp. 719–732, 2004; 
38. Noam Y., Bernard C., Baram T.Z., “Towards an integrated view of HCN channel role in 
epilepsy”, Current Opinion in Neurobiology, vol. 21, pp. 873–879, 2011; 
 52 
 
39. Paspalas C.D., Wang M, Arnsten A.F.T., “Constellation of HCN channels and cAMP regulating 
proteins in dendritic spines of the primate prefrontal cortex: potential substrate for working 
memory deficits in Schizophrenia”, Cerebral Cortex, vol. 23, pp. 1643–1654, 2013; 
40. Saito Y., Inoue T., Zhu G., Kimura N., Okada M., Nishimura M., Kimura N., Murayama S., Kaneko 
S., Shigemoto R., Imoto K.,  Suzuki T., “Hyperpolarization-activated cyclic nucleotide gated 
channels: a potential molecular link between epileptic seizures and Aβ generation in 
Alzheimer’s disease”, Molecular Neurodegeneration, vol. 7, pp. 50, 2012; 
41. Wang M., Ramos B.P., Paspalas C.D, Shu Y., Simen A., Duque A., Vijayraghavan S., Brennan A., 
Dudley A., Nou E., Mazer J.A., McCormick D.A.,  Arnsten A.F.T.,  “α2A-Adrenoceptors 
strengthen working memory networks by inhibiting cAMP-HCN channel signaling in Prefrontal 
Cortex”, Cell, vol. 129, pp. 397–410, 2007; 
42. Lewis A.S., Vaidya S.P., Blaiss C.A., Liu Z., Stoub T.R., Brager D.H., Chen X., Bender R.A., Estep 
C.M., Popov A.B., Kang C.E., Van Veldhoven P.P., Bayliss D.A., Nicholson D.A., Powell 
C.M., Johnston D., Chetkovich D.M., “Deletion of the hyperpolarization-
activated cyclic nucleotide gated channel auxiliary subunit TRIP8b impairs hippocampal Ih 
localization and function and promotes antidepressant behavior in mice”, J. Neurosci., vol. 
31(20), pp. 7424-40, 2011; 
43. Brager D.H., Lewis A.S., Chetkovich D.M., Johnston D., “Short- and long-term plasticity in CA1 
neurons from mice lacking h-channel auxiliary subunit TRIP8b”, J. Neurophysiol., vol. 110(10), 
pp. 2350-7, 2013; 
44. Marcelin B., Liu Z., Chen Y., Lewis A.S., Becker A., McClelland S., Chetkovich D.M., Migliore 
M., BaramT.Z., EsclapezM., BernardC.,“Dorsoventral differences in intrinsic properties in devel
oping CA1 pyramidal cells”, J. Neurosci., vol.  32(11), pp. 3736-47. 2012; 
45. Heys J.G., Hasselmo M.E., “Neuromodulation of I(h) in layer II medial entorhinal cortex stellate 
cells: a voltage-clamp study”, J. Neurosci., vol. 32(26), pp. 9066-72, 2012; 
46. Chow S.S., Van Petegem F., Accili E.A., “Energetics of cyclic AMP binding to HCN channel C 
terminus reveal negative cooperativity”, J. Biol Chem.,  vol. 287(1), pp. 600-6, 2011; 
47. Wider G., “Structure determination of biological macromolecules in solution using nuclear 
magnetic resonance spectroscopy”, Biotechniques., vol. 29(6), pp. 1278-82, 2000; 
48. Wishart D.S., Sykes B.D., Richards F.M.., “Relationship between nuclear magnetic resonance 
chemical shift and protein secondary structure”,  J. Mol. Biol., vol. 222, pp. 311–333, 1991; 
49. Wagner G., Pardi A., Wuthrich K., “Hydrogen-bond length and H-1-NMR chemical-shifts in 
proteins”,  J. Am. Chem. Soc., vol. 105, pp. 5948–5949, 1983; 
50. Case D.A., “Calibration of ring-current effects in proteins and nucleic acids.”,  J. Biomol. NMR, 
vol. 6, pp. 341–346, 1995; 
51. Shen Y., Lange O., Delaglio F., Rossi P., Aramini J.M., Liu G., Eletsky A., Wu Y., Singarapu 
K.K., Lemak A., Ignatchenko A., Arrowsmith C.H., Szyperski T., Montelione G.T., Baker D., Bax 
 53 
 
A., “Consistent blind protein structure generation from NMR chemical shift data”, PNAS, vol. 
105(12), pp. 4685-90, 2009; 
52. Lange O.F, Baker D., “Resolution-adapted recombination of structural features significantly 
improves sampling in restraint-guided structure calculation”, Proteins, vol. 80(3), pp. 884-95, 
2012; 
53. Raman S., Lange O.F., Rossi P., Tyka M., Wang X., Aramini J., Liu G., Ramelot T.A., Eletsky 
A., Szyperski T., Kennedy M.A., Prestegard J., Montelione G.T., Baker D., 
“NMR structure determination for larger proteins using backbone-only data”, Science, vol. 
327(5968), pp. 1014-8, 2010; 
54. Kay L.E., Torchia D.A., Bax A., “Backbone dynamics of proteins as studied by 15N inverse 
detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease”, 
Biochemistry, vol. 28(23), pp. 8972-9, 1989; 
55. Zuiderweg E.R., “Mapping protein-protein interactions in solution by NMR spectroscopy”, 
Biochemistry, vol. 41(1), pp. 1-7, 2002;  
56. Williamson R.A., Carr M.D., Frenkiel T.A., Feeney J., Freedman R.B., “Mapping the binding site 
for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of 
metalloproteinases-2 by NMR chemical shift perturbation”, Biochemistry, vol. 36, pp. 13882-
13889, 1997; 
57. Balbach J., Forge V., Lau W.S., van Nuland N.A., Brew K., Dobson C.M., “protein folding 
monitored at individual residues during a two-dimensional NMR experiment”, Science, vol. 
274(5290), pp. 1161-1163, 1996; 
58. Taraska J.W., Puljung M.C., Olivier N.B., Flynn G.E., Zagotta W.N., “Mapping the structure and 
conformational movements of proteins with transition metal ion FRET”, Nat. Methods, vol. 
6(7), pp. 532-7, 2009; 
59. Puljung M.C., Zagotta W.N., “A secondary structural transition in the C-helix promotes gating 
of cyclic nucleotide-regulated ion channels”, J. Biol. Chem., vol. 288(18), pp. 12944-56, 2013; 
60. Cukkemane A., Grüter B., Novak K., Gensch T., Bönigk W., Gerharz T., Kaupp U.B., Seifert R., 
“Subunits act independently in a cyclic nucleotide-activated K+ channel”, EMBO Rep.,  vol. 8(8), 
pp. 749-55, 2007; 
61. Brelidze T.I., Carlson A.E., Sankaran B., Zagotta W.N., “Structure of the carboxy-terminal region of 
a KCNH channel”, Nature, vol. 481(7382), pp. 530-3, 2012; 
62. Brelidze T.I., Gianulis E.C., DiMaio F., Trudeau M.C., Zagotta W.N., “Structure of the C-terminal 
region of an ERG channel and functional implications”, PNAS, vol. 110(28), pp. 11648-53, 2013; 
63. Wiseman T., Williston S., Brandts J.F., Lin L.N., “Rapid measurement of binding constants and 
heats of binding using a new titration calorimeter”, Anal. Biochem.,  vol. 179(1), pp. 131-7, 
1989; 
 54 
 
64. Ferentz A.E., Wagner G., “NMR spectroscopy: a multifaceted approach to macromolecular 
structure”,  Q. Rev. Biophys, vol. 33(1), pp. 29-65 2000; 
65. Neuhaus D., Vanmierlo C. P. M., “Measurement of heteronuclear NOE enhancements in 
biological macromolecules: a convenient pulse sequence for use with aqueous solutions”, J. 
Magn. Reson., vol. 100, pp. 221–228, 1992; 
66. Vranken W.F., Boucher W., Stevens T.J., Fogh R.H., Pajon A., Llinas M., Ulrich E.L., Markley J.L., 
Ionides J., Laue E.D., “The CCPN data model for NMR spectroscopy: development of a software 
pipeline”, Proteins, vol. 59(4), pp. 687-96, 2005; 
67. R. Keller, “The Computer Aided Resonance Assignment Tutorial”, CANTINA Verlag, 2004; 
68. Garrett D. S., Seok Y. J., Peterkofsky A., Clore G. M., Gronenborn A. M., “Identification by NMR 
of the binding surface for the histidine-containing phosphocarrier protein HPr on the N-
terminal domain of enzyme I of the Escherichia coli phosphotransferase system”, Biochemistry, 
vol. 36, pp. 4393-4398, 1997. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
 
 
 
 
PART II 
Cellular/Molecular
TRIP8b Regulates HCN1 Channel Trafficking and Gating
through Two Distinct C-Terminal Interaction Sites
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Hyperpolarization-activated cyclic nucleotide-regulated (HCN) channels in the brain associate with their auxiliary subunit TRIP8b (also
known as PEX5R), a cytoplasmic protein expressed as a family of alternatively spliced isoforms. Recent in vitro and in vivo studies have
shown that association of TRIP8bwithHCN subunits both inhibits channel opening and alters channelmembrane trafficking, with some
splice variants increasing and others decreasing channel surface expression. Here, we address the structural bases of the regulatory
interactions betweenmouse TRIP8b andHCN1.We find that HCN1 and TRIP8b interact at two distinct sites: an upstream site where the
C-linker/cyclic nucleotide-binding domain of HCN1 interacts with an 80 aa domain in the conserved central core of TRIP8b; and a
downstream site where the C-terminal SNL (Ser-Asn-Leu) tripeptide of the channel interacts with the tetratricopeptide repeat domain of
TRIP8b. These two interaction sites play distinct functional roles in the effects of TRIP8b on HCN1 trafficking and gating. Binding at the
upstream site is both necessary and sufficient for TRIP8b to inhibit channel opening. It is also sufficient tomediate the trafficking effects
of those TRIP8b isoforms that downregulate channel surface expression, in combination with the trafficking motifs present in the
N-terminal regionofTRIP8b. In contrast, binding at thedownstream interaction site serves to stabilize theC-terminal domainofTRIP8b,
allowing for optimal interaction between HCN1 and TRIP8b as well as for proper assembly of the molecular complexes that mediate the
effects of TRIP8b on HCN1 channel trafficking.
Introduction
The function and expression of many ion channels are regulated
by subunits that do not contribute to the channel pore, but stably
associate with pore-forming subunits. Recent studies provide
strong evidence that the cytoplasmic tetratricopeptide repeat-
containing Rab8b interacting protein TRIP8b (also known as
PEX5R) is a regulatory subunit of the hyperpolarization-
activated cyclic nucleotide-regulated (HCN) channels in the
brain (Santoro et al., 2004, 2009: Zolles et al., 2009; Lewis et al.,
2009). TRIP8b undergoes extensive alternative splicing at its N
terminus. All splice forms inhibit HCN channel activation by
antagonizing the ability of cyclic nucleotides to facilitate channel
opening (Santoro et al., 2009; Zolles et al., 2009). In contrast,
different splice variants produce diverse effects on HCN channel
membrane trafficking (Lewis et al., 2009; Santoro et al., 2009).
TRIP8b isoforms contain a large constant domain (exons 5–16)
preceded by a variable region at which exons 1a or 1b combine with
subsets of exons 2–4. The C-terminal half of TRIP8b (exons 9–16)
comprises an 350 aa tetratricopeptide repeat (TPR) protein-
bindingdomainwith57%identity to thePEX5peroxisomereceptor
TPRdomain. In contrast, TRIP8b and PEX5 have no sequence sim-
ilarity in their initial N-terminal250 aa, consistent with their di-
vergent functions. TRIP8b(1a-4) andTRIP8b(1a-2–4) (the naming
convention lists the alternatively spliced exons) cause a fourfold to
sixfold increase in surface expression ofHCN1 channelswhen coex-
pressed in Xenopus oocytes. In contrast, TRIP8b(1a) decreases
HCN1 surface expression by 10-fold, and both TRIP8b(1b-2) and
TRIP8b(1b-2–4) virtually eliminate channel surface expression
(50-fold decrease) (Santoro et al., 2009). The decrease in surface
expression requires N-terminal consensus sites for adaptor protein
(AP) complex binding in exons 2 and 5 that likely promote clathrin-
dependent channel endocytosis (Santoro et al., 2004, 2009; Popova
et al., 2008; Petrenko et al., 2010).
Our laboratory initially found that the TRIP8b TPR domain
interacts with the SNL (Ser-Asn-Leu) tripeptide at the C termi-
nus of HCN1,2, and4 (Santoro et al., 2004), which we refer
to as the “downstream” interaction site. More recently, Lewis et
al. (2009) identified a second “upstream” interaction site atwhich
theC-linker region and contiguous cyclic nucleotide-binding do-
main (CNBD) of HCN1 binds to an internal sequence in the
conserved middle region of TRIP8b. Here we map in finer detail
the boundaries of the two physical interaction sites between
HCN1 and TRIP8b, and define the roles of these interactions in
protein binding, channel trafficking, and channel gating.We find
that the upstream interaction site is necessary and sufficient to
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enable TRIP8b to downregulate channel surface expression and
inhibit channel activation. In contrast, the downstream interac-
tion site stabilizes theC-terminal domain of TRIP8b, allowing for
optimal interaction between HCN1 and TRIP8b. In addition, an
intact TPR domain is required for the effect of certain TRIP8b
splice forms to enhance HCN1 channel surface expression. Fi-
nally, we identify an 80 aa fragment within the core of TRIP8b
that is sufficient to inhibit the action of cyclic nucleotides to
facilitate HCN1 channel opening.
Materials andMethods
Plasmids and heterologous expression in Xenopus oocytes. All constructs
were cloned in pGHE or pGH19 vectors, linearized, and transcribed into
cRNA using T7 polymerase (MessageMachine, Ambion) as described
previously (Santoro et al., 2004, 2009). cDNA clones encoding HCN1
and TRIP8b both corresponded to the Mus musculus sequence. Site-
directed mutagenesis was performed using either the QuickChange Mu-
tagenesis kit (Stratagene) or PCR cloning. The enhanced green
fluorescent protein (GFP) tag (derived from vector pEGFP-C1, Clon-
tech) was always inserted at the N-terminal end of the target protein
(HCN1 or TRIP8b, wild-type or mutant) (Santoro et al., 2004), with the
exception of the CD8 fusion construct, where the GFP sequence was
inserted between the CD8 transmembrane domain and theHCN1776–910
domain (CD8-GFP-HCN1776–910). Mutant HCN1 constructs are as de-
scribed previously (Wainger et al., 2001; Santoro et al., 2004), with
HCN1SNL comprising residues HCN11–907, HCN1CX comprising res-
idues HCN11–610, and HCN1CNBD comprising residues HCN11–472.
Specific residue numbers for correspondingmutations introduced in the
background of the three TRIP8b splice variants are as follows:
TRIP8bNX, which lacks most of the initial N-terminal region that is
divergent from PEX5, corresponds to TRIP8b(1b-2)204–615 [identical to
TRIP8b(1a-4)191–602 or TRIP8b(1a)156–567]; TRIP8bNter, a larger
N-terminal deletion extending into the PEX5 homology domain, corre-
sponds to TRIP8b(1b-2)272–615 [identical to TRIP8b(1a-4)259–602 or
TRIP8b(1a)224–567]; TRIP8bCter, the complementary fragment to
TRIP8bNter (see also supplemental Fig. 1, available at www.jneurosci.
org as supplemental material), corresponds to TRIP8b(1b-2)1–271,
TRIP8b(1a-4)1–258, and TRIP8b(1a)1–223; TRIP8bTPR, which lacks all
but the first two helices of the C-terminal TPR domain, corresponds to
TRIP8b(1b-2)1–346, TRIP8b(1a-4)1–333, and TRIP8b(1a)1–298; the mini-
mal TRIP8b fragment (TRIP8bmini), which consists of an 81 aa stretch
immediately upstream of the TPR domain, corresponds to TRIP8b(1b-
2)236–316 [identical to TRIP8b(1a-4)223–303 or TRIP8b(1a)188–268];
TRIP8bint, in which a 22 aa region in the conserved core of TRIP8b is
internally deleted, corresponds to TRIP8b(1b-2)250–271, TRIP8b(1a-
4)237–258, and TRIP8b(1a)202–223; and TRIP8bNK, in which a conserved
asparagine in theTPRdomain ismutated to lysine, corresponds toTRIP8b(1b-
2)N501K, TRIP8b(1a-4)N488K, and TRIP8b(1a)N453K. Oocytes were injected
with 50 nl of cRNA solution each, at a concentration of 0.1–1.0g/l for
HCN1 channel constructs (as specified in figure legends) and 0.2 g/l
for TRIP8b constructs andGFP (or as specified in figure legends). In each
given set of experiments, we always used a constant ratio of HCN1 cRNA
to TRIP8b or GFP cRNA.
Coimmunoprecipitation and Western blots. Oocytes were screened for
GFP expression by live confocal microscopy 3 d after cRNA injection.
Positive oocytes were collected, briefly rinsed in Barth’s Saline (Millipore
Bioscience Research Reagents), and homogenized in ice-cold lysis buffer
(150 mM NaCl, 10 mM Tris-Cl pH 7.4, 1 mM EGTA, 2 mM EDTA, 1%
Triton) with protease inhibitors (Complete Mini, Roche) using a glass
Teflon homogenizer, at a constant ratio of 12 oocytes per 300l of buffer.
The homogenate was spun twice for 5 min at 12,000 g (4°C), and the
second supernatant was used forWestern blot analysis of protein expres-
sion levels (input) or coimmunoprecipitation. For coimmunoprecipita-
tion, 30 l of extract was mixed with 120 l of coimmunoprecipitation
buffer (150 mM NaCl, 10 mM Tris), precleared for 1 h at 4°C, and then
incubated overnight at 4°Cwith 15l of Protein-A-Sepharose beads (GE
Healthcare) bound to anti-GFP antibody (Abcam 290; 1.5 l of for each
sample) or anti-TRIP8b antibody (rabbit polyclonal 794, 2 l of serum
for each sample) (Santoro et al., 2009). Beads were washed three times
with TBST (150 mM NaCl, 10 mM Tris-Cl pH 7.4, 0.1% Triton) and
proteins eluted in Laemmli sample buffer. Proteins were resolved by 8%
SDS-PAGE, transferred to a polyvinylidene difluoride membrane (Poly-
Screen, PerkinElmer) in CAPS buffer (10 mM CAPS, pH 11, 10% meth-
anol) and Western blot analysis performed as described previously
(Santoro et al., 2009). Primary antibody dilutions were as follows: anti-
HCN1 (rat monoclonal 7C3, generous gift from Frank Mu¨ller, Forsc-
hungszentrum Ju¨lich, Ju¨lich, Germany) 1:500; anti-TRIP8b (rabbit
polyclonal 794) (Santoro et al., 2009) 1:5000; and anti-GFP (Abcam 290)
1:5000. HRP-anti-rat conjugate (Jackson ImmunoResearch) or HRP-
anti-rabbit conjugate (Cell Signaling Technology) were used as second-
ary antibodies. The protein bands were visualized by chemiluminescence
using SuperSignal reagent (Pierce).
Yeast two-hybrid assay. Assays were performed using the
Grow’NGlow Two-Hybrid kit (Bio 101) (Santoro et al., 2004) and yeast
strain EGY48. Bait constructs representing the indicated HCN1 channel
domainswere cloned into vector pEG202, and prey constructs represent-
ing the indicated TRIP8b domains (or mutants thereof) were cloned in
vector pJG4–5. Channel domains representing successive deletions of
the six (A–F) helixes that comprise the HCN1C-linker region (a highly
conserved 84 aa region, residues 387–471, connecting the channel trans-
membrane domain to the 120 aa CNBD) are as follows: CNBD alone,
HCN1472–592; E–F C-linker helixes plus the CNBD, HCN1453–592;
C–FC-linker helixes plus the CNBD,HCN1429–592; andA–FC-linker
helixes plus the CNBD, HCN1387–592. The construct representing the
C-terminal domain of HCN1 is as described previously (Santoro et al.,
2004) and comprises residues HCN1776–910. The C-linker/CNBD region
construct (see Fig. 4B,C) comprises residues HCN1390–610 (same
C-terminal ending as HCN1CX). Note that all TRIP8b constructs used
for the yeast two-hybrid assay comprise the constant domain of TRIP8b
only (exons 5–16); that is, they exclude all N-terminal alternatively
spliced exons. To facilitate referencing, however, numbering in Figure 4
is based on full-length TRIP8b(1b-2). Bait and prey plasmids were
cotransformedwith reporter plasmid pGNG1, and cells were plated onto
glucose-containing medium. Transformants were restreaked (in tripli-
cate) on galactose/Leu selective medium and screened for positive
GFP expression under a UV light following 3–5 d of growth.
Affinity purification of protein complexes from bacterial lysates. A cDNA
fragment encoding residues 470–672 of hHCN2 (Ludwig et al., 1999) was
cloned into a modified pET-24b vector (generous gift from Dan Minor,
University ofCalifornia, SanFrancisco, SanFrancisco,CA)downstreamof a
double His6-maltose binding protein (MBP) tag, while cDNA fragments
corresponding to residues 236–316 (TRIP8bmini) and 272–615 (TRIP8bNter)
ofTRIP8b(1b-2)werecloned intovectorpET-52b(Novagen)downstreamof
a Strep(II) tag sequence. Plasmids were cotransformed into Escherichia coli
BL21 Rosetta strain (Novagen), under double ampicillin and kanamycin
selection. Cells were grown at 37°C in Luria broth to 0.6OD600 and induced
with 0.4 mM isopropyl-1-thio-D-galactopyranoside. After 3 h, cells were
collected by centrifugation, resuspended in ice-cold lysis buffer (150 mM
NaCl, 100mMTris-ClpH8,1mMEDTA,1mM-mercaptoethanol, 5g/ml
leupeptin, 1g/mlpepstatin, 100Mphenylmethylsulphonyl chloride)with
the addition of 10g/ml DNase and 0.25mg/ml lysozyme, sonicated on ice
1220 s, and the lysatewas clearedby centrifugation for 30minat 20,000
g. Proteins were purified by affinity chromatography using StrepTrap HP
columns(GEHealthcare), according to themanufacturer’s instructions, and
eluted in 500 mM NaCl, 30 mM HEPES pH 7.5, 10% glycerol, plus 2.5 mM
desthiobiotin. All purification steps were performed at 4°C and monitored
using the A¨KTApurifier UPC 10 fast protein liquid chromatography system
(GE Healthcare). Samples were analyzed by SDS-PAGE using a NuPAGE
(Novex) Bis-Tris 4–12% gel, inMES buffer (Invitrogen).
Electrophysiology.Two-microelectrode voltage-clamp recordings were ob-
tained 3 d after cRNA injection, using a Warner Instruments OC-725C
amplifier. Data were digitized and acquired with an ITC-16 interface
(Instrutech), filtered at 1 kHz and sampled at 2 kHz, and analyzed using
Pulse software (HEKA). Microelectrodes filled with 3 M KCl had resis-
tances of 0.5–2.0 M. Oocytes were bathed in extracellular solution
containing the following (in mM): 94 NaCl, 4 KCl, 10 HEPES, and 2
MgCl2, pH 7.5. Three-second voltage steps were applied from a holding
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potential of 30 mV to a range of test poten-
tials between 15 and 125 mV in 10 mV
decrements, followed by a depolarizing step to
0 mV. Peak tail-current amplitudes were mea-
sured at 0 mV after the decay of the capacitive
transient, and tail-current current–voltage
curves fitted using the Boltzmann equation,
I(V) 	 A1  A2/{1  exp[(V  V1/2)/s]}, in
which A1 is the offset caused by holding cur-
rent, A2 is the maximal tail current amplitude,
V is the test pulse voltage, V1/2 is the midpoint
voltage of activation, and s is the slope factor (in
mV). All recordings were obtained at room tem-
perature (22–24°C).
Results
Structural mapping
Previous studies have identified upstream
and downstream HCN1/TRIP8b interac-
tion sites largely based on the binding
activity of isolated protein fragments
(Santoro et al., 2004; Lewis et al., 2009).
Here we have addressed the relative con-
tribution of the two putative interaction
domains to binding under more physio-
logical conditions by performing a series
of coimmunoprecipitation experiments
with wild-type and mutant TRIP8b and
HCN1 proteins coexpressed in Xenopus
oocytes from injected cRNAs. In addition
to expressing the channel in its native
membrane context, this approach allowed
us to titrate the amount of HCN1 and
TRIP8b protein in each cell to ensure that
wild-type and mutant proteins were ex-
pressed at similar levels, thus allowing
their binding activity to be compared in a
semiquantitative manner. Further, we
tagged the N terminus of wild-type and
mutant constructs with GFP so that, in
addition to monitoring expression levels,
all experiments could be performed using
the same antibody, independent of the
position of the deletion being studied.
In a first set of experiments, we com-
pared the binding of different HCN1 dele-
tion mutants with full-length, wild-type
TRIP8b (Fig. 1). Consistent with previous
results, truncation of the C-terminal SNL
tripeptide of HCN1 strongly reduced, but
didnot abolish, channel binding toTRIP8b.
Binding activity was still retained in a larger
HCN1 C-terminal truncation in which the
CNBDwas intact but all downstream300aa
were deleted (HCN1CX, containing resi-
dues 1–610) (Wainger et al., 2001). How-
ever, an even larger truncation in which
both the CNBD and downstream C-termi-
nal amino acidswere deleted (HCN1CNBD,
containing residues 1–472) (Wainger et al.,
2001) essentially abolishedTRIP8bbinding.
These findings suggest that the CNBD is an
essential component of the upstream inter-
action site, and that the N terminus, trans-
HCN1
HCN1∆SNL
HCN1∆CX
HCN1∆CNBD
CNGA1
CD8-GFP-HCN1776-910
387 472 592 776 910
TM C-link CNBD
SNLGFP
SNLTM C-link CNBD
TM C-link CNBD
TM C-link CNBD
TM C-link
G-HCN1 TRIP8b G-HCN1 (Co-IP)
G-CNGA1 TRIP8b G-CNGA1 (Co-IP)
CD8-G776-910 TRIP8b CD8-G776-910 (Co-IP)
Figure 1. Contribution of HCN1 upstream and downstream binding sites to the interaction with TRIP8b. Western blots show
binding of HCN1, its deletionmutants, and other membrane proteins to wild-type TRIP8b(1b-2) assessed by coimmunoprecipita-
tion from Xenopus oocyte extracts. Oocyteswere coinjectedwith TRIP8b cRNA (0.2g/l) and cRNAs (at indicated concentration)
of various constructs, all tagged with GFP: GFP-HCN1 (1.0 g/l), GFP-HCN1SNL (1.0 g/l), GFP-HCN1CX (0.1 g/l),
GFP-HCN1CNBD (0.1g/l), GFP-CNGA1 (0.5g/l), and CD8-GFP-HCN1776–910 (0.5g/l). The left column showsWestern
blot using GFP antibody as measure of input signal. The middle column shows the TRIP8b input signal using an anti-TRIP8b
antibody. The right column shows the amount of target protein coimmunoprecipitatedwith TRIP8b antibody (Western blot using
GFP antibody). Note that exposure times are directly comparable down each column, but not along each row. The twobands in the
CD8-GFP-HCN1776–910 samples likely represent the unglycosylated (lower) and glycosylated (upper) forms of the CD8 receptor
moiety (Pascale et al., 1992). Individual bands have been cut from intact gel pictures and aligned to allow direct comparison of
intensities forwild-type andmutant constructswith differingmolecularweights. Relevant HCN1 channel domains and amino acid
positions are indicated in the icons on the left (black, transmembrane domain; orange, C-linker region; purple, cyclic nucleotide
binding domain; light green, C-terminal SNL tripeptide).
A B
C D
E
CD8-GFP-HCN1776-910GFP-HCN1
GFP-HCN1 + TRIP8b(1b-2) CD8-GFP-HCN1776-910 + TRIP8b(1b-2)
CD8-GFP + TRIP8b(1b-2)
Figure 2. Functional assay of the interaction between TRIP8b(1b-2) and the HCN1 extreme C terminus in live cells. A–D, Live
confocal imaging of Xenopus oocytes injectedwith cRNAencoding either a GFP-HCN1 (A) or a CD8-GFP-HCN1776–910 fusion protein
alone (B), or in combinationwith TRIP8b(1b-2) (C,D). A redistribution of the GFP fluorescence into distinct puncta is visible in both
cases, indicating the ability of TRIP8b(1b-2) to alter the localization of both fusion proteins. E, Coexpression of TRIP8b(1b-2) with
a CD8-GFP fusion protein lacking the C-terminal domain of HCN1 does not show such redistribution, indicating that the action of
TRIP8b(1b-2) is specifically dependent on its binding to the target HCN1776–910 sequence.
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membrane domain, and C-linker region of the channel are not, by
themselves, sufficient to support significant HCN1/TRIP8b
interaction.
Given the high degree of conservation between the CNBD of
HCN channels and that of cyclic nucleotide-gated (CNG) chan-
nels, we asked whether these close relatives might also display
TRIP8b binding activity. However, when assayed in the same
conditions, no binding was observed between the CNGA1 chan-
nel and TRIP8b, demonstrating the specificity of the HCN/
TRIP8b interaction (Fig. 1). Finally, we asked whether
interaction at the downstream SNL/TPR site was sufficient for
protein binding in native conditions. To address this question,we
attached the extreme C-terminal 134 aa of HCN1 (residues 776–
910) to the C terminus of a fusion protein in which the single-
pass membrane protein CD8 was fused at its C terminus to GFP
(CD8-GFP-HCN1776–910). Coimmunoprecipitation experiments
showed that TRIP8b was able to bind effi-
ciently to theHCN1C terminus in the con-
textof thisminimalmembraneprotein (Fig.
1).WhenTRIP8b(1b-2) is coexpressedwith
HCNchannels, in eitherXenopusoocytes or
HEK293 cells, the channel protein relocal-
izes to intracellular puncta (Fig. 2A,C)
(Santoro et al., 2004, 2009). Interestingly,
coexpression in oocytes of TRIP8b(1b-2)
with CD8-GFP-HCN1776–910 similarly re-
sulted in the formation of distinct puncta
(Fig. 2B,D). The redistribution of CD8-
GFP-HCN1776–910 into puncta confirms
that TRIP8b(1b-2) is able to interact func-
tionally with the HCN1 extreme C termi-
nus, as the formation of the puncta was
clearly dependent on the presence of the
HCN1776–910 fragment (Fig. 2E).
In a complementary set of experi-
ments, we compared the binding of differ-
ent TRIP8b mutants, in the background
of isoform TRIP8b(1b-2), to full-length
wild-type HCN1 (Fig. 3). We first sought
to selectively disrupt the interaction be-
tween HCN1 and TRIP8b(1b-2) by intro-
ducing a point mutation in a conserved
TPR residue, N501K, which greatly di-
minishes the binding of the PEX5TPRdo-
main to the C-terminal SKL (Ser-Lys-
Leu) tripeptide in PEX5 target proteins
(Gatto et al., 2000). In the crystal structure
of the PEX5/target peptide complex, the
side-chain amide group of this asparagine
forms a direct hydrogen bond with the
C-terminal carboxylate of the SKL pep-
tide. As expected, TRIP8b(1b-2)N501K
binding to HCN1 was strongly reduced,
although not abolished, similar to what
we observed upon deletion of the HCN1
SNL tripeptide (compare Figs. 1, 3). This
suggests that the interaction between the
TRIP8b TPR domain and the HCN chan-
nel SNL sequence is similar to the interac-
tion of PEX5 with its SKL-containing
targets. Furthermore, this result indicates
that an intact TPR domain is not required
for an interaction between HCN1 and
TRIP8b at the upstream CNBD/core binding site in native
conditions.
We next examined whether the N-terminal region of TRIP8b,
which is not homologous with PEX5, plays any role in HCN1
binding. We first deleted the initial 203 aa of TRIP8b(1b-2),
which eliminates all alternatively spliced exons as well as the con-
sensus motifs required for the putative binding of TRIP8b to
intracellular trafficking factors (Santoro et al., 2009; Petrenko et
al., 2010). This TRIP8b(1b-2) N-terminal deletion mutant
(TRIP8bNX) still strongly binds to HCN1, indicating that the
extremeN terminus of TRIP8b is not necessary for channel bind-
ing. However, a larger N-terminal deletion mutant lacking the
first 271 residues (TRIP8bNter), a deletion that extends into the
initial segment of the homology region between TRIP8b and
PEX5 but leaves the TPR domain intact, exhibited a significant
TRIP8b
TRIP8bN501K
TRIP8b∆NX
TRIP8b∆Nter
TRIP8b∆Cter
TRIP8b
TRIP8b∆TPR
TRIP8b∆TPR
HCN1 G-TRIP8b HCN1 (Co-IP)
G-HCN1 TRIP8b G-HCN1 (Co-IP)
TRIP8b G-HCN1∆CX (Co-IP)G-HCN1∆CX
250 316 615
Figure 3. Contribution of TRIP8b upstream and downstream binding sites to the interaction with HCN1. Western blots show
binding of a set of TRIP8b(1b-2) mutants to wild-type HCN1 assessed by coimmunoprecipitation from Xenopus oocyte extracts, as
in Figure 1. Oocytes were coinjected with cRNA encoding HCN1 (0.5 g/l), GFP-HCN1 (1.0 g/l), or GFP-HCN1CX (0.1
g/l), as indicated, and cRNA for TRIP8b N-terminally tagged with GFP (GFP-TRIP8b; 0.2g/l, first five rows) or untagged
TRIP8b (0.2g/l, last three rows). Left column, HCN1 input signal (Western blot using HCN1 antibody for first five rows or GFP
antibody for last three rows). Middle column, TRIP8b input signal (Western blot using GFP antibody for first five rows or TRIP8b
antibody for last three rows). Right column, amount of HCN1 coimmunoprecipitated with TRIP8b (immunoprecipitation per-
formed using anti-GFP for first five rows or anti-TRIP8b antibody for last three rows). As in Figure 1, exposure times are directly
comparable down each column, but not along each row. Individual bands have been cut from intact gel pictures and aligned to
allow direct comparison of intensities for wild-type and mutant constructs with differing molecular weights. Relevant protein
domains andaminoacidpositions are indicated in the icons on the left. Theblack color denotes theN-terminal region that is unique
to TRIP8b. The blue color denotes the region of TRIP8b that is homologous to PEX5, with the red squares representing the
tetratricopeptide repeats. The yellow square represents a highly conserved core region, homologous to the corresponding region
of PEX5, immediately preceding the TPR repeats (see supplemental Fig. 1, available at www.jneurosci.org as supplemental
material). The vertical dotted line marks the position of residue 272 in isoform TRIP8b(1b-2), corresponding to residue 259 in
isoform TRIP8b(1a-4).
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reduction in binding activity (Fig. 3). This
finding is consistent with previous obser-
vations suggesting that the TRIP8bNter
fragment binds to the HCN channel ex-
tremeC terminus, but not to the C-linker/
CNBD region (Lewis et al., 2009). It
further suggests that the contribution of
the upstream interaction site to TRIP8b/
HCN channel binding in native condi-
tions is substantial and comparable to that
of the downstream TPR/SNL interaction
site. The portion of the homology region
removed in TRIP8bNter is not sufficient
to confer HCN binding activity, as the
complementary N-terminal fragment
(TRIP8bCter) failed to coimmunoprecipi-
tateHCN1(Fig. 3).However, a largerN-ter-
minal fragment that includes the first
tetratricopeptide repeat of TRIP8b
(TRIP8bTPR) did efficiently bind both
wild-type HCN1 as well as the HCN1 ex-
treme C-terminal truncation mutant
(HCN1CX), presumably due to its effi-
cient interaction with the CNBD of the
channel at the upstream binding site
(Fig. 3).
To localize further the sequences re-
quired for interaction at the upstream and
downstream binding sites, we used the
yeast two-hybrid system to assay the bind-
ing activities of a series of HCN1 and
TRIP8b constructs (Fig. 4). First, we ex-
plored the relative importance of the
HCN1 120 aa CNBD and 80 aa C-linker
region that connects the transmembrane
domain of the channel to the CNBD (Fig.
4A). Although a construct expressing the
CNBD alone produced large amounts of
protein in yeast, as assessed by Western
blot analysis (data not shown), it failed to
bind to TRIP8b. We therefore explored
CNBD constructs that included variable
lengths of the C-linker region, which con-
sists of sixhelixes (A–F) (Zagotta et al.,
2003). We found that the minimal con-
struct that bound to TRIP8b comprised the CNBD plus the two
immediate upstream E–F helixes. Given that a channel trunca-
tion mutant that contains an intact C-linker but lacks the CNBD
was not able to bind to TRIP8b (Fig. 1, HCN1CNBD), the E-F
helix pair probably does not directly interact with TRIP8b but
rather enables the proper folding of the CNBD. Indeed, in the
HCN2 crystal structure the E-F helix pair directly contacts the
CNBD, whereas the A-D helixes do not (Zagotta et al., 2003).
Next, we dissected the regions of TRIP8b involved in the up-
stream interaction with the HCN1 C-linker/CNBD domain and
the downstream interaction with the C-terminal SNL tripeptide
(HCN1776–910) (Fig. 4B). We found that a highly conserved80
aa TRIP8b fragment extending from position 236 to position 316
in TRIP8b(1b-2), located just upstream of the first tetratricopep-
tide repeat (see supplemental Fig. 1, available at www.jneurosci.
org as supplemental material), was sufficient to bind to the
C-linker/CNBD of HCN1. In contrast, this minimal TRIP8b
fragment (TRIP8bmini) failed to interact with the HCN1 extreme
C terminus, confirming that the 80 aa core region of TRIP8b
interacts with HCN1 only at the upstream site. Conversely, a
TRIP8b(1b-2) internal deletion mutant lacking 22 aa within the
middle of the core region (TRIP8bint, which is missing amino
acids 250–271) (supplemental Fig. 1, available at www.jneurosci.
org as supplemental material) lost the ability to bind to the up-
streamC-linker/CNBD site of HCN1 but retained the capacity to
interact with the downstream SNL site of the channel. Thus, se-
quences within TRIP8bmini are both necessary and sufficient to
interact with the HCN1 C-linker/CNBD site, as assayed through
the yeast two-hybrid screen.
To rule out potential artifacts of the yeast two-hybrid assay, we
sought to confirm the interaction between the TRIP8bmini fragment
and theHCNC-linker/CNBDregionbydirect biochemical analysis.
To this end, we coexpressed in E. coli the HCN2 C-linker/CNBD
region (Zagotta et al., 2003) tagged with a double His6-MBP se-
quence, together with Strep-tagged TRIP8b fragments correspond-
ing to either TRIP8bmini or TRIP8bNter. As shown in Figure 5, the
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TRIP8b
TRIP8b
TRIP8b
TRIP8b
TRIP8b
TRIP8b
TRIP8b
TRIP8b
TRIP8b
wt
∆TPR
mini
∆int
G356C
V391D
N395D
N501K
G504E
R532A
TRIP8b
ABCDEF
CDEF
EF
CNBD
CNBD
CNBD
CNBD
C-link CNBD SNL
C-link CNBD SNL
Figure 4. Minimal HCN1 and TRIP8b domains required for binding at the upstream and downstream interaction sites. The
binding activity of a set of HCN1 and TRIP8b fragments was assessed using the yeast two-hybrid assay. Activity was detected by
transactivation of a GFP reporter gene., Strong fluorescence;, very strong fluorescence;, no detectable fluores-
cence.A, Binding of TRIP8b to HCN1 C-linker and CNBD region. The TRIP8b construct (seeMaterials andMethods) failed to interact
with the CNBD alone, but showed strong binding to the CNBD plus two (E and F), four (C–F) or all six C-linker helixes (A–F). B,
Binding of different TRIP8b wild-type and mutant constructs to the HCN1 C-linker/CNBD region (HCN1390–611) or extreme
C-terminal 134 aa region, including the SNL tripeptide (HCN1776–910). C, Binding of TRIP8b bearing different TPR domain point
mutations toHCN1C-linker/CNBDor extremeC-terminus regions (as inB). All TPRmutants prevented interactionwith the extreme
C terminus of HCN1 but did not alter binding to the C-linker/CNBD fragment. TRIP8b numbering is based on isoform TRIP8b(1b-2),
as used in Figure 3 (see Materials and Methods).
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HCN2 C-linker/CNBD fragment was efficiently copurified follow-
ing passage over a Strep-tactin affinity column of the bacterial lysate
containing TRIP8bmini but not TRIP8bNter. These results confirm
that thebindingof theHCNC-linker/CNBDregion toTRIP8bmini is
direct and specific, and that removal of the initial segment of the
TRIP8b/PEX5 homology domain (as in TRIP8bNter) completely
abolishes interaction at the upstream site (Lewis et al., 2009).
Finally, we extended our analysis of the interaction between the
TRIP8b TPR domain andHCN1 by using the yeast two-hybrid sys-
tem to screen the ability of a range of TPR point mutations, which
have been found to disrupt the interaction between PEX5 and its
SKL-containing targets (Gatto et al., 2000; Klein et al., 2001), to alter
the binding of TRIP8b to the HCN1 C-linker/CNBD or extreme C
terminus (Fig. 4C). In addition toN501K, threemutations designed
to disrupt specific contact sites between the TPR domain and the
SNL tripeptide (V391D, N395D, R532A) abolished binding to
HCN1776–910. Furthermore, two mutations designed to disrupt the
formation of specific -helixes within the tetratricopeptide repeats
(G356C, G504E) also abolished binding to HCN1776–910, strongly
suggesting that the interaction between the TRIP8b TPR domain
and the HCN channel SNL tripeptide is very similar to the PEX5/
SKL interaction. Strikingly, none of the point mutations in the TPR
domainaltered thebindingofTRIP8b to theHCN1C-linker/CNBD
region (Fig. 4C), providing strong evidence that the upstream and
downstream interaction domains are independent sites of binding.
Role of upstream and downstream interaction sites in the
regulation of HCN1 gating and trafficking by TRIP8b
How do the upstream and downstream interaction sites contrib-
ute to the actions of TRIP8b to regulate HCN1 trafficking and
gating? To address this question, we examined the functional
effects of the mutations characterized in the above interaction
studies.HCN1hyperpolarization-activatedcurrentsweremeasured
by two-microelectrode voltage-clamp from Xenopus oocytes coex-
pressing wild-type or mutant TRIP8b with wild-type or mutant
HCN1 cRNAs, under the same conditions used for biochemical
analysis. Normally, coexpression of wild-type TRIP8b with wild-
type HCN1 in Xenopus oocytes shifts the voltage-dependent activa-
Figure6. TRIP8b inhibitionofHCN1opening isnotaffectedbydeletionofHCN1extremeCtermi-
nus. TRIP8b(1a-4) (0.2g/l) or GFP as a baseline control (0.2g/l) were coinjected in Xenopus
oocytes with wild-type HCN1 (0.5 g/l), HCN1SNL (0.5 g/l), or HCN1CX (0.1 g/l). A,
Two-microelectrode voltage-clamp current traces elicited from a holding potential of30mV to a
range of test potentials between15 and115mV in 10mVdecrements (as indicated), followed
byadepolarizingstep to0mV.Note thatTRIP8bcoexpressionslows the rateof currentactivationand
shifts opening to more negative potentials. B, Population data showing effect of TRIP8b to shift
voltage at which channels are half activated (V1/2).V1/2 was calculated by subtracting V1/2 values
obtainedwheneachHCN1constructwascoexpressedwithGFPfromcorrespondingV1/2valueswhen
sameHCN1constructswerecoexpressedwithTRIP8b(1a-4).NotethatV1/2valuesusedforsubtraction
were always obtained from the same batch of oocytes tominimize variability. Error bars show SEM.
MeanV1/2values
SEM(n	numberofobservations)areas follows:HCN1,11.5
0.5mV(n	
26, GFP; n	 26, TRIP8b); HCN1SNL, 11.3
 0.4 mV (n	 21, GFP; n	 21, TRIP8b); HCN1CX,
12.5
 0.5mV (n	 28, GFP;n	 28, TRIP8b).
Figure 5. Association of TRIP8bmini and HCN2470–672 fragments in bacterial lysates.A1,A2, Co-
expression of theMBP-tagged HCN2 C-linker/CNBD region (HCN2470–672) with either Strep-tagged
TRIP8bNter (A1) or TRIP8bmini (A2) in E. coli cells. Coomassie staining following SDS/PAGE shows
uninduced bacterial lysate (1) and IPTG-induced bacterial lysate (2). In each case, an amount
corresponding to 100l of bacterial culture was loaded per lane. Blue arrowhead marks posi-
tion of MBP-HCN2 band, red arrowhead Strep-TRIP8bNter and green arrowhead Strep-
TRIP8bmini. B1, B2, Bacterial lysates from cells coexpressingMBP-HCN2 and Strep-TRIP8bNter
(B1) or MBP-HCN2 and Strep-TRIP8bmini (B2) were loaded onto a Strep-Tactin column for
Strep-tagpurification. Equivalent sampleswere analyzedby Coomassie staining following SDS-
PAGE separation, at the following stages: flow-through (1), last wash (2), eluate (3). The MBP-
HCN2 fragment is found in the eluate along with the purified Strep-TRIP8bmini fragment,
indicating the formation of a stable complex between the two proteins, but not with the puri-
fied Strep-TRIP8bNter fragment which lacks the conserved core region required for upstream
site interaction. Labeling as in A. Asterisks mark the band corresponding to the lysozyme pro-
tein, which is added during the lysis stage. Molecular weight marker positions are indicated to
the left of each panel.
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tion of HCN1 channels to more negative
potentials by 10–15 mV (Santoro et al.,
2009). This negative shift is caused by
TRIP8b antagonizing the facilitatory effect
on HCN1 opening that is exerted by the
basal levels of cAMP present in the oocyte
(Chen et al., 2001b). We therefore assayed
theactivityofwild-typeandmutantTRIP8b
(following coexpression with wild-type or
mutantHCN1 channels) by testing their ef-
fects on theHCN1midpoint voltage of acti-
vation (V1/2), a measure of the voltage
dependence of channel gating, and on the
HCN1maximal tail-current amplitude (Imax)
following strong hyperpolarizations, a mea-
sure of channel surface expression (Santoro et
al., 2004, 2009).
Regulation of HCN1 channel gating by
TRIP8b depends selectively on the
upstream CNBD/core interaction site
To assess the gating phenotypes of HCN1
or TRIP8b mutations, we focused on
TRIP8b(1a-4) as this is the most abundant
isoform expressed in the brain and strongly
enhances HCN1 surface expression (San-
toro et al., 2009), ensuring the presence of
large, measurable hyperpolarization-acti-
vated currents. We first analyzed the effects
of coexpressing wild-type TRIP8b(1a-4)
with two HCN1 C-terminal deletions that
retain some TRIP8b binding activity (Fig.
1),HCN1SNL andHCN1CX.As illustrated
in Figure 6, neither of these deletions af-
fected the ability of TRIP8b(1a-4) to shift
the channel V1/2 to more negative poten-
tials. Thus, TRIP8b binding toHCN1 at the
upstream CNBD interaction site must be
sufficient to inhibit gating.
Next,weanalyzed theeffectsof a seriesof
mutations in TRIP8b on its ability to alter
the gating of wild-type HCN1 (Fig. 7) [see
Materials and Methods for exact positions
of mutations in TRIP8b(1a-4)]. Deletion of
the extreme N-terminal domain of TRIP8b
(TRIP8bNX), which contains sequences
important for the regulationof channel traf-
ficking but does not contribute to HCN1
binding (Fig. 3), had no effect on the ability
of the protein to induce a negative shift in
the V1/2 of HCN1. In contrast, the larger N-
terminal deletion extending into the 80 aa
TRIP8b core domain (TRIP8bNter) com-
pletely blocked the capacity of the mutant
protein to alter HCN1 gating. This result is
consistent with a previous report that the
same TRIP8b fragment failed to alter the facilitatory effect of cAMP
on gating of HCN2 in inside-out patches (Zolles et al., 2009).
As TRIP8bNterm can bind efficiently to HCN1 at the down-
stream SNL/TPR interaction site but cannot bind toHCN channels
at the upstream C-linker/CNBD site (Figs. 3, 5) (Lewis et al., 2009),
the upstream interaction must be necessary for the TRIP8b-
dependent inhibition of HCN1 channel opening.We directly tested
this idea by examining the ability of the 22 aa core deletionmutant,
TRIP8bint [deleting residues 237–258 of TRIP8b(1a-4)], to inhibit
HCN1 gating as this mutant protein binds to the downstream but
not upstream HCN1 interaction site (Fig. 4B). Indeed, the internal
deletion abolished the ability of TRIP8b(1a-4) to inhibit HCN1 gat-
ing (Fig. 7), confirming the importance of theupstreamCNBD/core
interaction in regulating channel opening. Conversely, selective dis-
ruptionof thedownstreaminteraction site, eitherby introducing the
TRIP8b
TRIP8b∆NX
TRIP8b∆Nter
TRIP8b∆int
TRIP8bNK
TRIP8b∆TPR
∆V   (mV)
0 5 10 15 
1/2  
Figure7. Effectof variousTRIP8b(1a-4)mutantson thegatingofwild-typeHCN1.Xenopusoocyteswere injectedwithcRNAencoding
wild-typeormutantTRIP8b(1a-4)(0.2g/l)orGFPasabaselinecontrol(0.2g/l), togetherwithcRNAencodingwild-typeHCN1(0.5
g/l). Populationdata showthedifferencebetween theV1/2 observedwhenHCN1was coexpressedwithGFPand theV1/2whenHCN1
was coexpressedwith indicated TRIP8b construct,with data pointsmatchedbybatch of oocytes as described for Figure 6. Specific residue
numbers for mutations introduced in the background of isoform TRIP8b(1a-4) are provided in Materials andMethods. MeanV1/2 val-
ues
 SEM (n) are as follows: TRIP8b, 11.5
0.5mV (n	26, GFP;n	26, TRIP8b); TRIP8bNX, 10.9
0.5mV (n	30, GFP;n	30,
TRIP8bNX);TRIP8bNter,0.7
0.7mV(n	11,GFP;n	11,TRIP8bNter);TRIP8bint,0.1
0.6mV(n	16,GFP;n	16,TRIP8bint);
TRIP8bNK, 9.1
 0.8mV (n	 12, GFP;n	 12, TRIP8bNK); TRIP8bTPR, 11.7
 0.5mV (n	 18, GFP;n	 18, TRIP8bTPR).
Figure 8. Characterization of a minimal TRIP8b domain that inhibits HCN1 gating using TRIP8b-HCN1 fusion proteins. Shift in
V1/2 produced when wild-type or mutant TRIP8b(1a-4) was fused to the N terminus of HCN1.V1/2 values obtained relative to
V1/2 of GFP-HCN1 fusion construct. All constructs expressed using cRNA injections in Xenopus oocytes (HCN1 fusions, 0.5g/l;
HCN1CX fusions, 0.2g/l). Population data show the difference between the V1/2 obtained when HCN1was fused to GFP and
the V1/2 when HCN1 was fused to indicated TRIP8b construct. All data points were matched by batch of oocytes, as above.
Mean V1/2 values
 SEM (n) are as follows: TRIP8b-HCN1, 13.8
 0.9 mV (n	 14, GFP-HCN1; n	 14, 1a4-HCN1);
TRIP8bmini-HCN1, 14.7 
 0.7 mV (n	14, GFP-HCN1; n 	 14, mini-HCN1); TRIP8bint-HCN1, 4.5 
 0.6 mV (n 	 12,
GFP-HCN1; n	 12, int-HCN1); TRIP8bmini-HCN1CX, 12.6
 0.4 mV (n	 14, GFP-HCN1CX; n	 14, mini-HCN1CX);
TRIP8bint-HCN1CX, 2.1
 0.5 mV (n	 14, GFP-HCN1CX; n	 14,int-HCN1CX).
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NtoKmutation in theTRIP8b(1a-4)TPRdomainorbyablating the
TPR domain in the TRIP8b(1a-4)TPR construct, had essentially no
effect on the ability of TRIP8b to inhibit HCN1 activation (Fig. 7).
Next, we asked whether the interaction between HCN1 and the
80aa core regionofTRIP8b is sufficient to regulate channelopening.
To obtain equimolar expression of this relatively small protein frag-
ment andHCN1 subunits inXenopus oocytes, we fused TRIP8bmini
to the N terminus of HCN1 (TRIP8bmini-HCN1). We then com-
pared the voltage dependence of the result-
ing fusion protein channel with that of two
other fusion constructs we previously char-
acterized:GFP-HCN1,whichgates identically
to wild-type HCN1, and TRIP8b(1a-4)-
HCN1, which shows a negative shift in its
V1/2 identical to the shift seen when
TRIP8b(1a-4) is coexpressedwithHCN1 as
independent proteins (Santoro et al., 2009).
As an additional control, we fused the
TRIP8b(1a-4) internal deletion mutant lack-
ing the central 22 aa of the core domain to the
N terminus ofHCN1 (TRIP8bint-HCN1).
When fused to HCN1, the 80 aa
TRIP8bmini fragmentwas as effective as full-
length TRIP8b(1a-4) in shifting the mid-
point of channel activation to more
negative potentials (Fig. 8). Conversely, the
TRIP8bint internal deletionmutant caused
only a minor shift in V1/2 when fused to
the N terminus of HCN1. Moreover,
TRIP8bmini also produced a full negative
shift inV1/2when fused to theN terminusof
the HCN1CX truncation mutant, consis-
tentwith the view that theTRIP8bcoredoes
not interact with the downstream HCN1
binding site, and that the extreme C termi-
nus of the channel does not contribute to
the effects of TRIP8b on gating. Using cell-
free inside-out patches, we further found
that a TRIP8bmini-HCN2 fusion protein
showed a reduced voltage shift in re-
sponse to cAMP, but no change in voltage-
dependent gating in the absence of cAMP
relative to a GFP-HCN2 fusion protein or
HCN2 alone (supplemental Fig. 2, available
at www.jneurosci.org as supplemental ma-
terial). These effects are similar to those seen
when full-length TRIP8b(1a-4) is fused to
HCN2 or when TRIP8b(1a-4) and HCN2
are coexpressed as independent proteins
(Zolles et al., 2009). These findings thus
provide strong evidence that an interac-
tion between the 80 aa TRIP8bmini core
with the HCN channel upstream C-link-
er/CNBD site is necessary and sufficient
for the regulatory effect that TRIP8b ex-
erts on cyclic nucleotide gating.
Upstream and downstream interaction sites
differentially participate in the regulation of
HCN1 channel trafficking by TRIP8b
As the upstream interaction site is both
necessary and sufficient for the action of
TRIP8b to inhibit HCN1 gating, we asked
whether the downstream interaction site
might be important in the control of HCN1 trafficking. To ex-
plore this possibility, we examined the effects of mutations in
HCN1 or in three selected TRIP8b splice variants—TRIP8b
(1a-4), TRIP8b(1a), and TRIP8b(1b-2). As mentioned above,
these isoforms exert distinct effects on HCN1 trafficking:
TRIP8b(1a-4) strongly increases HCN1 surface expression;
TRIP8b(1a) produces a 10-fold decrease of HCN1 surface ex-
Figure 9. HCN1 C-terminal deletions differentially alter the ability of three TRIP8b isoforms to regulate HCN1 surface expression.
Xenopus oocytes were injected with cRNA encoding wild-type HCN1 (0.5 g/l), HCN1SNL (0.5 g/l) or HCN1CX (0.1 g/l)
together with cRNA encoding one of the indicated TRIP8b splice variants (0.2g/l) or GFP (0.2g/l) to provide a baseline control.
Recordingswereperformed3dafter injection; two-microelectrodevoltage-clampcurrent tracesobtainedas inFigure6.A, Samplecurrent
traces elicited fromaholdingpotential of30mVtoa test potential of105mVshown forHCN1,HCN1SNL, orHCN1CX (as indicated)
coexpressedwithGFP (green traces), TRIP8b(1a-4) (black traces), TRIP8b(1a) (red traces), or TRIP8b(1b-2) (blue traces). Tail current traces
are shown at an expanded scale. Lower right, Current traces obtained at the105mV test potential upon coexpression of TRIP8b(1b-2)
withHCN1orHCN1SNL.B,Maximal tail currentamplitude(Imax) forHCN1constructs coexpressedwithagivenTRIP8b isoformnormalized
bymaximal tail current amplitude when the same channel construct was coexpressed with GFP. As in Figure 6, data points were
matched by batch of oocytes. Error bars show SEM.Mean normalized Imax values
 SEM (n) are as follows: HCN1 TRIP8b(1a-4),
5.35
 0.27 (n	 67, GFP; n	 70, 1a-4); HCN1 TRIP8b(1a), 0.14
 0.01 (n	 56, GFP; n	 60, 1a); HCN1 TRIP8b(1b-2),
undetectable current (n	 34, GFP; n	 27, 1b-2); HCN1SNL TRIP8b(1a-4), 4.65
 0.45 (n	 15, GFP; n	 14, 1a-4);
HCN1SNL TRIP8b(1a), 1.36
 0.1 (n	 15, GFP; n	 15, 1a); HCN1SNL TRIP8b(1b-2), 0.05
 0.005 (n	 15, GFP; n	 15,
1b-2); HCN1CX TRIP8b(1a-4), 4.15
 0.25 (n	 17, GFP; n	 16, 1a-4); HCN1CX TRIP8b(1a), 0.98
 0.06 (n	 17, GFP;
n	 17, 1a); HCN1CX TRIP8b(1b-2), undetectable current (n	 13, GFP; n	 13, 1b-2).
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pression in Xenopus oocytes (Santoro et
al., 2009) but enhances HCN1 expression
in a mammalian cell line (Lewis et al.,
2009); andTRIP8b(1b-2) essentially abol-
ishes surface expression inbothoocytes and
mammalian cells (50-fold decrease) by
promoting channel endocytosis (Santoro et
al., 2004, 2009; Lewis et al., 2009). Although
both TRIP8b(1a) and TRIP8b(1b-2) de-
crease surface expression ofHCN1 inXeno-
pus oocytes, the two splice variants depend
on distinct trafficking sequencemotifs, sug-
gesting the possibility that their effects rely
on distinct mechanisms. Thus, the effect of
TRIP8b(1a) to downregulate HCN1 re-
quires a dileucine-based traffickingmotif in
exon 5 whereas channel downregulation
with TRIP8b(1b-2) depends on a tyrosine-
based traffickingmotif in exon2 (Santoro et
al., 2009).
We first examined the ability of the three
wild-type TRIP8b isoforms to regulate the
trafficking of the HCN1SNL truncation
mutant characterized above that lacks the
downstream interaction site.Deletionof the
SNL tripeptide caused a selective impair-
ment in the downregulation of HCN1 sur-
face expression by either TRIP8b(1a) or
TRIP8b(1b-2). Surprisingly, the truncation
hadnoeffect on theupregulationof channel
surface expression with TRIP8b(1a-4)
(Fig. 9).We also found a quantitative differ-
ence in the effect of the SNL truncation on
channel downregulation with TRIP8b(1a)
versus TRIP8b(1b-2).Whereas the SNL de-
letion only partially inhibited channel
downregulation with TRIP8b(1b-2), it fully
blocked the effect ofTRIP8b(1a) todecrease
HCN1 expression. Thus, the downstream
SNL interaction site ofHCN1appears selec-
tively required for the effect of TRIP8b iso-
forms to downregulate HCN1 surface
expression. In contrast, binding at the
downstreamsitehas little role in the effect of
the TRIP8b(1a-4) isoform to upregulate
HCN1 surface expression or to inhibitHCN1gating (Figs. 6, 8).
Truncation of the entire extreme C terminus of HCN1 dis-
tal to the CNBD (HCN1CX) also fully blocked the capacity of
TRIP8b(1a) to decrease channel surface expression with no
effect on the enhancement of channel surface expression with
TRIP8b(1a-4), similar to the effects seen above with the SNL
deletion (Fig. 9). However, the effects of HCN1SNL and
HCN1CX diverged when tested against TRIP8b(1b-2); sur-
prisingly, truncation of the entire HCN1 extreme C terminus
restored the capacity of TRIP8b(1b-2) to fully abolish channel
surface expression. This result reinforces the idea that
TRIP8b(1a) and TRIP8b(1b-2) are likely to downregulate sur-
face expression through distinct mechanisms (Santoro et al.,
2009). Moreover, it suggests that the extreme C-terminus of
HCN1, when not bound to the TPR domain of TRIP8b, may
exert an inhibitory effect on the ability of TRIP8b to promote
channel endocytosis.
Next, we analyzed the effects of mutations in each of the three
TRIP8b isoforms on their ability to regulate the trafficking of
wild-type HCN1 channels. Neither of the two N-terminal deletion
mutants (TRIP8bNX and TRIP8bNter) exerted any regulatory ef-
fect on the surface expression ofHCN1 (Fig. 10), consistentwith the
presence of key trafficking consensus sequences in the deleted re-
gions (Santoro et al., 2009; Petrenko et al., 2010).
As our results show that the downstream SNL interaction site
in HCN1 is important in the downregulation of channel surface
expression by TRIP8b isoforms, we performed complementary
experiments to probe the importance of the downstream inter-
action site in TRIP8b by introducing the equivalent of the N501K
point mutation in the TPR domains of the three TRIP8b splice
variants. The resulting phenotypes closely mirrored the effects
seen with the HCN1 SNL truncation (compare Figs. 9, 10). Thus,
the N to K mutation significantly inhibited the ability of both
TRIP8b(1a) and TRIP8b(1b-2) to downregulate HCN1 surface
expression, but had little effect on the ability of TRIP8b(1a-4) to
1a 
1b-2 
1a-4 
TRIP8b∆NX 
TRIP8b∆int 
TRIP8b∆Nter 
TRIP8b∆TPR 
TRIP8bNK 
*
0 1 2 3 4 5 6 7
1a-4 
1a 
1b-2 
1a-4 
1a 
1b-2 
TRIP8b  
1a 
1b-2 
1a-4 
fold change 
Figure10. Both downstreamandupstream interaction sites in TRIP8b contribute to regulation of HCN1 trafficking by the three
TRIP8b isoforms. Population data showing maximal tail current amplitudes (Imax) upon coexpression of wild-type HCN1 with the
indicated mutant TRIP8b isoform, normalized to the baseline current value determined following coexpression of HCN1 with GFP
control, with data points matched by batch of oocytes. As the N-terminal deletion mutants are identical for all three TRIP8b
isoforms, only one set of data is shown for each mutant. Specific residue numbers for mutations introduced in the background of
each isoform are provided inMaterials andMethods. Mean normalized Imax values
 SEM (n) are as follows: HCN1 TRIP8b(1a-
4), 5.35
0.27 (n	67, GFP;n	70, 1a-4); HCN1 TRIP8b(1a), 0.14
0.01 (n	56, GFP;n	60, 1a); HCN1 TRIP8b(1b-2),
undetectable current (n	 34, GFP; n	 27, 1b-2); HCN1 TRIP8bNX, 1.24
 0.09 (n	 30, GFP; n	 30,NX); HCN1
TRIP8bNter, 1.57
0.23 (n	11, GFP;n	11,Nter); HCN1 TRIP8b(1a-4)int, 2.29
0.18 (n	19, GFP;n	23, 1a-4int);
HCN1 TRIP8b(1a)int, 2.87
 0.18 (n	 19, GFP; n	 23, 1aint); HCN1 TRIP8b(1b-2)int, 0.18
 0.02 (n	 19, GFP; n	
23, 1b-2int); HCN1 TRIP8b(1a-4)NK, 5.68
 0.49 (n	 12, GFP; n	 12, 1a-4 NK); HCN1 TRIP8b(1a)NK, 2.96
 0.2 (n	 19,
GFP; n	 23, 1aNK); HCN1 TRIP8b(1b-2)NK, 0.07
 0.01 (n	 15, GFP; n	 15, 1b-2NK); HCN1 TRIP8b(1a-4)TPR, 1.13

0.07 (n 	 18, GFP; n 	 18, 1a-4TPR); HCN1  TRIP8b(1a)TPR, 0.29 
 0.02 (n 	 18, GFP; n 	 18, 1aTPR); HCN1 
TRIP8b(1b-2)TPR, undetectable current (n	 15, GFP; n	 10, 1b-2TPR). One-way ANOVA was used to determine that all
experimental groups, except for TRIP8bNX, TRIP8bNter, and TRIP8b(1a-4)TPR, significantly differ from the GFP baseline control
group ( p 0.01, Tukey’s multiple-comparison test).
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upregulate channel surface expression. In fact, the TRIP8b(1a)
mutant now caused a significant increase in HCN1 surface ex-
pression, similar to what we previously observed upon mutation
of N-terminal trafficking consensus site in this isoform (Santoro
et al., 2009).
Having established that the upstream interaction site is
critical for the regulation of HCN1 channel gating by TRIP8b
(Figs. 7, 8), we wondered whether it might also play a role in
the control of HCN1 trafficking. We tested this hypothesis by
coexpressing HCN1 with internal deletion mutants of each of
the three TRIP8b isoforms lacking the central 22 aa of the core
domain (TRIP8bint). As shown in Figure 10, disruption of the
upstream interaction site clearly altered the ability of all three
TRIP8b isoforms to modulate channel surface expression. In-
deed, the effects of the internal deletion resembled the effects
of the HCN1 SNL truncation and TRIP8b N to K mutations
described above, with a significant loss of the ability of
TRIP8b(1a) and TRIP8b(1b-2) to downregulate HCN1 surface
expression. The ability of TRIP8b(1a-4) to enhance channel surface
expression was also somewhat reduced, though still present (Fig.
10). Thus, disruption of TRIP8b/HCN1 binding at either the
upstream or downstream interaction sites greatly reduces the
ability of TRIP8b isoforms to downregulate HCN1 surface ex-
pression but has a limited effect on the ability of TRIP8b isoforms
to enhance surface expression.
As the TPR point mutations disrupt the ability of TRIP8b(1a)
and TRIP8b(1b-2) to downregulate HCN1 surface expression,
we expected to observe a similar phenotype when we deleted the
TPR domain of these isoforms (TRIP8bTPR). Surprisingly, both
of these truncated TRIP8b isoforms efficiently downregulated
HCN1 surface expression, very similar to the effects of the wild-
type isoforms (Fig. 10). This observation is consistent with the fact
that the TRIP8bTPR truncation mutant can efficiently bind to
HCN1 at its C-linker/CNBD interaction site, and exert a normal
inhibitory effect on channel gating (Figs. 3, 7).Moreover, it indicates
that the presence of an unboundTPRdomain can impair the ability
of TRIP8b to downregulate HCN1 surface expression (see Discus-
sion) (Fig. 11), similar to the inhibitory effect seen above with the
unbound extreme C-terminus of HCN1 (Fig. 9). Of interest, dele-
tion of the TPR domain of TRIP8b(1a-4) completely blocked the
capacity of this isoform to enhance HCN1 surface expression
[TRIP8b(1a-4) TPR] in contrast to the lack of effect of the TPRN to
HCN1 + TRIP8b HCN1 + TRIP8b∆TPR
HCN1∆SNL + TRIP8bHCN1 + TRIP8b∆int
V1/2 shift
Imax increase
Imax decrease
V1/2 shift
Imax increase
Imax decrease
V1/2 shift
Imax increase
Imax decrease
V1/2 shift
Imax increase
Imax decrease
A
B
C
D
Figure11. Schematic representation of HCN1/TRIP8b interactions in the presence of intracellular trafficking factors. A, Summary of interactions between HCN1, TRIP8b, and trafficking
proteins. The HCN1 channel protein is represented in gray, with C-linker helices E and F indicated by rectangles, and the C-terminal SNL sequence indicated by a circle. The TRIP8b
protein is color coded as in previous figures (black, unique N-terminal region; yellow, highly conserved core domain; blue, region of homology to PEX5 with TPR repeats indicated in red).
Dileucine- or tyrosine-based AP binding motifs are present in the N-terminal domain of TRIP8b, indicated by black triangles. AP complex proteins (AP-1 or AP-2) are represented in pink,
positioned closely to the plasma membrane (Bonifacino and Traub, 2003), and bind to the N terminus of TRIP8b. An additional trafficking factor (potentially Rab8b), indicated in green,
is shown to interact with the C-terminal TPR region of TRIP8b. Note that both of these interacting elements are hypothetical. Gating and trafficking phenotypes are indicated in each panel
for their respective mutants. B, Deletion of a critical sequence within the conserved core domain of TRIP8b (int) results in a loss of the ability to modulate channel gating and to
downregulate channel expression. A hypothetical displacement of the TRIP8b N-terminal domain is shown to impede the binding of AP complex proteins, but not of factors involved in
the upregulation of HCN1 surface expression. C, Deletion of the portion of the TPR domain following the first tetratricopeptide repeat (TPR) leads to a loss in the ability of TRIP8b to
upregulate surface expression. We speculate that this is because required factors are unable to bind the protein’s C-terminal domain. Efficient interaction at the upstream CNBD/core
binding site and between the N terminus of TRIP8b and AP complex proteins would still allow for the regulation of channel gating and endocytosis. D, Deletion of the HCN1 channel’s
C-terminal SNL tripeptide (HCN1SNL) or the N to K point mutation in the TPR domain (TRIP8bNK) results in a loss of the ability of TRIP8b to downregulate surface expression. We speculate
that failure to interact at the downstream SNL/TPR binding site leads to a displacement of the C-terminal half of the TPR domain, which prevents the access of AP complex proteins to their
target sequences in the TRIP8b N terminus. Interaction at the upstream CNBD/core site and with factors bound to the TPR domain that upregulate channel surface expression would not
be impaired, resulting in normal gating and Imax increase phenotypes.
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K point mutation on channel upregulation
(Fig. 10). This suggests that, in addition to
binding to HCN1 at the downstream in-
teraction site, the TPR domain may
serve to recruit specific factors impor-
tant for the enhancement of channel
trafficking to the surface membrane.
Discussion
Here we have mapped distinct upstream
and downstream sites of interaction be-
tween HCN1 and TRIP8b, and defined the
differential roles of these sites in the func-
tional effects of three different TRIP8b
splice variants on channel trafficking and
cyclic nucleotide gating. The interactions
between wild-type HCN1 and TRIP8b are
summarized in schematic forminFigure11,
which also provides a more speculative
model to explain certain phenotypes of
HCN1 and TRIP8bmutants.
Structural findings
Usingbiochemical andmolecularbiological
approaches, we confirmed the presence of
upstream and downstream interaction sites
on HCN1 and TRIP8b (Lewis et al., 2009),
and refined the localization of the interac-
tion surfaces (Fig. 11A). We found that
the upstream interaction involves binding
of the CNBD and last two helixes of the
C-linker region of HCN1 (E–F/CNBD)
to an 80 aa conserved core region of
TRIP8b [TRIP8bmini, residues 236–316 in
TRIP8b(1b-2)], immediately upstream of
the TPR domain. At the downstream site,
the C-terminal SNL tripeptide of the chan-
nel interacts with the TPR domain of
TRIP8b, similar to the interaction of the
PEX5 TPR domain with its SKL-containing
targets (Gatto et al., 2000).
Using coimmunoprecipitation as-
says from Xenopus oocytes, we further
determined that, in native conditions,
both interaction sites contribute to the
stability of the TRIP8b/HCN1 complex.
Interestingly, the crystal structure of
PEX5 in complex with the sterol carrier
protein 2 (SCP2) similarly reveals a second interaction site
outside the TPR domain’s contact with the C-terminal AKL
sequence of SCP2 (Stanley et al., 2006). The binding affinity of
full-length SCP2 for PEX5 is 5- to 10-fold higher than the
affinity of its C-terminal PTS1 peptide (PGNAKL), suggesting a
substantial contribution of the secondary interface to overall bind-
ing. An analogous situation is found in the PEX5/alanine:glyoxylate
aminotransferase complex, where an ancillary targeting domain is
present60 aa upstreamof the C-terminal PTS1 peptide (Huber et
al., 2005) (see also PDB accession 3IMZ for solved crystal structure
of the complex). Indeed, it has been suggested that bipartite target
binding by a second topologically distinct interaction site could
be a general feature of target recognition by the PEX5 receptor
(Stanley et al., 2006). Given the close evolutionary relationship
between the two proteins, a similar strategy may have been ad-
opted by TRIP8b for the recognition of its HCN channel target.
Functional findings
Our studies indicate that the two TRIP8b/HCN1 interaction sites
play distinct functional roles in the effects of the different TRIP8b
isoforms to inhibit channel gating compared with the effects of
these isoforms to upregulate versus downregulate channel traf-
ficking. Interaction at the upstream site between the channel
CNBD and the conserved 80 aa core of TRIP8b is both necessary
and sufficient to mediate the inhibitory effects of TRIP8b on
HCN1 channel opening. Specifically, the ability of full-length
TRIP8b to shift the channel V1/2 to more negative potentials is
fully reproduced by TRIP8bmini and is unaffected by deletion of
the TRIP8b TPR domain or extreme C terminus of the channel.
Figure 12. Homologymodel of the TRIP8b tetratricopeptide repeat domain in bound and unbound form.A, Top view (left) and
bottom view (right) of homology model of TRIP8b TPR domain in complex with the HCN channel C-terminal tripeptide (SNL,
yellow stick figure representation) based on PEX5 structure. The side chains of four TRIP8b amino acid residues predicted tomake
critical contacts with the target peptide are shown in green stick figure representations (V391, N395, N501, R532) (Fig. 4C). Note
that the N-terminal two helices, corresponding to the first tetratricopeptide repeat (TPR1, in red) do not contact the SNL target
peptide. These helices are preserved in TRIP8bTPR (only the gray portion of the TPR domain is deleted in this construct). The
N-terminal end of the structure is colored in blue, and corresponds to the C-terminal tail of the TRIP8bmini construct (no structural
information is available N-terminal to this point). B, Homologymodels of different conformations assumed by the TPR domain of
TRIP8buponbindingor unbindingof theSNL target peptide. Theholo (bound) structure (black) is superimposedon twoalternative
conformations assumedby theapo (unbound) structure (light blueandgreen).Note that theC-terminal TPR segments rotate away
from the N-terminal TPR segments, with the two halves of the TPR domain behaving as near-rigid bodies (Stanley et al., 2007).
Models were constructed using the programMODELLER based on Protein Data Bank accessions 1FCH, 2C0M, and 2J9Q. Molecular
figuresweregeneratedusingPyMOL (DeLano, 2002). The viewof the structure inB is rotated90°with respect to the viewshown
inA, as indicated by the arrow. For orientation purposes, the holo structure is reproduced on the right, showing the position of the
SNL peptide. Structure in A corresponds to residues 297–615 of TRIP8b(1b-2), and structures in B to residues 304–615 (see
supplemental Fig. 3, available at www.jneurosci.org as supplemental material). The loop between TPR3 and TPR4 (Gatto et al.,
2000), as well as the loop between TPR7 and the C-terminal three-helical bundle (7C loop) (Stanley et al., 2006), have been
substituted by a dotted line, as these elements are not resolved in the PEX5 structures.
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The structural bases for the effects of the three TRIP8b iso-
forms on trafficking are complex. Interaction at the upstream
site is necessary (TRIP8bint) (Fig. 11B) and also sufficient
(TRIP8bTPR) (Fig. 11C) for TRIP8b(1a) or TRIP8b(1b-2) to
downregulate HCN1 surface expression, as long as the trafficking
motifs in the N-terminal region of TRIP8b are present. Interac-
tion at the downstream site between the TPR domain of TRIP8b
and the SNL tripeptide of HCN1 is not strictly required for the
downregulation of HCN1 surface expression with TRIP8b(1a) or
TRIP8b(1b-2), given that normal downregulation is observed in
the absence of the TRIP8b TPR domain (though see discussion
below). In contrast, deletion of the TPR domain fully blocks the
ability of TRIP8b(1a-4) to upregulate HCN1 surface expression
(TRIP8bTPR) (Fig. 11C). This effect cannot be explained by the
simple loss of binding at the downstream interaction site because
channel upregulation by TRIP8b(1a-4) is unaffected in the
TRIP8bNK and HCN1SNL mutants, which both have disrupted
downstream binding (Fig. 11D). Rather, we suggest that the TPR
region may recruit some cytoplasmic trafficking factor indepen-
dent of the TPRdomain’s role in binding to the SNL site ofHCN1
(e.g., Rab8b) (Chen et al., 2001a; Fransen et al., 2008). To upregu-
late HCN1 surface expression, the recruitment of such a factor
must act in combination with sequences present in the N-terminal
regionofTRIP8b, asupregulation isnotobservedwhen this region is
deleted (TRIP8bNX and TRIP8bNter).
One surprising result is that relatively small perturbations in
the downstreambinding site of eitherHCN1 (e.g., HCN1SNL) or
TRIP8b (e.g., TRIP8bNK) are more effective in disrupting the
downregulation of channel surface expression than are larger
truncations of either the C-terminal TPR domain of TRIP8b
(TRIP8bTPR) or the extreme C terminus of HCN1 (HCN1CX).
We hypothesize that the unbound TPR domain of TRIP8b may
exert an inhibitory effect to prevent the assembly of macromo-
lecular complexes involved in channel trafficking at the N termi-
nus of TRIP8b (Fig. 11D). This implies that the normal
interaction of HCN1 and TRIP8b at the downstream binding site
may induce a conformational change in the TPR domain that
allows for assembly of the trafficking complex.
The idea that the downstream interaction of the HCN1 SNL
tripeptide with TRIP8b triggers a conformational change in the
TPR domain is consistent with x-ray crystal structures of the
PEX5 TPR region when bound and unbound to its cargo target
peptide. Such studies reveal that cargo binding causes the TPR
region to undergo a conformational change from amore open to
a more closed structure (Stanley et al., 2006, 2007). Based on the
high degree of amino acid similarity between the TPR regions of
PEX5 and TRIP8b (see supplemental Fig. 3, available at www.
jneurosci.org as supplemental material), we generated a struc-
tural homologymodel for TRIP8b with its SNL peptide bound or
absent (Fig. 12). In the model, unbinding of the cargo peptide
causes the C-terminal half of the TRIP8b TPR domain to swing
away from the N-terminal half, which remains relatively immo-
bile (Fig. 12B), similar to the PEX5 results. Thus, the downstream
TPR/SNL interaction site might primarily act to stabilize the
C-terminal structure of TRIP8b. A displaced TPR domain could
interfere with clathrin-mediated endocytosis of the HCN1/
TRIP8b complex; deletion of the C-terminal portion of the TPR
domain would remove this inhibitory effect, rescuing the ability
of TRIP8b to mediate HCN channel endocytosis.
Given that the conserved core region of TRIP8b is contiguous
with the TPR domain, a similar scenario may explain how an
internal deletion in the upstream site (TRIP8bint) interfereswith
the downregulation of HCN1 surface expression. Loss of the up-
stream interaction may lead to the improper positioning of the
N-terminal domain of TRIP8b, preventing it from interacting
with its normal protein trafficking partners (Fig. 11B). Alterna-
tively, the upstream site could help anchor the SNL/TPR complex
to the rest of the channel to prevent it from interfering with
the assembly of protein complexes required for membrane
trafficking.
Physiological consequences of the bipartite
TRIP8b-HCN1 interaction
Our findings that mutations that perturb the downstream inter-
action between TRIP8b and HCN1 differentially alter the func-
tional consequences of residual binding at the upstream site have
interesting implications for the dynamic regulation of the
TRIP8b/HCN1 interaction in vivo. For example, our results with
HCN1SNL suggest that a post-translational modification that
weakens the downstream interactionmight prevent downregula-
tion of channel expression with TRIP8b(1a) without changing
the upregulation of channel expression with TRIP8b(1a-4) (Fig.
9) or the effect of either isoform to regulate cyclic nucleotide-
mediated channel gating (Fig. 6).
Given this potential for regulation, it is of interest that two
proteomic screens of phosphopeptides from mouse brain syn-
apses identified in vivo phosphorylation sites within TRIP8b
(Trinidad et al., 2006; Munton et al., 2007). One such phosphor-
ylation site, located in the loop between TPR3 and TPR4, is
poised to regulate the downstream interaction between TRIP8b
and HCN1. A second phosphorylation site, located in the con-
served core region (TRIP8bmini), could potentially affect binding
at the upstream site and thus disrupt the gating and trafficking
effects of all TRIP8b isoforms (Fig. 10). Differential phosphory-
lation may also explain why TRIP8b(1a) downregulates HCN1
surface expression in Xenopus oocytes (Santoro et al., 2009),
whereas it upregulates HCN1 in a mammalian cell line (Lewis et
al., 2009).
As the proper assembly of trafficking complexes appears to
depend on the specific conformation of TRIP8b N-terminal and
C-terminal domains, might the large cytoplasmic N-terminal
and C-terminal domains of the HCN channels play a similar
regulatory function? Indeed, we find that whereas the extreme N
and C termini of HCN1 (outside of the SNL sequence) do not
directly bind TRIP8b, these domains appear to modulate the
functional association between HCN1 and TRIP8b. Thus, the
decreased ability of TRIP8b(1b-2) to abolish HCN1 surface ex-
pression seen with truncation of the SNL tripeptide of the chan-
nel is rescued upon truncation of the entire nonconserved C
terminus of HCN1 (Fig. 9). Moreover, deletion of the extreme N
terminus ofHCN1 strongly enhances the ability of TRIP8b(1a) to
downregulate channel surface expression (A.Kushnir andB. San-
toro, unpublished observation). Given that the extreme N and C
termini of the four HCN channel isoforms diverge in length and
sequence, the association of TRIP8b with different channel iso-
forms could result in different functional phenotypes. Indeed,
whereas TRIP8b(1a-4) strongly increases HCN1 surface expres-
sion (Lewis et al., 2009; Santoro et al., 2009), this isoform de-
creases the surface expression of HCN2 (Zolles et al., 2009) (L.
Hu, unpublished observation). Such variations could add a fur-
ther layer of complexity and versatility to the regulatory roles
played by the HCN channel TRIP8b auxiliary subunit within the
nervous system.
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I N T RODUC T I ON
The electrical activity of the nervous system depends 
on the precise tuning of the electrophysiological proper-
ties of neurons through various mechanisms. The inter-
action of auxiliary subunits of voltage-gated channels 
with their pore-forming -subunits provides one power-
ful means of regulating neural function by controlling 
channel expression and gating (Arikkath and Campbell, 
2003; Vacher and Trimmer, 2011). The actions of neu-
rotransmitters to modulate voltage-gated channel func-
tion through various second messenger signaling 
pathways provide another means for the more dynamic 
control of neural firing properties. We now find that the 
cAMP-dependent modulation of hyperpolarization-
activated cyclic nucleotide–regulated cation (HCN) chan-
nels undergoes a surprising form of regulation by the 
brain-specific auxiliary HCN channel subunit TRIP8b 
(Santoro et al., 2004).
HCN channels are composed of four pore-forming 
-subunits encoded by members of a small gene family 
(HCN1–4) that is part of the larger voltage-gated channel 
Correspondence to Steven Siegelbaum: s a s 8 @ c o l u m b i a . e d u 
Abbreviations used in this paper: CNBD, cyclic nucleotide–binding 
domain; HCN, hyperpolarization-activated cyclic nucleotide–regulated 
cation; TPR, tetratricopeptide repeat.
superfamily (Robinson and Siegelbaum, 2003; Biel et al., 
2009). Unlike most voltage-gated channels, the HCN 
channels are nonselective cation channels that are acti-
vated by membrane hyperpolarization, resulting in the 
hyperpolarization-activated cation current, Ih. The bind-
ing of cAMP to the highly conserved HCN cytoplasmic 
C-terminal cyclic nucleotide–binding domain (CNBD) en-
hances channel opening by shifting the voltage depen-
dence of HCN channel gating to more positive potentials 
(DiFrancesco and Tortora, 1991; Wainger et al., 2001). 
This effect is sometimes associated with an increase in the 
maximal current through the population of HCN chan-
nels (Imax) at strongly hyperpolarized voltages (Craven and 
Zagotta, 2004; Shin et al., 2004). These results are consis-
tent with a model in which channel opening consists of a 
voltage-dependent activation step coupled to a voltage-in-
dependent opening step: cAMP binding enhances chan-
nel opening and shifts the voltage dependence of gating 
to more positive potentials by stabilizing the closed to open 
transition of the channel (Zhou and Siegelbaum, 2007).
Binding of the auxiliary subunit TRIP8b to HCN channels shifts  
the mode of action of cAMP
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Hyperpolarization-activated cyclic nucleotide–regulated cation (HCN) channels generate the hyperpolariza-
tion-activated cation current Ih present in many neurons. These channels are directly regulated by the bind-
ing of cAMP, which both shifts the voltage dependence of HCN channel opening to more positive potentials 
and increases maximal Ih at extreme negative voltages where voltage gating is complete. Here we report that 
the HCN channel brain-specific auxiliary subunit TRIP8b produces opposing actions on these two effects of 
cAMP. In the first action, TRIP8b inhibits the effect of cAMP to shift voltage gating, decreasing both the sen-
sitivity of the channel to cAMP (K1/2) and the efficacy of cAMP (maximal voltage shift); conversely, cAMP 
binding inhibits these actions of TRIP8b. These mutually antagonistic actions are well described by a cyclic 
allosteric mechanism in which TRIP8b binding reduces the affinity of the channel for cAMP, with the affinity 
of the open state for cAMP being reduced to a greater extent than the cAMP affinity of the closed state. In a 
second apparently independent action, TRIP8b enhances the action of cAMP to increase maximal Ih. This 
latter effect cannot be explained by the cyclic allosteric model but results from a previously uncharacterized 
action of TRIP8b to reduce maximal current through the channel in the absence of cAMP. Because the bind-
ing of cAMP also antagonizes this second effect of TRIP8b, application of cAMP produces a larger increase in 
maximal Ih in the presence of TRIP8b than in its absence. These findings may provide a mechanistic explana-
tion for the wide variability in the effects of modulatory transmitters on the voltage gating and maximal am-
plitude of Ih reported for different neurons in the brain.
© 2013 Hu et al. This article is distributed under the terms of an Attribution–Noncommercial– 
Share Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Creative Com-
mons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described 
at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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600 TRIP8b shifts mode of cAMP action on HCN channels
Here we have investigated the effects of TRIP8b on 
HCN channel function using both TRIP8b-HCN2 fu-
sion proteins and direct application of the TRIP8b core 
region to HCN2 channels in inside-out patches. Our re-
sults indicate that TRIP8b acts through an allosteric 
mechanism to decrease the affinity of the channel for 
cAMP. Moreover, we report a previously uncharacter-
ized action of TRIP8b to reduce maximal current 
through the channel in the absence of cAMP. By reversing 
this action of TRIP8b, cAMP produces an increase in 
maximal current significantly greater than that seen in 
the absence of the auxiliary subunit. Thus, TRIP8b ex-
erts opposing influences on the two major actions of 
cAMP on HCN channel function. The auxiliary subunit 
reduces the effect of cAMP to shift the voltage depen-
dence of channel gating but enhances the action of 
cAMP to increase maximal current. These effects have 
important implications for the physiological actions of 
cAMP to alter neuronal excitability.
MAT E R I A L S  AND  M E THOD S
Constructs and expression
All constructs were cloned in pGHE or pGH19 vectors, linear-
ized, and transcribed into cRNA using T7 polymerase (Mes-
sageMachine; Ambion) as described previously (Santoro et al., 
2004, 2009). cDNA clones encoding HCN2 and TRIP8b both 
correspond to the Mus musculus sequence. GFP, TRIP8b, and 
TRIP8bcore fused to HCN2 channels were created as described 
previously (Santoro et al., 2011). Site-directed mutagenesis was 
performed using either the QuikChange Mutagenesis kit (Agi-
lent Technologies) or PCR cloning. Xenopus laevis oocytes were 
injected with 30–50 nl cRNA solutions at a concentration of 
0.5–1 µg/µl.
Biochemical binding assays
The yeast two-hybrid assay and coimmunoprecipitation techniques 
used here were described in detail in a previous publication (Santoro 
et al., 2011). In brief, yeast two-hybrid assays were performed using 
the Grow’N’Glow Two-Hybrid kit (Bio 101) and yeast strain EGY48. 
Bait constructs representing the indicated HCN1 channel domains 
were cloned into vector pEG202, and prey constructs representing 
the indicated TRIP8b domains (or mutants thereof) were cloned in 
vector pJG4-5. Bait and prey plasmids were cotransformed with re-
porter plasmid pGNG1, and cells were plated onto glucose-con-
taining medium. Transformants were restreaked (in triplicate) on 
galactose+/Leu selective medium and screened for positive GFP 
expression under a UV light after 3–5 d of growth. For coimmuno-
precipitation, Xenopus oocytes were injected with 50 nl of cRNA solu-
tion each, at a concentration of 1.0 µg/µl for HCN1 channel 
constructs and 0.2 µg/µl for TRIP8b or GFP-TRIP8b fusion con-
structs. Oocytes were collected 3 d after injection, and protein 
extracts were prepared in ice-cold lysis buffer, followed by coimmu-
noprecipitation and Western blot analysis as described previously 
(Santoro et al., 2011). Primary antibodies used were anti-HCN1 (rat 
monoclonal 7C3; gift of F. Müller [Institute of Complex Systems, 
Jülich, Germany] and U.B. Kaupp [Center of Advanced European 
Studies and Research, Bonn, Germany]), anti-TRIP8b (rabbit poly-
clonal 794; Santoro et al., 2009), and anti-GFP (290; Abcam). HRP-
anti–rat conjugate (Jackson ImmunoResearch Laboratories, Inc.) or 
HRP-anti–rabbit conjugate (Cell Signaling Technology) was used as 
One puzzling aspect of the actions of modulatory 
transmitters on Ih is that the relative extent by which 
they alter maximal Ih or shift the voltage dependence 
of channel gating can vary widely among different clas-
ses of neurons. In most neurons, neurotransmitters act 
through second messenger cascades primarily to shift 
the voltage dependence of Ih gating; in some cells, how-
ever, transmitters produce substantial changes in maximal 
Ih elicited by voltage steps to extreme negative poten-
tials where voltage gating has reached completion, with or 
without an accompanying shift in voltage gating (Bobker 
and Williams, 1989; McCormick and Williamson, 1991; 
Kiehn and Harris-Warrick, 1992; Larkman and Kelly, 
1992; Erickson et al., 1993; Gasparini and DiFrancesco, 
1999; Bickmeyer et al., 2002; Schweitzer et al., 2003; 
Frère and Lüthi, 2004; Battefeld et al., 2010; Heys and 
Hasselmo, 2012).
Here we report that the binding of TRIP8b to the 
HCN2 -subunit differentially alters the two major actions 
of cAMP on HCN channel function. TRIP8b, the major 
auxiliary subunit of HCN channels in the brain, controls 
HCN channel membrane trafficking, dendritic localiza-
tion, and cAMP-dependent voltage gating (Santoro et al., 
2004, 2009, 2011; Lewis et al., 2009; Zolles et al., 2009; 
Han et al., 2011; Piskorowski et al., 2011). TRIP8b under-
goes extensive alternative splicing at its N terminus, gen-
erating at least 10 splice variants expressed in the brain 
that produce diverse effects to either enhance or suppress 
channel plasma membrane expression. However, all iso-
forms exert an identical action to inhibit the ability of 
cAMP to shift HCN channel opening to more positive po-
tentials (Santoro et al., 2009; Zolles et al., 2009), an effect 
which has been mapped to a specific interaction site. 
TRIP8b interacts with HCN channels at two distinct sites: 
an upstream site in which a conserved central core region 
of TRIP8b binds to the HCN CNBD and a downstream 
site in which the C-terminal tetratricopeptide repeat 
(TPR) domain of TRIP8b interacts with the Ser-Asn-Leu 
(SNL) tripeptide at the C terminus of the channel (Lewis 
et al., 2009; Han et al., 2011; Santoro et al., 2011). It is 
the interaction of the central core domain of TRIP8b with 
the CNBD that is responsible for the effect of the auxil-
iary subunit to antagonize the action of cAMP (Santoro 
et al., 2011).
The precise mechanism by which TRIP8b binding re-
duces the response to cAMP is controversial. In a bio-
chemical study, Han et al. (2011) have suggested that 
TRIP8b directly antagonizes the binding of cAMP by a 
competitive interaction with the ligand-binding site of 
the CNBD. In contrast Zolles et al. (2009), using an 
electrophysiological approach, reported that TRIP8b 
reduces the maximal voltage shift in response to satu-
rating concentrations of cAMP, Vmax, an effect incom-
patible with direct competition. No study to date has 
addressed whether TRIP8b binding alters the ability of 
cAMP to enhance maximal HCN channel current.
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Model fitting
The modulation of HCN2 channel opening by voltage, cAMP, 
and TRIP8b was described by a 12-state allosteric model (Fig. 6). 
Definitions of all terms are described in Fig. 6. The open proba-
bility of the channel is determined from the equation
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The relationship in Eq. 3 for V1/2 as a function of cAMP concen-
tration and TRIP8b concentration was used in the model fitting 
of Fig. 7.
At extreme negative voltages in the absence of cAMP, the maxi-
mal open probability is given by
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The current reduction caused by the TRIP8bcore polypeptide can 
be described from the following relationship:
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Fitting of the current reduction as a function of TRIP8bcore pep-
tide concentration (data in Fig. 4 B) by the model yields the fol-
lowing values: KC
T  = 0.34 µM and KO
T  = 1.90 µM. The fitting of 
the model was conducted in MATLAB with the fitnlm function.
Online supplemental material
Detailed derivations and fitting procedures are provided in the 
supplemental text. Online supplemental material is available at 
http://www.jgp.org/cgi/content/full/jgp.201311013/DC1.
a secondary antibody. The protein bands were visualized by chemilu-
minescence using SuperSignal reagent (Thermo Fisher Scientific).
Affinity purification of TRIP8bcore peptide
A cDNA fragment encoding residues 223–303 (TRIP8bcore) of 
TRIP8b (1a-4) was cloned into vector pET52b (EMD Millipore) 
downstream of a Strep (II) tag sequence. The plasmid was trans-
formed into Escherichia coli BL21 Rosetta strain (EMD Millipore) 
under ampicillin selection. Cells were grown at 37°C in Luria broth 
to 0.6 OD600 and induced with 0.4 mM isopropyl-1-thio-d-galacto-
pyranoside. After 3 h, cells were collected by centrifugation, resus-
pended in ice-cold lysis buffer (150 mM NaCl, 100 mM Tris-Cl, 
pH 8, 1 mM EDTA, 1 mM -mercaptoethanol, 5 mg/ml leupeptin, 
1 mg/ml pepstatin, and 100 µM phenylmethylsulfonyl fluoride) 
with the addition of 10 µg/ml DNase and 0.25 mg/ml lysozyme, 
and sonicated on ice 12 times for 20 s, and the lysate was cleared 
by centrifugation for 30 min at 20,000 g. Protein was purified 
by affinity chromatography using StrepTrap HP columns (GE 
Healthcare) according to the manufacturer’s instructions and 
eluted in 150 mM KCl, 30 mM HEPES, pH 7.4, and 10% wt/vol 
glycerol plus 2.5 mM desthiobiotin. All purification steps were 
performed at 4°C and monitored using the ÄKTApurifier UPC 
10 fast protein liquid chromatography system (GE Healthcare). 
The eluted protein was then loaded into HiLoad 16/60 Super-
dex 200 prep grade size exclusion column (GE Healthcare), 
which was equilibrated with 150 mM KCl, 30 mM HEPES, pH 7.4, 
and 10% wt/vol glycerol, and the protein purity was confirmed 
by SDS-PAGE.
Inside-out patch recordings and data analysis
Macroscopic currents were recorded from excised patches 2–3 d 
after cRNA injection using an EPC-9 amplifier and PULSE acqui-
sition software (HEKA). Patch pipettes had resistances around 
1 MΩ after fire polishing. External (pipette) solutions contained 
(mM): 96 KCl, 1 NaCl, 1 MgCl2, 1.8 CaCl2, and 10 HEPES, pH 7.4 
(titrated with 50% KOH). Internal (bath) solutions contained 
(mM): 96 KCl, 1 NaCl, 10 HEPES, and 5 EGTA, pH 7.4. 3-s voltage 
steps were applied from a holding potential of 30 mV to a range 
of test potentials between 70 and 140 mV in 10-mV decre-
ments, followed by a depolarizing step to 40 mV to measure tail 
currents. All recordings were obtained at room temperature 
(22–24°C). Peak tail current amplitudes were measured at either 
0 mV for two electrode voltage clamp or 40 mV for patch clamp 
recordings after the decay of the capacitive transient, and tail cur-
rent–voltage curves were fitted using the Boltzmann equation 
I(V) = A1 + A2/{1 + exp[(V  V1/2)/s]}, in which A1 is the offset 
caused by holding current, A2 is the maximal tail current ampli-
tude, V is the test pulse voltage, V1/2 is the midpoint voltage of 
activation, and s is the slope factor (in mV). Because the 3-s long 
pulse was not sufficient to reach steady-state activation levels at 
less negative voltage steps, these represent isochronal activation 
curves rather than true steady-state curves. Nonetheless, they are 
likely to provide a good approximation of true V1/2 values, espe-
cially in the absence of cAMP or in the presence of relatively high 
cAMP levels (Wang et al., 2002) and have been routinely used in 
the literature because of problems with membrane breakdown 
with longer hyperpolarizations (Wainger et al., 2001; Zhou and 
Siegelbaum, 2007; Zolles et al., 2009).
The Hill equation was fitted to the cAMP dose–response data 
(Figs. 1, 3, and 7): V1/2 = Vmax/{1 + (K1/2/[cAMP])h}, where 
V1/2 is the V1/2 shift produced by a given cAMP concentration, 
Vmax is the maximal V1/2 shift produced by saturating cAMP, K1/2 
is the concentration of cAMP producing half of the maximal shift, 
and h is the Hill coefficient. In Fig. 5 F, the Hill equation was fitted 
to the TRIP8bcore peptide dose–response data. The data analysis 
and function fitting were performed in PULSE FIT (HEKA) and 
Igor Pro (WaveMetrics).
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intracellular modulatory factor (Santoro et al., 2009). 
In contrast, we found that the regulatory effect of 
TRIP8b was robustly maintained in cell-free patches 
with a TRIP8b-HCN1 fusion protein (Santoro et al., 2009). 
In our present study of the action of TRIP8b on HCN2, 
we have therefore covalently linked the N terminus 
of HCN2 to either the C terminus of TRIP8b or to GFP 
(as a control).
As shown in Fig. 1, application of cAMP to GFP-HCN2 
channels in inside-out patches produces a large, dose-
dependent depolarizing shift in the voltage depen-
dence of channel activation and increases the rate of 
channel opening, actions which are identical to those 
seen in WT HCN2 channels (Pian et al., 2006). In cell-
free patches in the absence of cAMP, TRIP8b-HCN2 
channels exhibit a similar voltage dependence and rate of 
activation compared with GFP-HCN2 channels (Fig. 1, 
A–C). However, TRIP8b-HCN2 channels show a marked 
reduction in sensitivity to cAMP compared with GFP-
HCN2 channels (Fig. 1, A–C). An examination of the 
cAMP dose–response curves for GFP-HCN2 and TRIP8b-
HCN2 demonstrates that the presence of TRIP8b 
causes a 40-fold increase in the concentration of cAMP 
required to produce a half-maximal shift in the voltage 
R E S U L T S
TRIP8b exerts opposing actions on the ability of cAMP  
to shift voltage-dependent gating and increase  
maximal current through HCN2 channels
In this study, we examined the biophysical mechanisms 
that underlie the action of TRIP8b to alter the response 
of HCN channels to cAMP by addressing two questions: 
(1) How does the binding of TRIP8b to HCN chan nels 
inhibit the effect of cAMP to shift HCN channel voltage 
gating to more positive voltages, and (2) does TRIP8b 
alter the action of cAMP to enhance the maximal 
tail current carried by HCN channels after steps to ex-
treme negative voltages? We focused on the inter action 
of TRIP8b with HCN2 because this -subunit forms 
channels that respond to cAMP with a large depolariz-
ing voltage shift and noticeable enhancement in maxi-
mal current.
In a previous study, our laboratory found that the ac-
tion of TRIP8b to antagonize the cAMP-dependent shift 
in HCN1 voltage gating observed in intact cells was 
greatly diminished upon patch excision when TRIP8b 
and HCN1 were expressed independently, perhaps be-
cause of instability of the complex and/or loss of some 
Figure 1. Effect of fusion of TRIP8b to HCN2 on re-
lationship between [cAMP] and voltage dependence 
of channel gating. (A) Currents elicited by hyperpo-
larizing voltage steps in inside-out patches from oo-
cytes expressing TRIP8b-HCN2 fusion channels or 
GFP-HCN2 channels in 0, 0.1, or 100 µM [cAMP]. 
The membrane was held at 40 mV for 0.5 s and 
then stepped for 3 s to test potentials from 70 to 
140 mV in 10-mV decrements. (B and C) Normal-
ized tail current G-V relationship for GFP-HCN2 (B) 
or TRIP8b-HCN2 (C) channels in the presence of 0, 
0.1, or 100 µM [cAMP]. Fits of Boltzmann relation 
yield the following values for V1/2 and slope with dif-
ferent [cAMP]. GFP-HCN2 0 cAMP: V1/2 = 116.0 mV, 
s = 4.98; 0.1 cAMP: V1/2 = 105.7 mV, s = 5.33; and 
100 cAMP: V1/2 = 96.9 mV, s = 4.65. TRIP8b-HCN2 
0 cAMP: V1/2 = 114.8mV, s = 4.05; 0.1 cAMP: V1/2 = 
113.3 mV, s = 4.91; and 100 cAMP: V1/2 = 104.2 
mV, s = 4.42. (D) V1/2 as a function of [cAMP] 
for GFP-HCN2, GFP-HCN2 + TRIP8b expressed as 
independent proteins, and TRIP8b-HCN2 fusion 
channels in inside-out patches. Solid lines show fits 
of Hill equation. Fits of the Hill equation yield GFP-
HCN2: Vmax = 17.3 mV, K1/2 = 0.08 µM, h = 1.43; 
GFP-HCN2 + TRIP8b: Vmax = 14.2 mV, K1/2 = 0.19 µM, 
h = 0.83; and TRIP8b-HCN2: Vmax = 11.1 mV, K1/2 = 
3.42 µM, h = 0.79. Error bars indicate SEM.
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whereas cAMP increases maximal current in GFP-HCN2 
channels by only 37 ± 9%, the nucleotide enhances max-
imal current in TRIP8b-HCN2 channels by 83 ± 9%, 
more than a twofold increase (P < 0.05; n = 10). Thus, 
TRIP8b exerts opposing actions on the two modula-
tory effects of cAMP: TRIP8b inhibits the ability of 
cAMP to shift voltage gating to more positive potentials, 
whereas it increases the action of cAMP to enhance 
maximal current.
An 81–amino acid domain in the conserved core of TRIP8b 
is both necessary and sufficient to produce the opposing 
actions of TRIP8b on cAMP-dependent modulation of HCN2
Are the two distinct actions of TRIP8b mediated by the 
same region of the molecule? We previously found that 
an 81–amino acid core region of TRIP8b, TRIP8bcore 
corresponding to residues 223–303 in TRIP8b(1a-4), is 
sufficient to fully reproduce the effect of full-length 
TRIP8b to antagonize the actions of cAMP on HCN1 
channel voltage gating, based on the action of the 
TRIP8bcore-HCN1 fusion protein in intact oocytes 
(Santoro et al., 2011). However, these experiments did 
not quantify the effect of the TRIP8b core region on 
the relation between cAMP concentration and the 
voltage shift in HCN channel gating. Moreover, these 
experiments did not examine whether the core region 
could mimic the effect of full-length TRIP8b to en-
hance the ability of cAMP to increase HCN channel 
maximal current.
We therefore next examined the effect of cAMP on 
voltage gating and maximal current of TRIP8bcore-
HCN2 fusion protein channels. We found that the rela-
tively small core region is necessary and sufficient to 
both inhibit the ability of cAMP to alter voltage gating 
dependence of channel activation (K1/2; Fig. 1 D). More-
over, there is a 40% decrease in the maximal shift in the 
V1/2 in response to saturating concentrations of cAMP 
(Vmax), a measure of ligand efficacy (Fig. 1 D).
We found a qualitatively similar inhibitory action on the 
modulatory effects of cAMP when TRIP8b is coexpressed 
with GFP-HCN2 as independent proteins (Fig. 1 D). How-
ever, similar to our previous results with HCN1 (Santoro 
et al., 2009), the quantitative extent of inhibition pro-
duced by the independent TRIP8b protein is much less 
than with the TRIP8b-HCN2 fusion. Thus, expression of 
TRIP8b with GFP-HCN2 causes only a 2.5-fold increase in 
the K1/2 for cAMP and a 20% decrease in Vmax. Our re-
sults differ slightly from those of Zolles et al. (2009), who 
found that coexpression of TRIP8b with HCN2 caused a 
somewhat larger decrease in Vmax (40%) and pro-
duced a slight decrease in the K1/2 (40%) for cAMP. 
These discrepancies may reflect small differences in re-
cording conditions or relative levels of protein expres-
sion. We also found that the Hill coefficient is reduced by 
44% by TRIP8b coexpression or fusion to HCN2 (from 
1.43 to 0.8), suggesting that TRIP8b might inhibit the 
cooperativity of cAMP binding. Neither TRIP8b coexpres-
sion or fusion to HCN2 alters the voltage dependence of 
HCN2 channel gating in the absence of cAMP, indicating 
that this regulatory subunit has minimal effect on the 
basal channel voltage gating (V1/2 values: GFP-HCN2, 
116.2 ± 0.86 mV; GFP-HCN2 + TRIP8b, 116.0 ± 0.98 
mV; and TRIP8b-HCN2, 114.7 ± 0.74 mV).
Next we asked whether TRIP8b alters the action of 
cAMP to enhance maximal HCN2 current after voltage 
steps to extreme hyperpolarized potentials. Unexpectedly, 
we found that fusion of TRIP8b to HCN2 increases the 
extent to which cAMP enhances Imax (Fig. 2). Thus, 
Figure 2. cAMP causes a larger in-
crease in maximal current with TRIP8b-
HCN2 and TRIP8bcore-HCN2 channels 
than with GFP-HCN2 channels. The 
membrane was held at 40 mV and 
then hyperpolarized to 140 mV with 
a 3-s test pulse, followed by a depolar-
izing pulse to 40 mV to measure the 
tail current. (A) Representative cur-
rents for GFP-HCN2, TRIP8b-HCN2, 
and TRIP8bcore-HCN2 channels before 
(black traces) and after (red traces) ap-
plication of saturating concentrations 
of cAMP (100 µM for GFP-HCN2 and 
1 mM for the other two channels) to 
inside-out patches. (B) Percent increase 
in maximal tail current amplitude 
in response to cAMP for GFP-HCN2, 
TRIP8b-HCN2, and TRIP8bcore-HCN2; 
error bars indicate SEM. Mean percent 
increases in maximal current ± SEM 
are as follows: GFP-HCN2: 37 ± 9% 
(n = 9); TRIP8b-HCN2: 83 ± 9% (n = 10); and TRIP8bcore-HCN2: 116 ± 18% (n = 9). Current amplitude increase with GFP-HCN2 by cAMP 
is significantly less than that seen with TRIP8b-HCN2 and TRIP8bcore-HCN2 (*, P < 0.05, ANOVA). There is no significant difference in 
current increase between the latter two constructs (P > 0.05, t test).
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actions of cAMP with TRIP8b fusion proteins are not 
the result of some nonspecific effects of the fusion per se, 
as the effects are completely dependent on the short 
internal stretch of 22 amino acids. Consistent with re-
sults using full-length TRIP8b, neither the TRIP8bInt 
nor the TRIP8bcore fusion proteins show altered volt-
age-dependent gating in the absence of cAMP (Fig. 3 B), 
further indicating that basal voltage gating is not af-
fected by this regulatory subunit.
Effects of acute application of a TRIP8bcore peptide 
to HCN2 channels
How does TRIP8b exert its opposing effects on the 
cAMP-dependent modulation of HCN2, inhibiting the 
action of cAMP to shift voltage gating while enhancing 
the action of cAMP to increase maximal current? Previ-
ous studies have suggested that channel opening 
involves a voltage-dependent activation step followed by 
a voltage-independent opening reaction. cAMP binding 
is thought to stabilize the open state of the channel, 
thereby enhancing maximal open probability and, 
thereby, maximal current (Shin et al., 2004; Chen et al., 
2005; Zhou and Siegelbaum, 2007). The relatively large 
maximal open probability of HCN2 in the absence of 
cAMP (>0.5) normally limits the extent to which cAMP 
can enhance maximal current (Zhou and Siegelbaum, 
2007). We therefore hypothesized that TRIP8b might 
enhance the ability of cAMP to increase maximal cur-
rent by depressing maximal channel open probability in 
the absence of cAMP, thereby providing a larger dynamic 
range by which cAMP can increase channel opening.
To directly address this possibility, we examined the 
effect of acute application of a soluble, purified TRIP8b 
core peptide (TRIP8b residues 223–303) to HCN2 chan-
nels in cell-free inside-out patches (using oocytes where 
TRIP8b was not coexpressed with HCN2). Consistent 
with the above hypothesis, application of 4 µM TRIP8b 
core peptide to HCN2 channels in the absence of cAMP 
causes a marked, 40%, decrease in current amplitude 
in response to a hyperpolarizing voltage step to 140 mV, 
a potential at which voltage-dependent activation is 
complete (Fig. 4 A). In contrast, the core peptide pro-
duces no detectable change in the voltage dependence 
of channel gating (Fig. 3 B). Over a range of concentra-
tions, the core peptide causes a dose-dependent reduc-
tion in HCN2 channel maximal current (in the absence 
of cAMP), resulting in a 60% decrease in current at 
40 µM, the maximum concentration of core peptide that 
was soluble (Fig. 4 B).
To determine whether the effects of TRIP8bcore on 
maximal current are specific, we examined the action 
of a mutant core peptide in which a conserved penta-
peptide sequence (EEEFE) is replaced with a charge-
reversed sequence (RRRAR; Fig. 4, C and D). In a yeast 
two-hybrid assay, we find that this mutation abolishes 
the ability of TRIP8b to bind to the HCN1 CNBD 
and facilitate the action of cAMP to increase maximal 
current (Figs. 2 and 3 A). Surprisingly, the magnitude 
of some of the effects of TRIP8bcore on the cAMP-depen-
dent modulation of HCN2 are even greater than those 
seen with full-length TRIP8b-HCN2. Thus, TRIP8bcore-
HCN2 fusion protein channels exhibit a >2,000-fold 
increase in the K1/2 for cAMP relative to HCN2 alone, 
a 50-fold larger effect than seen with the full-length 
TRIP8b-HCN2 fusion (Fig. 3 A). The TRIP8bcore-HCN2 
channels also display a decrease in Vmax with saturat-
ing cAMP (27% decrease). cAMP increased the maxi-
mal current carried by TRIP8bcore-HCN2 channels by 
116 ± 18%, slightly greater than the 83% increase in max-
imal current seen with cAMP with full-length TRIP8b 
fusion protein channels (P > 0.05; n = 9; Fig. 2). We 
next confirmed previous results obtained using HCN1 
channels in intact oocytes, that the TRIP8b core is nec-
essary for the action of full-length TRIP8b to inhibit 
the effects of cAMP on voltage gating (Santoro et al., 
2011). Thus, a fusion protein consisting of HCN2 plus 
full-length TRIP8b lacking only 22 amino acids in the 
core domain (TRIP8bInt-HCN2) generates channels 
whose response to cAMP is identical to that of HCN2 
expressed alone without TRIP8b (Fig. 3 A). These re-
sults further suggest that the alterations in the regulatory 
Figure 3. TRIP8b core domain is necessary to antagonize ac-
tion of cAMP on HCN2. (A) V1/2 as a function of [cAMP] for 
TRIP8bInt-HCN2 and TRIP8bcore-HCN2 channels in inside-out 
patches, compared with GFP-HCN2 and TRIP8b-HCN2 channels. 
Solid lines show fits of the Hill equation. Fits of the Hill equa-
tion yield TRIP8bInt-HCN2: Vmax = 18.2 mV, K1/2 = 0.08 µM, h = 
1.11; and TRIP8bcore-HCN2: Vmax = 13.3 mV, K1/2 = 190 µM, h = 
0.69. Note that TRIP8bInt, with internal deletion of 22 residues 
of the core domain, fails to alter cAMP dose–response relation. 
(B) V1/2 values of various indicated constructs in the absence of 
cAMP show no significant differences (P > 0.05, ANOVA). Error 
bars indicate SEM.
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potentials, similar to what we observe when the core 
peptide is fused to HCN2. Indeed, application of the 
core peptide rapidly antagonizes the ability of cAMP to 
shift HCN2 gating to more positive potentials (Fig. 5). 
At a concentration of 4 µM, TRIP8bcore almost fully 
abolishes the voltage shift in response to 0.1 µM cAMP 
and significantly reduces the voltage shift with 10 µM 
cAMP (Fig. 5, A–C). Importantly, the effect of cAMP 
recovers rapidly after wash-out of the peptide (Fig. 5 A), 
indicating that the binding between TRIP8b and HCN2 
is reversible. This rapid reversibility may explain the 
finding that the modulatory action of TRIP8b on HCN 
channel function is diminished after patch excision 
when TRIP8b and HCN subunits are coexpressed as in-
dependent proteins (Santoro et al., 2009, 2011). Impor-
tantly, the action of the core peptide to inhibit the 
effect of cAMP to shift HCN2 voltage gating results 
from a specific action of the peptide as it is prevented by 
the EEEFE to RRRAR mutation (Fig. 5 D).
Examination of the action of a range of cAMP con-
centrations reveals that, at a concentration of 4 µM, 
the TRIP8bcore peptide shifts the cAMP dose–response 
(Fig. 4 C). Application of this mutant peptide to HCN2 
channels has no effect on maximal current, arguing for 
a specific action dependent on the conserved core se-
quence (Fig. 4 D).
Is the effect of the core peptide to reduce maximal 
current related in any way to the action of cAMP to en-
hance maximal current? The two processes do indeed 
interact as the application of 100 µM cAMP fully reverses 
the inhibitory action of the core peptide on maximal 
current. Thus, cAMP application is able to increase max-
imal current to a level similar to that seen when cAMP is 
applied in the absence of core peptide (Fig. 4 A). As a 
result, cAMP application in the presence of core peptide 
produces a larger percentage increase in maximal cur-
rent amplitude compared with that seen when cAMP 
is applied in the absence of core peptide. This action 
therefore accounts for the increased effect of cAMP to 
enhance maximal current observed above with TRIP8b-
HCN2 or TRIP8bcore-HCN2 channels (Fig. 2).
We next asked whether acute application of the core 
peptide also inhibits the ability of cAMP to shift the volt-
age dependence of HCN2 opening to more positive 
Figure 4. Direct application of TRIP8bcore polypeptide to inside-out patches suppresses HCN2 maximal current in the absence of cAMP. 
(A) Representative experiment showing effects of TRIP8bcore polypeptide on HCN2 currents in inside-out patches elicited by a hyperpo-
larization to 140 mV, either in the absence or presence of cAMP. The current recording protocol is described in Fig. 3. The internal 
bath solution contained control solution, 4 µM TRIP8bcore with no cAMP, 4 µM TRIP8bcore plus 100 µM cAMP, or 100 µM cAMP with no 
TRIP8b. (B) Dose–response curve for the percent reduction in current amplitude at extreme negative voltages as a function of TRIP8bcore 
polypeptide concentration (in the absence of cAMP). Error bars show SEM. (C) The binding activity of the HCN1 C-linker/CNBD 
(residues 390–611) with WT and mutant TRIP8b (constant region, exons 5–16) assessed using a yeast two-hybrid assay. For TRIP8b, the 
yellow square represents the conserved core region. In TRIP8bcore-mut, the WT EEEFE core residues are substituted by RRRAR. The red 
colors denote the TPR domains. Activity was detected by transactivation of a GFP reporter gene. “+++” indicates very strong fluorescence; 
“” indicates no detectable fluorescence (see Santoro et al. [2011]). (D) Representative HCN2 currents before (black trace) and after 
(blue trace) the application of TRIP8bcore-mut polypeptide to inside-out patches. The current recording protocol is described in Fig. 3.
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curve for TRIP8b. Although these results are consistent 
with a competition of cAMP and TRIP8b for a single 
binding site, the finding that TRIP8b reduces the maxi-
mal response to saturating concentrations of cAMP is 
more consistent with an allosteric interaction, as dis-
cussed in the next section.
TRIP8b inhibits the effect of cAMP to facilitate HCN2 
voltage gating through an allosteric mechanism
To explore the mechanism by which TRIP8b alters the 
function of HCN2 channels, we examined whether the 
actions of TRIP8b are consistent with an extension of a 
six-state cyclic allosteric model previously used to de-
scribe the modulatory action of cAMP on HCN2 gating 
in the absence of TRIP8b (Fig. 6; Zhou and Siegelbaum, 
2007). According to this model, in the absence of cAMP, 
membrane hyperpolarization causes the channel to un-
dergo a voltage-dependent transition from a closed rest-
ing state (CR) to a closed active state (CA), from which the 
channel undergoes a voltage-independent conforma-
tional change to the open state (O). cAMP (A) can bind 
and unbind the CNBD in all three states, yielding three 
curve to higher agonist concentrations, causing a 70-
fold increase in the K1/2 for cAMP and a small decrease 
in Vmax (Fig. 5 E). The shift in K1/2 with 4 µM TRIP8bcore 
is intermediate between the results with TRIP8b-HCN2 
and TRIP8bcore-HCN2 fusion protein channels, suggest-
ing that the local effective concentration of TRIP8b in 
the two fusion proteins may be, respectively, lower and 
higher than 4 µM. Alternatively, the efficacy or affinity 
of the core peptide may differ from that observed with 
the two fusion protein channels.
We next explored the effect of a range of concentra-
tions of TRIP8bcore on the action of cAMP. The core 
peptide produces a dose-dependent inhibition of the 
effect of a given concentration of cAMP to shift the V1/2 
to more positive potentials (Fig. 5 F). Moreover, as the 
cAMP concentration is increased, higher concentrations 
of TRIP8bcore are required to produce a given level of 
inhibition of the cAMP response. Thus, TRIP8b and 
cAMP exert reciprocal inhibitory effects on each other’s 
action. TRIP8b shifts the dose–response curve for cAMP 
to higher concentrations, and conversely, cAMP produces 
a concentration-dependent shift in the dose–response 
Figure 5. Effects of TRIP8bcore polypeptide on 
action of cAMP on HCN2 channel voltage gat-
ing. (A) Representative experiment showing V1/2 
of HCN2 channels in inside-out patches with so-
lutions containing the indicated [cAMP] in the 
absence or presence of 4 µM TRIP8bcore polypep-
tide. Open circles indicate V1/2 in the absence of 
both cAMP and TRIP8bcore; closed circles indi-
cate V1/2 in the presence of 0.1 or 10 µM cAMP, 
with or without 4 µM TRIP8bcore polypeptide, 
as indicated. (B) Normalized G-V relationship 
for HCN2 channel tail currents in 0, 0.1, or 
10 µM cAMP. (C) Normalized G-V relationship for 
HCN2 channel tail currents in the presence of 4 
µM TRIP8bcore polypeptide plus 0, 0.1, or 10 µM 
cAMP. (D) Normalized G-V relationship for HCN2 
tail currents in the presence of 4 µM TRIP8bcore-
mut polypeptide plus 0, 0.1, or 10 µM cAMP. (E) 
Shift in V1/2 as a function of [cAMP] in the absence 
(open circles) or presence (closed circles) of 4 µM 
TRIP8bcore polypeptide. Solid lines show fits of the 
Hill equation, which yield HCN2: Vmax = 18.1 
mV, K1/2 = 0.08 µM, h = 0.86; and HCN2 plus 4 
µM TRIP8bcore: Vmax = 15.8 mV, K1/2 = 5.64 µM, 
h = 0.86. (F) Percent decrease in V1/2 produced 
by the indicated concentrations of cAMP as a func-
tion of TRIP8bcore concentration (left ordinate). 
Fits of the Hill equation (solid lines) yield 0.1 µM 
cAMP: K1/2 = 0.22 µM, h = 1.35, percent maximal 
decrease in V1/2 = 100%; 1 µM cAMP: K1/2 = 1.57 
µM, h = 1.69, percent maximal decrease in V1/2 = 
97%; 10 µM cAMP: K1/2 = 2.34 µM, h = 1.19, per-
cent maximal decrease in V1/2 = 69%; and 100 
µM cAMP: K1/2 = 3.96 µM, h = 0.74, percent maxi-
mal decrease in V1/2 = 42%. The Hill fit to the 
TRIP8b dose–response curve for HCN2 maximal current reduction from Fig. 4 B is replicated here for comparison (red dashed line, 
right ordinate). Error bars indicate SEM.
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TRIP8b must reduce cAMP binding to the open state 
more than it reduces cAMP binding to the closed state. 
Finally, as the various states are incorporated in a cyclic 
reaction scheme, cAMP binding must necessarily re-
duce the affinity of the channel for TRIP8b. We ad-
justed the parameters of the model to obtain the best fit 
to the measured relation between [cAMP] and V1/2, in 
the presence of 0–12 µM TRIP8bcore peptide (Fig. 7; see 
supplemental text for details).
The model provides a good fit to the cAMP dose– 
response curves in both the absence and presence of 
increasing concentrations of TRIP8b. In particular, the 
model reproduces the effect in which increasing con-
centrations of TRIP8b cause both a progressive shift 
in the cAMP dose–response curve to higher concentra-
tions of cAMP and a progressive decrease in the maxi-
mal response to saturating cAMP (Fig. 7). Based on the 
parameters obtained from the fit (see legend to Fig. 7), 
we infer that binding of TRIP8b produces a 70-fold de-
crease in the affinity of the closed channel for cAMP. 
Conversely, binding of cAMP produces an identical de-
crease in the affinity of the closed channel for TRIP8b. 
For the open channel, cAMP or TRIP8b binding pro-
duces an even greater 300-fold decrease in affinity for 
the antagonistic ligand. The finding that the K KTC
A
TO
A/  
ratio (9.6) is much smaller than the K KC
A
O
A/  ratio (105) 
indicates that TRIP8b binding does indeed reduce the 
corresponding agonist bound states: ACR, ACA, and AO. 
The key property of this model is that the opening transi-
tion is allosterically coupled to a conformational change 
in the CNBD that enhances the affinity of the open state 
for cAMP (dissociation constant KO
A ), relative to the af-
finity of the two closed states (identical dissociation con-
stant KC
A ). Thus, cAMP binding to the open state is 
energetically more favorable than binding to the closed 
state, causing agonist binding to shift the equilibrium 
toward the open transition by the factor K KC
A
O
A/ .  Be-
cause the voltage-independent opening reaction is ki-
netically coupled to the voltage-dependent activation 
step, the cAMP-dependent enhancement of channel 
opening both shifts the apparent voltage dependence of 
channel gating to more positive potentials and increases 
maximal open probability.
We incorporated TRIP8b (T) into this model by as-
suming it binds to the open and closed states of the 
channel, in both the cAMP-bound or unbound states. 
This results in an additional six states for the TRIP8b-
bound channel, three states with the CNBD unoccu-
pied by cAMP (TCR, TCA, and TO; Fig. 6, top face), and 
three states with the CNBD occupied by cAMP (ACRT, 
ACAT, and AOT; Fig. 6, back face). According to the 
model, TRIP8b binding may, in principle, alter the af-
finity of both the closed and open states for cAMP. Our 
finding that TRIP8b decreases Vmax implies that 
Figure 6. 12-state allosteric model for regulation of HCN2 channel opening by voltage, cAMP, and TRIP8b. The vertical and front-
back transitions of the cubic scheme represent the cAMP and TRIP8b binding reactions to the channel, respectively. The two hori-
zontal transitions are the voltage-dependent activation step reflecting voltage sensor movement, followed by a voltage-independent 
opening step. The front face of the cube is the six-state cyclic allosteric model that represents the effects of voltage and cAMP on 
channel opening in the absence of bound TRIP8b (Zhou and Siegelbaum, 2007); the top face is a six-state cyclic allosteric model 
that represents the actions of voltage and TRIP8b binding on channel opening in the absence of bound cAMP. TRIP8b and cAMP 
can both bind to the channel at the same time, as represented by the back and bottom faces of the cube. Definition of states and 
ligands: CR, unliganded closed channel with voltage sensor in the resting state; CA, unliganded closed channel with voltage sensor in 
the activated state; O, unliganded channel in the open state; A, cAMP; T, TRIP8b. Definition of parameters: KV, equilibrium constant 
for transition of closed channel transition between resting state and activated state; L, intrinsic equilibrium constant for channel 
opening; KC
A  and KO
A ,  dissociation equilibrium constants for cAMP binding to closed and open states, respectively; KC
T  and KO
T ,  
dissociation equilibrium constants of TRIP8b binding to channel in closed and open states, respectively; KTC
A  and KTO
A ,  dissociation 
equilibrium constants for cAMP binding to TRIP8b-bound channels in closed and open states, respectively; KAC
T  and KAO
T ,  dissocia-
tion equilibrium constants for TRIP8b binding to cAMP-bound channels in closed and open states, respectively.
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with a separate low-affinity binding site on the channel 
distinct from the high-affinity site responsible for the 
action of TRIP8b to antagonize the cAMP-dependent 
shift in HCN2 voltage gating. Consistent with such a dis-
sociation, we find that a point mutation in a conserved 
arginine, HCN2R591E, which profoundly disrupts the 
binding to the CNBD of both cAMP (Chen et al., 2001; 
Zhou and Siegelbaum, 2007) and TRIP8b (Han et al., 
2011), has no effect on the ability of the TRIP8b core 
polypeptide to reduce HCN2 maximal current (Fig. 8). 
Collectively, these observations strongly argue that 
TRIP8b reduces maximal current through a kinetic and 
structural mechanism that is distinct from its action to 
antagonize the effect of cAMP on HCN2 voltage gating. 
We next explore in more detail the mechanism for this 
second action of TRIP8b to suppress maximal current.
Molecular mechanism underlying the action of TRIP8b  
to reduce HCN2 channel current
TRIP8b and HCN1 have been previously found to inter-
act at two sites (Lewis et al., 2009; Han et al., 2011; 
Santoro et al., 2011). At an upstream site the core re-
gion of TRIP8b binds to the CNBD of the channel; at a 
downstream site the C-terminal TPR domain of TRIP8b 
binds the extreme C-terminal SNL tripeptide of the 
channel. Which channel domains are required for the 
action of the TRIP8b core peptide to regulate HCN2 
maximal current? We find that truncation of HCN2 at 
the N terminus of the CNBD blocks the ability of TRIP8b 
to reduce HCN2 channel current (HCN2CNBD; Fig. 8). 
In contrast, as stated above, the HCN2R591E point muta-
tion does not alter the action of 4 µM TRIP8b to reduce 
maximal HCN2 current (Fig. 8). These results suggest 
that, although a direct interaction of TRIP8b with the 
CNBD may not be required and some other previously 
unrecognized low-affinity binding site may be impor-
tant for the reduction in channel current, the presence 
of the CNBD is still essential for TRIP8b to exert its ef-
fect to reduce maximal current amplitude (either by 
contributing to the integrity of the low affinity binding 
site or by acting as an effector domain).
If the action of TRIP8b to reduce HCN2 maximal 
channel current does not depend directly on its interac-
tion with the CNBD, how does cAMP antagonize this ac-
tion? A previous study has suggested that cAMP binding 
enhances HCN channel opening by relieving an inhibi-
tory action of the CNBD on channel gating (Wainger 
et al., 2001). At a structural level, cAMP is thought to act 
by promoting assembly of the four CNBDs in a channel 
into a tetrameric gating ring (Zagotta et al., 2003). We thus 
hypothesized that the inhibitory action of TRIP8b on 
channel current is only manifest when the gating ring is 
disassembled, that is, in the absence of cAMP. To test this 
hypothesis, we took advantage of a triple point mutation 
our laboratory previously identified in the first (A) helix 
of the cytoplasmic C-linker region of the channel, which 
affinity of the open state for cAMP to a greater extent 
than it reduces affinity of the closed state for cAMP. 
Moreover, this accounts for the action of TRIP8b to in-
hibit the efficacy with which cAMP shifts the voltage de-
pendence of channel gating, resulting in the decrease 
in Vmax.
In principle, the model could also account for our ob-
servation that TRIP8b reduces HCN2 maximal current in 
the absence of cAMP (as shown in Fig. 4), if TRIP8b were 
to bind to the cAMP-free closed state more tightly than 
it were to bind to the cAMP-free open state. However, the 
best fit of the model yields nearly identical values for KC
T  
(0.089 ± 0.027 µM) and KO
T  (0.064 ± 0.010 µM). A sec-
ond discrepancy is seen when we independently adjusted 
KC
T  and KO
T  to fit the observed reduction in Imax (Fig. 4 B). 
In this case, the model predicts that TRIP8b should pro-
duce a 3-mV shift in the voltage dependence of gating 
in the absence of cAMP, an effect we do not observe 
(Fig. 3 B). Moreover the estimates of KC
T  and KO
T  obtained 
from the fits in the absence of cAMP are 4- to 30-fold 
larger (KC
T  = 0.34 µM; KO
T  = 1.90 µM) than those ob-
tained when we fit the relation between TRIP8b core 
polypeptide concentration and the magnitude of the 
shift in voltage gating with cAMP (compare Fig. 4 B  
with Fig. 5 F; see Model fitting subsection of Materials 
and methods).
The above discrepancies suggest that the effects of 
TRIP8b to inhibit maximal current amplitude in the ab-
sence of cAMP are mediated through an interaction 
Figure 7. V1/2 as a function of [cAMP] and [TRIP8bcore] poly-
peptide, fitted by the 12-state allosteric model. The TRIP8bcore 
polypeptide concentrations are indicated. The parameters of 
the front face of the model (corresponding to the six-state cyclic 
model) are adopted from Zhou and Siegelbaum (2007): L = 0.43, 
s = 4.4, KC
A  = 0.844 µM, KO
A  = 0.008 µM. The best fit of the model 
yields the following values for the other parameters: KC
T  = 0.089 ± 
0.027 µM, KO
T  = 0.064 ± 0.010 µM, KTC
A  = 33.58 ± 8.18 µM, 
KTO
A  = 3.53 ± 1.33 µM. KAC
T  and KAO
T  are then derived from the 
other parameters: KAC
T  = K K KTC
A
C
T
C
A⋅ /  = 3.54 µM and KAO
T  = 
K K KTO
A
O
T
O
A⋅ /  = 28.24 µM. Error bars show SEM. See supplemen-
tal text for further details.
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2007). In this model, cAMP facilitates channel open-
ing by binding more tightly to the open than to the 
closed state of the channel. In the expanded 12-state 
model, TRIP8b exerts an allosteric action that reduces 
the affinity of both the closed and open states of the 
channel for cAMP. Conversely, cAMP binding pro-
duces an allosteric effect to reduce the affinity of the 
closed and open channel for TRIP8b. Because TRIP8b 
also reduces Vmax, its binding must reduce the cAMP 
affinity of the open state to a greater extent than it re-
duces the cAMP affinity of the closed state, a predic-
tion which was confirmed by our detailed modeling 
results. In contrast, unlike cAMP, which binds much 
more favorably to the open state than the closed state, 
TRIP8b binds with similar affinity to the open and 
closed states of the channel.
A recent biochemical study focused on the nature of 
the interaction between TRIP8b and HCN1 at the up-
stream interaction site, using a channel in which the 
C-terminal SNL tripeptide was deleted to prevent the 
interaction at the downstream site (Han et al., 2011). 
Under these conditions the binding between TRIP8b 
and HCN1 is reduced by cAMP in a concentration-
dependent manner. Moreover the binding of TRIP8b 
to the HCN1SNL truncation mutant is abolished when 
a highly conserved arginine residue in the CNBD, 
which interacts with the cyclized phosphate of cAMP, 
is mutated to glutamate (R538E in HCN1 and R591E 
in HCN2). This led Han et al. (2011) to conclude that 
the core region of TRIP8b may directly bind to this 
conserved arginine, thereby competing with cAMP for 
the CNBD.
connects the S6 transmembrane segment to the CNBD. 
We found that this mutation promotes gating ring assem-
bly in the absence of cAMP (Zhou et al., 2004). We there-
fore predicted that this mutation should also block the 
action of TRIP8b to reduce channel current. As shown in 
Fig. 8 (HCN2FPN), the triple point mutation does indeed 
block the effect of TRIP8b to inhibit HCN2 maximal cur-
rent, supporting the hypothesis outlined above.
DISCUSSION
In this study, we report that TRIP8b exerts multiple effects 
on HCN2 channel function. The auxiliary subunit shifts 
the relation between V1/2 and [cAMP] to higher concen-
trations, decreasing the sensitivity of the channel to cAMP. 
TRIP8b also decreases the maximal voltage shift in re-
sponse to a saturating concentration of cAMP (Vmax), re-
flecting a reduction in cAMP efficacy. Finally, in the 
absence of cAMP, TRIP8b inhibits the maximal current 
through the channel. Because this latter effect is antago-
nized by cAMP, TRIP8b enhances the action of cAMP to 
increase maximal current through the channel.
An allosteric mechanism accounts for the action  
of TRIP8b to inhibit the effect of cAMP to shift  
the voltage dependence of HCN2 channel opening
The effect of TRIP8b to inhibit the cAMP-dependent 
modulation of HCN2 voltage gating can be accounted 
for by an expansion of a six-state allosteric model that 
has been previously used to describe the dual actions 
of voltage and cAMP to promote HCN2 channel open-
ing in the absence of TRIP8b (Zhou and Siegelbaum, 
Figure 8. Importance of C-terminal regions of HCN2 for the ability of TRIP8b to reduce maximal current. (A) Representative currents 
through HCN2 WT and mutant channels before (black traces) and after (blue traces) the application of 4 µM TRIP8bcore polypeptide to 
inside-out patches (no cAMP present). HCN2CNBD, truncation after residue V526 removing entire CNBD and all downstream residues; 
HCN2R591E, point mutation of conserved arginine in CNBD required for high-affinity cAMP binding; HCN2FPN, triple point mutation 
substituting FPN sequence for residues QEK in A helix of C-linker (residues 450–452 in HCN2). The recording protocol is described 
in Fig. 2. (B) Percent reduction in maximal tail current amplitude for HCN2 WT and mutant channels in response to 4 µM TRIP8bcore 
polypeptide. Error bars indicate SEM. Mean percent reductions ± SEM are as follows: HCN2, 43 ± 4% (n = 9); HCN2CNBD, 1.6 ± 2% (n = 3); 
HCN2R591E, 48 ± 9% (n = 3); and HCN2FPN, 1 ± 2% (n = 3).
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TRIP8b inhibits maximal current through HCN2 channels 
through a second action
What is the relation between the action of TRIP8b to 
reduce maximal Ih in the absence of cAMP and the ac-
tion of TRIP8b to decrease the affinity of the CNBD for 
cAMP? As discussed in the Results, although in princi-
ple the 12-state allosteric model can account for both of 
these actions through TRIP8b binding more tightly to 
the closed than open state of the channel, this single 
mode of action is not consistent with our experimental 
and modeling results. Rather, the reduction in maximal 
macroscopic current appears to be caused by a second, 
low-affinity action of TRIP8b to reduce maximal chan-
nel current. Such an effect could result from a reduc-
tion in channel open probability or from a reduction in 
single channel conductance.
One important caveat with our modeling results is 
that the 12-state allosteric reaction scheme does not take 
into account the tetrameric nature of the channel and 
its interaction with cAMP (Ulens and Siegelbaum, 2003) 
and TRIP8b (Bankston et al., 2012). Furthermore, a re-
cent study suggests that the gating of HCN2 channels is 
much more complex than our model, involving a pro-
found cooperative interaction (Kusch et al., 2012). Al-
though our initial attempts to fit a model with multiple 
equivalent cAMP and TRIP8b binding sites did not yield 
a significant improvement in our ability to describe the 
two effects of TRIP8b through a single mechanistic ac-
tion, some more complex model with nonequivalent 
binding sites (Ulens and Siegelbaum, 2003; Kusch et al., 
2012) may prove adequate to explain our results based 
on a single underlying action of TRIP8b.
If TRIP8b does indeed exert separate high- and low-
affinity actions at two distinct binding sites that, respec-
tively, antagonize the action of cAMP on voltage gating 
and reduce maximal current in the absence of cAMP, 
where are these sites located? One possibility is that 
TRIP8b binds to two separate sites within the CNBD. 
However it is unclear as to how the relatively compact 
CNBD could accommodate multiple TRIP8b proteins. 
Also, any interaction of TRIP8b with a second CNBD-
binding site that reduces maximal current must be 
impervious to the R591E mutation, which disrupts 
high-affinity binding of TRIP8b to the CNBD (Fig. 9; 
Han et al., 2011). Rather, we favor a model in which the 
core region of TRIP8b binds to two separate sites on the 
channel, a high-affinity site on the CNBD that allosteri-
cally reduces cAMP binding and a low-affinity site located 
elsewhere in the channel that reduces maximal current, 
perhaps by decreasing apparent single channel conduc-
tance. As we previously failed to detect an interaction 
between the TRIP8b core peptide and the C-terminal 
downstream HCN1 binding site using a yeast two-hybrid–
based assay (Santoro et al., 2011), this second site is likely 
to be located either within the C-linker or within the 
channel’s intracellular loops.
However, the finding that TRIP8b reduces the maxi-
mal voltage shift with saturating concentrations of 
cAMP (Zolles et al., 2009) indicates that the auxiliary 
subunit does not directly compete with cAMP for the 
channel but acts through an allosteric mechanism to 
decrease the affinity of the CNBD for ligand. More-
over, several additional lines of evidence make it un-
likely that TRIP8b directly interacts with the binding 
domain arginine (R591 in HCN2). First, the crystal 
structure of the HCN2 CNBD with cAMP bound shows 
that the arginine is embedded in the binding pocket 
and surrounded by the CNBD -roll (Zagotta et al., 
2003). Although cAMP or cGMP are small enough to 
enter the pocket and interact with the arginine, it is 
unclear how the internal core domain of TRIP8b 
would have ready access to this site. Second, we find 
that the binding of TRIP8b to HCN1 is not altered 
when the corresponding arginine (R538) is substi-
tuted with alanine (HCN1 R538A), although we con-
firmed that the R538E mutation does weaken the 
binding of TRIP8b to the channel (Fig. 9). These re-
sults can be reconciled if the conserved arginine of the 
CNBD does not directly interact with TRIP8b, but 
rather its substitution by glutamate results in a local 
disruption of the CNBD, thereby weakening the bind-
ing of TRIP8b. We further hypothesize that this local 
structural change in the CNBD may not occur with 
the less disruptive alanine substitution. More detailed 
structural studies, including x-ray crystallography, are 
needed to identify the precise location of the TRIP8b 
binding site.
Figure 9. The effect of mutations in the HCN1 key CNBD residue 
R538 on TRIP8b binding. Western blot analysis shows binding of 
HCN1, HCN1R538A, and HCN1R538E mutants to WT TRIP8b(1b-2) 
assessed by coimmunoprecipitation from Xenopus oocyte extracts 
coinjected with TRIP8b and HCN1 cRNA. The top row shows the 
HCN1 input signal using an HCN1 antibody. The middle row 
shows the TRIP8b input signal using an anti-TRIP8b antibody. The 
bottom row shows the amount of HCN1 protein coimmunoprecipi-
tated with the TRIP8b antibody (Western blot probed using HCN1 
antibody). Note that exposure times are directly comparable along 
each row but not down each column. Individual bands have been 
cut from intact gel pictures and aligned to allow direct comparison 
of intensities for WT and mutant constructs.
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PART III 
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MATERIALS AND METHODS 
 
 
Preparation of proteins 
 The cDNA fragment encoding residues 521–672 of human HCN2 (HCN2 CNBD) was cloned into a 
modified pET-24b downstream of a double His6-maltose-binding protein (MBP) tag and 
transformed into Escherichia coli Rosetta strain under Kanamycin and chloramphenicol selection. 
In order to uniformly label HCN2 CNBD with 15N or 15N/13C, cells were grown in M9 minimal 
medium containing 1.0 g/L 15NH4Cl (Isotec), 3% glucose or 
13C-U, 1 mM MgSO4, 0.01 mg/mL 
thiamine-HCl, 18.5 µM FeCl3 6H2O, 0.1 mM CaCl2 2H2O. HCN2 CNBD was expressed and purified 
using the protocol described in reference 31, with an additional step of purification. After the size 
exclusion chromatography the fractions containing HCN2 CNBD were combined and buffer 
exchanged using PD10 column to buffer A (5 mM KCl, 20 mM potassium phosphate, pH 6). A 
cation-exchange chromatography column Mono S G 5/5 (GE Healthcare) was used to remove 
remaining protein contaminants. Buffer A was used as binding buffer and elution was directed 
with buffer B (500 mM KCl, 20 mM potassium phosphate, pH 6). The constructs encompassing 
residues 188–268 (miniTRIP8b) and 188-240 (microTRIP8b) of TRIP8b (1a) were expressed and 
purified as described in reference 26.  
 
 
Purification of protein complexes 
The modified pET-24b containing HCN2470-672 (C-linker + CNBD), previously described in reference 
31, was co-transformed with vector pET-52b containing miniTRIP8b (see reference 26) into 
Escherichia coli Rosetta strain under Kanamycin and Ampicillin selection. Cells were grown at 37°C 
in Luria Broth to a OD600nm of 0.6 and induced with 0.4 mM isopropyl-1-thioβ-D-galactopyranoside. 
After 3 h cells were collected by centrifugation and resuspended in ice-cold lysis buffer (500 mM 
KCl, 30 mM Hepes, pH 7.4, 10% w/v glycerol) with the addition of 1 mM β-mercaptoethanol, 10 
µg/ml DNase, 0.25 mg/ml lysozyme, 100 µM phenylmethylsulfonyl fluoride, 5 µM leupeptin, and 1 
µM pepstatin. The cells were sonicated on ice 12 times for 20 s each, and the lysate was cleared by 
centrifugation. The HCN2 C-linker/CNBD was purified by affinity chromatography on Ni2+-NTA and 
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eluted in lysis buffer plus 300 mM imidazole and cAMP at different concentrations: from 0 to 1 
mM. 
The cDNA fragments encoding HCN2521-645, HCN2521-651, HCN2521-657 and HCN2521-663, HCN2521-666, 
HCN2521-669 were cloned into the same modified pET-24b described above. Each of these plasmids 
(including the one containing HCN2 CNBD earlier described) was co-transformed with pET-52b 
containing miniTRIP8b into Escherichia coli Rosetta strain under Kanamycin and Ampicillin 
selection. Cells were grown at 37°C in Luria broth to OD600nm of 0.8 and induced with 0.1 mM 
isopropyl-1-thioβ-D-galactopyranoside for 3 h. The copurifications were performed using the 
protocol described in reference 26. Samples were analyzed by SDS-PAGE using a 8-16% PreciseTM 
Tris-Glycine Gel (12 well) (Thermo scientific), in Tris-Glycine-SDS buffer. 
 
 
Isothermal Titration Calorimetry  
Measurements were carried out at 25 °C using an microcalorimeter (MicroCal VP-ITC System, GE 
Healthcare). The volume of sample cell was 2 ml; the reference cell contained water. The proteins 
were buffer exchanged with a PD10 column to PBS buffer. HCN2 CNBD (20 µM) was titrated with 
miniTRIP8b (200 µM) using injection volumes of 1 µl. Calorimetric data were analyzed with Origin 
software (version7, MicroCal), using equations described for the single-site binding model [63]. 
 
 
Circular Dichroism Measurements 
Circular dichroism (CD) spectra were recorded with Jasco J-810 spectropolarimeter (Jasco Europe) 
at 22 °C using a 1 mm pathlength cuvette. Data were acquired every 1 nm. For the CD experiments 
the proteins were were buffer exchanged with a PD10 column to PBS buffer. 
 
NMR Spectroscopy 
Resonance Assignment of the cAMP-unbound CNBD  
For NMR experiments the protein samples were buffer exchanged with a PD10 column to the 
following buffer: 150 mM KCl, 20 mM potassium phosphate, pH 7, 10 % (v/v) 2H2O (Sigma). The 
protein concentration used in the NMR experiments was 1 mM. NMR experiments were carried 
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out at 298 K on a Bruker AvanceIII 800 MHz NMR spectrometer equipped with a QXI-HCN gradient 
probe and a Bruker AvanceIII 600 MHz NMR spectrometer equipped with a TCI-cryoprobe. The 
sequence specific assignment of the protein backbone resonances were obtained by analyzing the 
2D [1H, 15N]-HSQC, 3D HNHA, 3D HNCO, 3D HN(CA)CO, 3D CBCA(CO)NH, 3D HNCACB spectra [64]. 
For the side chain assignment 2D [1H, 13C]-HSQC and 3D (H)CCH-TOCSY experiments were 
performed [64]. The side chain of the aromatic residues were assigned using the [1H-13C] HSQC-
NOESY experiment. The N1 and N2 of histidine imidazole ring were assigned by performing 2J 
2D NMR experiments, using a standard [1H, 15N]-HSQC experiment with 1/(2J) = 36 ms, an offset of 
170 ppm, and a spectral width of 200 ppm for the 15N dimension. Most of the aromatic ring 
protons HD and HE were assignment by acquiring 2D (HB)CB(CGCD)HD and (HB)CB(CGCD)HE 
spectra, which correlates CB with either HD or HE aromatic protons, together with the analysis of 
[1H, 13C] HSQC and [1H, 13C] HSQC -NOESY. 
 
 
15N NMR relaxation measurements  
15N R1 (=1/T1) and R2(=1/T2) experiments were acquired using the pulse sequences described in 
reference 54, at 800 MHz spectrometer described above. R1 and R2 delay times were set as 128, 
256 (x2), 384, 512, 40 8x2), 769, 897 ms and 20, 40, 60, (x2), 80, 100, 120 (x2), 140, 160 ms 
respectively. The 15N heteronuclear NOE (nuclear Overhauser effect) experiments were collected 
with a relaxation delay of 5 s with and without saturation of the amide protons that was achieved 
using 120° high-power pulses. [65]. The spectra was analysed in Analysis-CCPN [66], and the 
relaxation times were calculated using the scripts present in the software, as exponential fit of 
single exponential decays to peak intensity values: I=I0exp(−t/Tx) where Tx=T1 or T2, and 
I=resonance intensity at time t. Heteronuclear NOEs were calculated using the expression:  
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The standard deviation of NOE value, σNOE can be determined using the measured background 
noise levels:  
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2D NMR titrations 
Sample preparation 
 Both 15N-CNBD and mini or microTRIP8b proteins were buffer exchanged with a PD10 column to 
the following buffer: 150 mM KCl, 20 mM potassium phosphate, pH 7, 10 % (v/v) 2H2O (Sigma). 
The protein concentration used in the NMR experiments was 0.1 mM of CNBD.  
 
2D NMR titrations  
Each of the titration points was prepared independently by adding an aliquot of miniTRIP8b (or 
microTRIP8b) to a solution of 15N-CNBD until a ratio of [mini or micro]/[HCN2] of 2.0 and keeping 
constant the concentration of CNBD. [15N, 1H] HSQC spectra were obtained using a phase sensitive 
and water flip-back pulse sequence. The spectral widths were 14 ppm for 1H and 27 ppm for 15N. 
A total of 2048 data points in t2 and 4 transients for each of the 256 t1 were used. Spectra were 
acquired at 298 K on a Bruker Avance 600 MHz spectrometer equipped with a TCI Z-Grad cryo-
probe. The NMR spectra were processed with TOPSPIN 2.1 provided by Bruker and analyzed with 
CARA 1.8.4 [67]. Chemical shift perturbation for each amide resonance, ΔδHN (ppm), was 
calculated as a combination of the changes in the proton (ΔδH) and nitrogen (ΔδN) dimensions 
according to the following equation: 
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